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Abstract 
Despite the evidence demonstrating benefits of continuous glucose 
monitoring (CGM), the technology has not been widely implemented in routine 
management of type 1 diabetes due to several challenges. Our group has 
developed a novel sensor for CGM based on microprobe technology. The 
sensor consists of an array of solid microprobes, which are functionalised for 
in situ electrochemical measurement of dermal interstitial fluid glucose. The 
unique minimally-invasive non-extractive approach provides several avenues 
to enhance CGM accuracy.  
In this thesis, I describe the work carried out aiming to transfer this novel 
technology from bench side to bedside.  
To evaluate sensor’s ability to penetrate stratum corneum, human skin was 
utilised ex vivo to assess the force required for microprobes’ insertion 
compared to that required for their fracture. These studies guided a change in 
the fabrication technique and a modification in microprobes’ design.  
In vitro studies showed high sensitivity to glucose, providing the potential to 
enhance sensor accuracy. Further evaluation showed that neither skin 
insertion nor gamma ray sterilisation had impacted sensor performance.  
Clinical evaluation of sensor safety and proof of concept started with phase 1. 
The six-hour study demonstrated that sensor use was associated with barely 
noticeable skin reaction and minimal pain.  
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The work also includes a mixed-method study aimed at capturing patients’ 
views in relation to CGM and describes the role of patient and public 
involvement in this project. 
These findings have important implications for the development of an 
accurate, cost-effective and user-friendly CGM system. This may help in 
widespread implementation of CGM technology and enhance compliance with 
CGM use with subsequent improvement in clinical effectiveness. 
Finally, a re-analysis of 448 glucose profiles from the Juvenile Diabetes 
Research Foundation CGM study is presented. This describes measures of 
glycaemic variability in type 1 diabetes and demonstrates the value of CGM in 
reducing these measures.  
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%CV Percentage coefficient of variation 
CV Cyclic voltammetry 
DCCT Diabetes Control and Complications Trial 
DET Direct electron transfer 
DSP Dexcom Seven Plus 
EDC Ethyl-dimethyl-aminopropylcarbodiimide 
EDM Electrical Discharge Milling 
EGA Error grid analysis 
FAD Flavin adenine dinucleotide 
FBR Foreign body reaction 
FSN FreeStyle Navigator 
GDH Glucose dehydrogenase 
GOx Glucose Oxidase enzyme 
GRADE Glycaemic risk assessment diabetes equation 
GV Glycaemic variability 
HBGI High blood glucose index 
ICHTB Imperial College Human Tissue Bank 
ISF Interstitial fluid 
LBGI Low blood glucose index 
LGS Low glucose suspend 
LI Lability index 
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MAG Mean absolute glucose 
MAGE Mean Amplitude of Glycaemic Excursion 
MARD Mean absolute relative difference 
MDI Multiple daily injection 
MODD Mean of daily difference 
NAD Nicotine adenine dinucleotide 
NADP Nicotine adenine dinucleotide phosphate 
NHS N-hydroxy- succinimide 
OCT Optical coherence tomography 
PARD Precision absolute relative difference 
PBS Phosphate buffered saline 
PDMS Polydimethoxy Siloxane 
PPI Patient and public involvement 
PQQ Pyrroloquinoline quinone 
PU Polyurethane 
QoL Quality of life 
RCT Randomised controlled trial 
RT-CGM Real-time continuous glucose monitoring 
SAM Self-assembly monolayer 
SAP Sensor augmented pump therapy 
SD Standard Deviation 
SEM Scanning electron microscopy 
SG Sensor glucose 
SMBG Self-monitoring of blood glucose 
TEWL Transepidermal water loss 
THF Tetrahydrofuran 
TMA Thiomalic acid 
TTF tetrathiafulvalene 
VAS Visual analogue scale 
YSI Yellow Springs Instrument 
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1.1.   GLUCOSE MONITORING: 
Glucose monitoring is a core component of a successful management 
strategy for people with diabetes, especially for those who are insulin-treated. 
It facilitates intensification of insulin therapy, with a subsequent reduction in 
diabetes-related complications, while minimising the risk of hypoglycaemia, 
(Tamborlane et al., 2008, Beck et al., 2009b). Since 1971, when the first 
glucose monitor was used (Hubert, 1971), the most common method of 
glucose monitoring has been the use of intermittent capillary blood glucose 
monitoring using standard finger-prick methods. It has revolutionized diabetes 
management in several ways. It allows patients to immediately detect and 
treat hyperglycaemic or hypoglycaemic excursions; it facilitates change in 
patients’ lifestyle by demonstrating the effect of lifestyle activities on 
glycaemia; and it allows therapy adjustment to achieve target HbA1c level in 
the long-term (Klonoff, 2007). 
There are many advantages for this method of testing. It is fast, accurate, 
portable, simple and cost-effective (Neeser K et al., 2006, Pfutzner et al., 
2014). Devices used for self-monitoring of blood glucose (SMBG) have 
evolved with many developments allowing improved accuracy, reduced size, 
memory function, reduced required blood volume, rapid analysis, ability to test 
for blood ketones and bolus advisor integration (Smart SMBG).  
There is evidence for improvement in glycaemic control with increased 
frequency of SMBG in patients with type 1 diabetes (Miller et al., 2013a). 
However, SMBG only provides a snap shot of the glucose profile at the point 
of testing. Therefore, missing important information about magnitude, 
direction, and duration of glycaemic excursions. This can be crucial especially 
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at important times, from glycaemia point of view, when the patient is unable to 
test like driving, exercise or sleeping. Furthermore, the procedure is invasive 
and painful, which can result in reduced compliance with the recommended 
frequency of monitoring with subsequent negative impact on diabetes control.  
1.2. CONTINUOUS GLUCOSE MONITORING (CGM):  
Emergence of CGM technology, as a complementary tool alongside SMBG, 
has addressed an important drawback of SMBG technology by providing 
patients and healthcare professionals with continuous information about the 
glucose profile. A CGM system comprises two essential components; a body 
worn glucose sensor and an electronic unit for signal processing and wireless 
data transmission. Some CGM systems also comprise a unit to display 
glucose values in real time. 
Glucose biosensors combine a glucose recognition component with a 
physiochemical detector. They can be classified according to sensing 
technique, level of invasiveness or target biofluid (blood or ISF) (figure 1.1). 
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1(a)
1(b) 
Figure 1.1: Classification of glucose sensors based on 1(a) invasiveness, 
method of access to biofluid and 1(b) sensing technique. 
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In general, electrochemical biosensors are the most common class of 
biosensors. They are based on the generation or consumption of electrons 
during the electrochemical reaction with subsequent generation of 
electrochemical signal. Currently, the only CGM systems licensed for clinical 
practice use Glucose Oxidase enzyme (GOx) (EC 1.1.3.4) for amperometric 
electrochemical detection of the interstitial fluid (ISF) glucose. These either 
rely on in vivo electrochemical sensing of ISF glucose or are coupled with 
microdialysis for glucose extraction before electrochemical analysis in vitro. 
Glucoday S (A. Menarini Diagnostics, Florence, Italy) is the only CGM system 
based on microdialysis technology. 
These systems can either display glucose values in real-time (RT-CGM) or 
store glucose data from retrospective analysis by healthcare professionals 
(blinded CGM). Real-time devices display the sensor glucose value 
accompanied by a trend arrow to show direction and magnitude of rate of 
change. These devices also feature an alarm function when glucose level is 
outside a pre-determined range or when a hypoglycaemic event is predicted. 
Several RT-CGM systems are licensed for clinical use (table 1.1). Ipro2 
system (Medtronic Diabetes, Northridge, California) is a blinded CGM system. 
FreeStyle Libre Flash Monitoring System (Abbott Diabetes Care, Alameda, 
California) is a new glucose monitoring system where glucose data can be 
accessed by scanning a reader over the sensor rather than being 
continuously displayed in real-time. 
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Manufacturer RT-CGM system 
Medtronic Diabetes, 
Northridge, California, USA 
 
Guardian REAL-Time system using sof-
sensor, enlite
  
sensor 
Paradigm VEO systems using sof-sensor or 
enlite
 
sensor 
Abbott Diabetes Care, 
Alameda, California, USA 
 
FreeStyle Navigator 
FreeStyle Navigator II 
DexCom Inc.,  
San Diego, California, USA 
DexCom SEVEN PLUS 
DexCom G4 PLATINUM 
DexCom G4 PLATINUM with software 505 
(G4AP) 
A. Menarini Diagnostics, 
Florence, Italy 
Glucoday S 
GlucoMen Day (not approved) 
 
Table 1.1: List of RT-CGM systems that are currently licensed for clinical use. 
 
On the basis of available evidence, as will be discussed later in this chapter, 
RT-CGM can be used therapeutically for further optimisation of subcutaneous 
continuous insulin pump therapy regimen if the target HbA1c has not been 
achieved. It can also be used for protection against recurrent disabling 
hypoglycaemia, those with hypoglycaemia unawareness or debilitating fear of 
hypoglycaemia (Hammond et al., 2010). 
 
1.2.1. Structure and operation of electrochemical glucose sensors: 
Amperometric electrochemical sensing of ISF glucose is based on a cascade 
of redox reactions, resulting in generation of an electrical current that is 
proportionate to ISF glucose concentration and the transfer of electrons from 
the reaction site (redox centre of the enzyme) to the electrode surface to 
measure the generated current.  
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GOx(FAD) + glucose -----! GOx(FADH2) + gluconolactone 
GOx(FADH2) + O2  ---!  GOx(FAD) + H2O2 
H2O2 -------! O2 + 2H
+ + 2e- 
The redox reaction cascade in first generation glucose biosensors 
An amperometric enzymatic electrochemical glucose sensor designed for in 
vivo CGM typically consists of a three-electrode system, Enzyme – electron 
acceptor system and membrane coating. 
1- Three electrode system: 
A three-electrode system is required for the redox reactions’ cascade and 
measurement of the generated current. It consists of a working electrode 
(rendered specific to glucose via immobilisation of GOx enzyme), a counter 
electrode and a reference electrode. A constant potential is maintained at the 
working electrode, with respect to the reference electrode, to complete the 
cascade of redox reactions (e.g. oxidation of hydrogen peroxide in first 
generation sensors), whilst current flows between the working electrode and 
the counter electrode. If current densities are low (< 2uA/cm-2), the reference 
and counter electrodes can be combined into one electrode (two-electrode 
system) (Bartlett, 2008). The nature of the working electrode and its surface 
activity plays an important role in defining sensor sensitivity. The noble metals 
(e.g. gold, silver or platinum) can considerably reduce the overpotential 
required for hydrogen peroxide oxidation. Determining the operating potential 
is important since relatively high applied potential can lead to oxidation of 
other electroactive ISF analytes, such as uric acid, ascorbic acid, 
acetaminophen, causing interference with sensor performance (Vaddiraju, 
2009). In general, the lower the working electrode potential, the lower the 
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sensor’s susceptibility to interferent species with subsequent enhancement of 
sensor’s selectivity. 
2- Enzymes and electron acceptors: 
Rendering the working electrode specific to glucose requires immobilisation of 
glucose oxidoreductase enzyme such as GOx or glucose dehydrogenase 
(GDH). GOx is a structurally rigid glycoprotein with a molecular weight of ca. 
160 kDa and consists of two identical polypeptide subunits, each containing a 
flavin adenine dinucleotide (FAD) redox centre (Kotanen et al., 2012). GOx 
catalyses the oxidation of glucose to gluconolactone. In this process, the 
enzyme gets converted to its reduced form GOx(FADH2). Conversion of the 
enzyme back to its oxidised form GOx(FAD) requires an electron acceptor, 
which defines the generation of the biosensors. Electron acceptors can be 
either oxygen (physiological electron acceptor) in first-generation sensors or 
redox mediator (synthetic electron acceptor) in second-generation sensors. 
Release of electrons from the reduced electron acceptors requires the 
application of a constant voltage between working and reference electrodes 
with subsequent generation of an electrical current that is proportionate to ISF 
glucose. 
GDH enzymes are defined as oxidoreductases that are unable to utilise 
oxygen as the electron acceptor and instead transfer electrons to various 
natural and artificial electron acceptors. Glucose dehydrogenases are 
classified according to their redox cofactors, which are the essential non-
protein component that act as the primary electron acceptor, mainly into 
nicotine adenine dinucleotide dependent GDH (NAD-GDH) (EC 1.1.1.118), 
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nicotine adenine dinucleotide phosphate dependent GDH (NADP-GDH) (EC 
1.1.1.119), pyrroloquinoline quinone dependent GDH (PQQ-GDH) (EC 
1.1.5.2), flavin adenine dinucleotide dependent GDH (FAD-GDH) (EC 
1.1.99.10), which is further subdivided into bacterial and fungal FAD-GDHs 
(Ferri et al., 2011).  
 Use of GDH enzymes instead of GOx for amperometric biosensing of 
glucose provides higher catalytic activity, enabling rapid glucose sensing, and 
independence of measurements from the oxygen concentration. However, 
this can be at the expense of specificity.  A clear example was the detection of 
non-glucose sugar maltose by PQQ-GDH glucose monitors, resulting in 
falsely elevated blood glucose levels. In one case, maltose interference led to 
13 reported deaths when patients were mistakenly treated for hyperglycaemia 
diagnosed on the basis of false high glucose meter readings (Felice et al., 
2013). Also, the thermal stability of PQQ-GDH is inferior to that of GOx 
(Bartlett, 2008).  
 
3- Membrane coating:  
As the concentration of oxygen in the ISF is only 0.1 mM (Vaddiraju, 2009) 
compared to 5.6 mM for glucose in the physiological conditions, a glucose 
diffusion limiting membrane covering the enzyme layer is required to modulate 
the glucose diffusion in comparison to oxygen diffusion. This allows glucose 
oxidation process to “keep up” with glucose diffusion, with subsequent 
increase in the linear range of glucose concentration, without being limited by 
oxygen deficit in the tissues (Heller and Feldman, 2008). Permselective 
membrane coating also plays an important role in resisting interference from 
other electroactive ISF analytes based on interferents’ size (e.g. cellulose 
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acetate films) or charge (e.g. Nafion). Membrane coating also helps to confine 
GOx enzyme close to electrode surface. Furthermore, It provides a 
biocompatible interface between the sensor and the tissues and enhances 
sensors’ stability by protecting their surface from surface-active 
macromolecules and reducing foreign body reaction (FBR). This, however, 
comes at the expense of reduced sensor sensitivity and increased sensor 
response time. Examples of biocompatible membrane coatings include 
Nafion, polyurethane and cellulose acetate (Wang, 2008). 
1.2.2. Classification of electrochemical glucose sensors: 
The transfer of electrons between the GOx active site and the electrode 
surface is an important limiting factor in the operation of amperometric 
glucose biosensors. GOx does not directly transfer electrons to conventional 
electrodes because of a thick protein layer surrounding its FAD redox centre 
and introducing an intrinsic barrier to direct electron transfer (Wang, 2008). 
According to the method of electron transfer between redox centre and 
electrode surface, electrochemical glucose sensors are classified into 3 
generations: 
a. First-Generation Glucose Biosensors 
First-generation glucose sensors rely on the use of oxygen as a physiological 
electron acceptor. 
The biocatalytic reaction starts with reduction of the FAD redox centre of the 
GOx enzyme by reaction with glucose to give the reduced form of the enzyme 
(FADH2) and gluconolactone. This is followed by re-oxidation of the enzyme 
by oxygen to regenerate the oxidised form of the enzyme GOx(FAD) and 
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generate hydrogen peroxide. Hydrogen peroxide is then oxidised at the 
electrode surface, upon the application of an electrical potential of around 
+700 mV (vs Ag/AgCl reference electrode), giving a current signal 
(proportional to the ISF glucose concentration) whilst regenerating oxygen. 
Both Medtronic and Dexcom use first generation glucose sensors. These 
have the advantage of being simpler, especially when miniaturised devices 
are concerned. However, these devices suffer from oxygen dependence  (as 
they rely on oxygen as a physiological electron acceptor) and are more 
susceptible to interference from other endogenous or exogenous electroactive 
analytes (as they require a relatively large potential to oxidise hydrogen 
peroxide, which can also oxidise other electroactive ISF analytes).  
b. Second-Generation Glucose Biosensors 
In 1984, Cass et al first demonstrated the use of ferrocene derivatives (Cass 
et al., 1984), as synthetic electron acceptors, replacing oxygen in carrying 
electron between the redox centre of the enzyme and electrode surface, 
through the following reaction cascade: 
GOx(FAD) + glucose -----! GOx(FADH2) + gluconolactone 
GOx(FADH2)+ 2 Mediator(oxidised)  ---!  GOx(FAD) + 2 Mediator(reduced) +2H 
2 Mediator(reduced) -------! 2 Mediator(oxidised)  + 2e- 
The redox reaction cascade in second generation glucose biosensors 
Examples of redox mediators include ferrocene derivatives, ferricyanide, and 
osmium complexes. 
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The use of synthetic electron acceptors (mediators) avoids issues related to 
oxygen dependence and also allows the use of relatively small electrical 
potential with subsequent reduction in the risk of interference from other 
electroactive ISF analytes. However, as mediators are small molecules, they 
can diffuse out of the coating membrane immobilised on the electrode 
surface, which results in a loss of catalytic activity. In addition, potential 
leaching and toxicity of most of redox mediators have restricted their use to 
SMBG devices (Bott, 2005). 
 “Wired” enzyme technology, developed by Heller’s group in 1987 (Degani 
and Heller, 1987), provides a solution to prevent diffusion of the mediators out 
of the coating membrane by connecting the redox centre of the enzyme to the 
electrode surface using a long flexible hydrophilic polymer backbone 
[poly(vinylpyridine) or poly(vinylimidazole)] having a dense array of covalently 
linked osmium-complex electron relays (mediators). The created 3-
dimensional network facilitates electron transfer between redox centre and 
electrode surface thereby allowing; oxygen independence, the use of low 
electrical potential and large current densities with subsequent improvement 
in sensors’ selectivity and specificity. Enzyme wiring technology is currently 
used by Abbott’s FreeStyle Navigator and FreeStyle Libre systems, which 
uses an operating potential of only +40 mV (Feldman et al., 2003). 
c. Third-Generation Glucose Biosensors 
Direct electron transfer (DET) from the redox centre of the enzyme to the 
electrode surface, which eliminates the need for an electron acceptor 
(whether physiological or synthetic), allows the use of very low operating 
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potential with subsequent very high selectivity. Recently, Sode’s group has 
reported the development of a DET glucose senor using engineered FAD-
dependent GDH from Burkholderia cepacia (Yamashita et al., 2013). 
However, their use of a relatively large operating potential (+250 mV (vs 
Ag/AgCl)) raises questions as to whether the sensor truly relies on DET. 
 
 
Figure 1.2: !A schematic representation of the principles of first-, second-, 
and third-generation glucose sensors. Electrons from the glucose oxidation 
reaction are first taken up by the enzyme’s cofactor (primary electron 
acceptor) and transferred to either oxygen (first generation), an electron 
mediator (second generation), or directly to the electrode (third generation). 
“Reprinted from Ferri, S., K. Kojima, and K. Sode, Review of glucose oxidases and 
glucose dehydrogenases: a bird's eye view of glucose sensing enzymes. J Diabetes 
Sci Technol, 2011. 5(5): p. 1068-76, Copyright (2011), with permission from SAGE 
journals” http://dst.sagepub.com/content/5/5/1068 
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FreeStyle 
Navigator  
(Liu et al., 2013) 
Medtronic 
 (Van Antwerp, 1998) 
DexCom  
(Brister et al., 2008) 
Sensor 
Generation 
Second 
Generation 
First Generation First Generation 
Electron 
acceptor 
Osmium complex Oxygen Oxygen 
Operating 
potential 
+40 mV +500-700 mV +700 mV 
Working 
electrode 
Carbon Platinum Platinum 
Reference 
electrode 
Ag/AgCl Ag/AgCl Ag/AgCl 
Counter 
electrode 
Carbon Platinum Combined 
reference/counter 
Membrane poly(vinylpyridine
-co-styrene) 
copolymer 
Diisocynate/polyuret
hane/polyurea/polye
thyleneglycol/polysil
oxane copolymer 
polyurethane/ 
polyethylene glycol 
copolymer 
 
Table1.2: Comparison between commercially available continuous glucose 
sensors with regards to sensor structure and operation. 
 
1.2.3. Technical challenges facing implantable electrochemical sensors 
for in vivo CGM: 
There are several challenges that face implantable electrochemical glucose 
sensors resulting in reduced sensor accuracy and reduced sensor life span. 
These include:  
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1.2.3.1. Interferences (selectivity): 
Application of relatively high potential, for oxidation of hydrogen peroxide at 
the working electrode, can result in oxidation of other endogenous or 
exogenous ISF electroactive analytes. This can cause an overestimation of 
the ISF glucose concentration. Strategies employed to reduce interference 
include the use of a permselective membrane to minimize access of 
interferents to the working electrode based on size or charge. An alternative 
approach is the use of a secondary working electrode to measure the 
background current (generated by interferents) with subsequent subtraction of 
the background current from the current measured by the primary working 
electrode (Vaddiraju et al., 2010). Advances in sensor technology, which allow 
the use of low potential, can also help in reducing the risk of interference.  
1.2.3.2. Oxygen deficit: 
Since oxygen concentration in ISF is significantly lower in comparison to 
physiological glucose concentration (0.1 mM in comparison to 5.6 mM), 
oxygen can be the limiting factor in generation of hydrogen peroxide in the 
redox reaction cascade in first generation glucose sensors. This results in a 
generated current that is proportional to oxygen rather than glucose 
concentration. In addition, a change in tissue oxygen level (e.g. in case of 
anaesthetics or hypoxia) can affect sensor performance. 
To overcome this problem, glucose sensors employ a mass transport limiting 
membrane that increases the oxygen/glucose permeability ratio and limits 
glucose diffusion to the electrode surface allowing glucose concentration to be 
the limiting factor in hydrogen peroxide generation.  An alternative way to 
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overcome the problem of oxygen deficit is the use of synthetic electron 
acceptor (mediators) as in second generation glucose sensors. 
1.2.3.3. Foreign body reaction (FBR): 
Glucose sensor implantation in subcutaneous tissue results in initiation of 
wound healing cascade and the development of FBR. Proteins rapidly adhere 
to the biomaterial surface in a process referred to as biofouling, which 
represents an integral part of subsequent development of FBR. The FBR is 
composed of three main layers. The innermost layer is composed generally of 
macrophages and foreign body giant cells (the barrier cell layer). The 
intermediate layer is a wide zone (30-100 µm) composed primarily of 
fibroblasts and fibrous matrix (the fibrous zone). The outermost layer is loose 
connective granular tissue containing new blood vessels (the vascular zone) 
(Brauker et al., 2004). FBR has a significant impact on the implanted glucose 
sensor and its function. Other than chemical and physical alterations (e.g. 
local drop in pH and resistance to glucose mass transfer by fibrous tissue) 
that happen at the tissue-sensor interface, FBR can also result in degradation 
of sensor layers (Nichols et al., 2013).  
Various strategies have been employed to mitigate the effect of FBR. 
Considerable efforts have been paid to employ more biocompatible elements 
for sensor fabrication and the use of biocompatible and inert membrane 
coating (e.g. Nafion, polyurethane, polyethylene glycol, and hydrogels). 
Another strategy is the release of locally active molecules to modulate local 
FBR by either; suppressing inflammation (e.g. dexamethasone), inducing 
neovascularization (e.g. vascular endothelial growth factor) or causing 
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vasodilatation (e.g. nitric oxide) (Wisniewski et al., 2000). Also, reducing the 
size of the sensor was shown to be effective in reducing FBR as will be 
discussed later in this chapter. 
1.2.3.4. Lag time between blood and ISF: 
Currently the most commonly used CGM devices in clinical practice use a 
needle-type electrochemical glucose sensor with the sensor tip in the 
subcutaneous tissue to measure ISF glucose. Glucose concentration in the 
ISF is dependent on blood flow, metabolic rate and the rate of change of 
glucose concentration in the blood (Oliver et al., 2009). Comparison of 
glucose levels in subcutaneous ISF and finger capillary blood showed high 
correlation with estimated lag time between 0 and 45 minutes (Cengiz and 
Tamborlane, 2009). The time lag between plasma and ISF glucose appears to 
differ depending on the CGM system used (sensor size, sensor type, 
algorithm) and whether plasma glucose values are rising or falling (Basu et 
al., 2014). A study that evaluated the time lag between blood glucose and 
subcutaneous ISF, measured by a commercially available electrochemical 
sensor, following an oral meal in 14 subjects with type 1 diabetes suggested 
that the mean lag time is 6-7 minutes (Boyne et al., 2003). This was 
supported in recent studies that reported a mean lag of 5.3-6.2 minutes in 
healthy subjects and a median time lag of 6.8 minutes in subjects with type 1 
diabetes (Basu et al., 2013, Basu et al., 2014). In these studies, time lag was 
estimated by direct measurement of the transport of glucose tracers from the 
vascular to the subcutaneous ISF compartment in subjects under overnight 
fasting condition. Glucose tracers were administered intravenously and 
measured in the abdominal subcutaneous tissue using 4 microdialysis 
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catheters. 
In comparison to subcutaneous ISF glucose, there are limited data on dermal 
ISF glucose content and dynamics. Using a microdialysis technique to 
compare dermal and subcutaneous ISF glucose against blood glucose 
showed that dermal ISF glucose concentration is similar to that of the blood 
(99.1%), while subcutaneous ISF glucose concentration is only 50% in 
comparison to blood glucose (Petersen et al., 1992, Boschmann et al., 2001). 
It also demonstrated that dermal ISF glucose has identical peak concentration 
to blood glucose and suffers from less lag in comparison to subcutaneous ISF 
glucose. This is consistent with cutaneous blood supply, where blood flow 
reaches the dermis first then the subcutaneous tissue (Petersen et al., 1992, 
Boschmann et al., 2001, Stout et al., 2001). 
Commercially available electrochemical sensors provide an estimate of ISF 
glucose every 5 minutes (288 values per 24 hours) and are licensed for use 
for up to 7 days, with the exception of FreeStyle Libre, which measures ISF 
glucose every minute and is licensed for use for up to 14 days. 
As these sensors use ISF as the diagnostic biofluid and because they are 
prone to signal drift post-implantation, resulting from FBR and alteration in 
sensor chemistry, they require calibration to capillary blood glucose. The aim 
of calibration is to convert the electrical signal obtained from the sensor, which 
is proportional to ISF glucose, into a glucose value by using a capillary blood 
glucose value. The calibration process can be a significant source of error and 
needs to be carried out with care.  A single error in calibration will get carried 
forward until it is corrected by an appropriately performed calibration. 
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Several requirements need to be fulfilled to fabricate a calibration-less 
continuous ISF glucose sensor. These include: reproducible manufacturing 
allowing minimal variation between sensors; stable sensor sensitivity in vitro 
and in vivo; lack of significant difference in in vivo sensor sensitivity between 
different insertion sites and different persons; and for the in vivo sensor 
sensitivity to be inferable from in vitro sensitivity. Two clinical studies were 
conducted to evaluate the performance of the FreeStyle Libre sensor over 5 
days and 14 days in a total of 88 subjects with type 1 and type 2 diabetes. 
The studies reported: minimal inter-sensor variability (the coefficient of 
variation between sensors was only 2.9%); minimal change in sensor 
sensitivity (decline by 0.25% per day in vitro and by 0.66% in vivo); and that 
the difference between sensor sensitivity between subjects and between 
sensors inserted in the abdomen or those inserted in the arm was not 
statistically significant. This implies reproducible manufacturing, minimal FBR 
and stable sensor performance in different subjects, regardless of insertion 
site, over 14 days. To establish the relationship between in vitro and in vivo 
sensitivity, the authors compared a standard finger-stick calibration algorithm 
to a simulation of factory calibration using one universal calibration factor 
applied to all sensors in the study. This single sensor calibration factor was 
calculated for each sensor from the median of the individual sensitivity values 
(sensor signal divided by capillary blood glucose). All paired blood glucose 
reference points following the first hour post sensor insertion, up to the end of 
the sensor wear period, were used for this calculation. The analytical and 
clinical accuracy of the two calibration algorithms showed that the single 
calibration algorithm was superior in one study but inferior in the other, 
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compared to the standard calibration algorithm (Hoss et al., 2013, Hoss et al., 
2014).  The FreeStyle Libre system is currently marketed as a calibration-less 
glucose monitoring system. 
1.2.3.5. Stability: 
Implantable glucose sensors can fail secondary to membrane degradation, 
biofouling of electrode surface, loss of enzyme activity or enzyme leaching. To 
overcome these problems, different strategies can be employed for effective 
membrane coating and effective enzyme immobilisation techniques. 
Examples of immobilisation techniques include fixation of the enzyme onto the 
electrode surface by electrostatic interactions generated by polyelectrolytes or 
cross-linking of the enzyme with bovine serum albumin with glutaraldehyde 
(Nichols et al., 2013). 
From the technical aspect, glucose sensors need to fulfill several 
requirements including specificity, accuracy, wide linear range, sensitivity, 
rapid response, and resistance to interferents, biocompatibility and stability. 
Therefore design and optimisation of a glucose biosensor requires careful 
choice of working electrode material, enzyme load and its immobilisation 
method, electron acceptor, type and thickness of the coating membrane and 
the operating potential. While any of these components serves an important 
function, there is usually a trade off between them. For example while the use 
of a thick membrane coating enhances sensor’s selectivity by reducing 
interference from other electroactive ISF analytes, this comes at the expense 
of reduced sensitivity to glucose and increased response time.  
 
 
45
! 46!
1.2.4. Assessment of CGM system accuracy: 
Several recommendations exist for performance evaluation of monitoring 
devices for SMBG. According to International Organization for 
Standardization (ISO) 15197:2013 guidelines, ≥95% of sensor glucose (SG) 
results should be within 0.8 mmol/L (15 mg/dL ) or 15% of the blood 
glucose (BG) reference results for samples with glucose concentrations <5.6 
mmol/L (<100 mg/dL) and ≥5.6 mmol/L (≥100 mg/dL), respectively (Pfutzner 
et al., 2014). Manufacturers and academic researchers have extended the 
use of these guidelines to evaluate CGM system performance. Bland-Altman 
plot (bias plot) compares glucose meter accuracy against a reference method. 
In this method, the difference between sensor glucose and reference glucose 
is plotted against reference glucose values.  Therefore, it provides information 
on sensor accuracy over the range of absolute glucose values, as defined by 
the reference method. It also displays the bias (mean difference between 
sensor glucose and reference glucose measurements) and limits of 
agreement (bias ± 1.96 x standard deviation of the bias) to show the 95% 
confidence interval in agreement between the two measurement methods. 
Another method to evaluate numerical accuracy of CGM systems is by using 
mean and median absolute relative difference (ARD). Mean absolute relative 
difference (MARD) is more commonly reported, as it is more sensitive to 
outliers. ARD is calculated using paired SG and reference BG values in the 
equation ([SG – BG]/BG) x 100). In addition to reporting the overall 
aggregated MARD when evaluating accuracy of a CGM system, MARD can 
be categorised according to glycaemic range, day of sensor implantation or 
for individual sensor performance. For evaluation of clinical accuracy of 
46
! 47!
glucose meters, Clarke error grid analysis (EGA) is used to categorise paired 
SG - BG values according to the consequences of treatment decisions 
(Clarke et al., 1987). Zone A represents the clinically accurate zone with SG 
within 20% of reference BG and/or SG reading <3.9 mmol/L (<70 mg/dL) 
when BG is <3.9 mmol/L (<70 mg/dL); Zone B, benign errors, SG difference 
>20% but error would not lead to either serious hypo or hyperglycaemia; Zone 
C, overcorrection errors, SG above or below the target range of 3.9–10 
mmol/L (70-180 mg/dL) when reference BG is within target, and treatment 
would result in either hypo- or hyperglycaemia; Zone D, failure to detect 
(hypo- or hyperglycaemia) errors, SG values within target range when 
reference BG is either above or below target; and Zone E, erroneous 
treatment errors, SG is either above or below target and reference BG is in 
the opposite extreme, resulting in insulin being given when BG is <3.9 mmol/L 
(<70 mg/dL) or rapid-acting glucose being given when reference is >10 
mmol/L (>180 mg/dL) (figure 1.3(A)). A limitation to the Clarke EGA is related 
to the transition between adjacent zones (for example zone D is contiguous to 
zone A, skipping zones B and C). Therefore two results with the same amount 
of error can result in different clinical outcomes. To overcome this limitation, 
Parkers EGA was proposed (figure 1.3(B)). 
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A 
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Figure 1.3: Clarke (A) and Parkers (B) error grid analyses designed to 
evaluate clinical point accuracy of glucose meters, divided into zones A-E. 
 
However, all these measures reflect point accuracy. As CGM systems are 
capable of glucose measurement as a process of time, Continuous Glucose-
EGA (CG-EGA) has been proposed to evaluate trend accuracy of CGM 
systems to allow assessment of accuracy of rate and direction of BG change. 
CG-EGA combines point EGA with rate EGA (figure 1.4) by expanding the 
point clinical accuracy of EGA to incorporate rapidly changing glucose values 
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based on the rate and direction of change and the assumed lag time between 
BG and ISF glucose (Clarke and Kovatchev, 2009). MARD can also be 
categorised according to the rate and direction of change. 
 
Figure 1.4: Rate error grid analysis divided into zones A-E for SG rate vs BG 
rate (presented in mg/dL/min). [l, lower; R, rate; u, upper].  
Reprinted from Clarke, William, and Boris Kovatchev. “Statistical Tools to Analyze 
Continuous Glucose Monitor Data.” Diabetes Technology & Therapeutics 11.Suppl 1 
(2009): S–45–S– 54.Copyright (2009), with permission from Mary Ann Liebert, Inc” 
 
Whilst the MARD evaluates CGM system’s accuracy by examining the 
relationship between SG and reference BG, the precision absolute relative 
difference (PARD) has been proposed to evaluate precision of CGM systems 
by examining the relationship between two CGM sensors running 
simultaneously, but independently, in one patient. This avoids limitations 
related the limited number of paired data points that are used to calculate 
MARD, which may lead to inability to detect certain issues (e.g. transient 
signal drop due to tissue compression resulting in erroneous errors) 
!70mg=dL),12 target range (70mg=dL<BG! 180mg=dL),
and hyperglycemia (BG >180mg=dL). Percentage of time
within additional ranges can be computed as well to em-
phasize the frequency of extreme glucose excursions. For ex-
ample, when it is important to distinguish between
postprandial and postabsorptive (fasting) conditions, a fast-
ing target range of 70–140mg=dL is suggested. Further, per-
centage of time <50mg=dL would quantify the frequency of
significant hypoglycemia, whereas percentage of time
>300mg=dL would quantify the frequency of significant hy-
perglycemia occurring during a clinical trial. Table 1 includes
the numerical measures of average glycemia (Table 1A) and
deviations from target (Table 1B). All these measures are
computed per CGM trace per person, after which they can be
used as a base for further group comparisons and other sta-
tistical analyses.
Graphs. While plotting the CGM trace observed during
the experiment would represent the general pattern of a per-
son’s BG fluctuation, additional graphs are suggested to em-
phasize details of such a pattern corresponding to the
numerical measures of the previous section. To illustrate the
effect of treatment observed via CGM we use previously
published 72-h glucose traces observed pre- and 4weeks post-
islet transplantation.13
Figure 2 presents the glucose traces [process BG(t)] pre- and
post-transplantation with superimposed aggregated glucose
traces. These traces are related to time spent below=within=
above target range. The premise behind aggregation is as
follows: frequently one is not particularly interested in the
exact BG value because close values such as 150 and
156mg=dL are clinically indistinguishable. It is, however,
important whether and when BG crosses certain thresholds,
e.g., 70 and 180mg=dL as specified in the previous section.
Thus, the entire process BG(t) can be aggregated into a process
described only by the crossings of the thresholds of hypo-
glycemia and hyperglycemia.
In Figure 2 the aggregated process is depicted by squares
that are red for hypoglycemia, green for target range, and
yellow for hyperglycemia. To reduce the influence of CGM
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FIG. 1. Rate Error Grid analysis that categorizes rate and
direction sensor errors in zones similar to those for the
original Clarke Error Grid4: Zone A, clinically accurate; Zone
B, benign errors; Zone C, overcorrection errors; Zone D,
failure to treat errors; and Zone E, erroneous treatment
errors.
Table 1. Numerical Measures of Summarizing CGM Data
A: Average glycemia and deviations from target
Mean BG Computed from CGM or BG data for the entire test
Mean pre-meal BG Mean BG restricted to time window 60–0min pre-meals
Mean post-meal BG Mean BG restricted to time window 60–120min post-meals
B: Deviations from target
% time spent within target range of 70–180mg=dL,
below 70mg=dL, and above 180mg=dL
For CGM, this generally equals percentage of readings
within each of these ranges. For BG measurements
that are not equally spaced in time we suggest
calculating the percentage of time within each range
via linear interpolation between consecutive
glucose readings.
% time !50mg=dL Optional, to emphasize occurrence of extreme
hypoglycemia
% time >300mg=dL Optional, to emphasize occurrence of extreme
hyperglycemia
C: Variability and risk assessment
Interquartile range BGRI Measure of variability suitable for non-symmetric
distributions; ¼LBGIþHBGI, a measure of overall
variability and risks of hypo- and hyperglycemia
LBGI Measure of the frequency and extent of low BG readings
HBGI Measure of the frequency and extent of high BG readings
SD of BG Rate of Change A measure of the stability of closed-loop control over time
D: Events and other clinical characteristics
Events of low BG <70mg=dL (or events of BGs <50mg=dL)
Events of high BG >180mg=dL (or BGs >300mg=dL)
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(Obermaier et al., 2013). Similar to MARD, PARD can be categorised 
according to range of glycaemia, day of sensor implantation and rate and 
direction of glucose change (Zschornack et al., 2013). 
A novel metric was proposed for evaluating CGM inaccuracies (Leelarathna et 
al., 2012). To evaluate the severity of CGM inaccuracy, 3 levels of sensor 
error were defined. Sensor error was estimated using absolute deviation (AD) 
for plasma glucose levels< 6 mmol/L or MARD for plasma glucose levels ≥ 6 
mmol/L. Level 1 (least severe) is defined as AD ≥ ±2.4 mmol/L or MARD ≥ 
±40%, level 2 is AD ≥ ±3 mmol/L or MARD ≥ ±50%, and level 3 (most severe) 
is AD ≥ ±3.6 mmol/L or MARD ≥ ±60%. This metric quantifies the incidence 
and duration of each error level. The incidence of each error level is further 
categorised into sensor over-reading or sensor under-reading.   
Performance of existing CGM systems has been evaluated in several studies. 
In a study evaluating the performance of the Dexcom G4AP against that of G4 
PLATINUM, G4AP showed improved accuracy particularly at day 1 of sensor 
implantation with MARD (measured against YSI venous blood glucose) of 
14.7% compared to 16.8% for the G4 PLATINUM. The new CGM system 
employs the same sensor and transmitter as the G4 PLATINUM but contains 
updated de-noising and calibration algorithms. The new algorithm was applied 
to raw sensor data of 72 subjects (108 sensors). This resulted in improvement 
in the overall MARD (for 7 days of sensor use) from 13.2% to 11.7% for a 
glucose range of 2.2-22.2 mmol/L. Similarly, the overall MARD for a glucose 
range of 2.2-4.4 mmol/L improved from 11.1% to 9.5%. However, G4AP did 
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not reduce the proportion of large errors (levels 1-3) lasting for more than 60 
minutes when compared to G4 PLATINUM (Garcia et al., 2013). 
A clinical study evaluating the performance of the Abbott Diabetes Care 
FreeStyle Libre glucose monitoring system in 62 subjects with type 1 diabetes 
and type 2 diabetes reported a MARD (measured against capillary blood 
glucose) of 13.9% over 14 days of sensor use. However, the use of a single 
calibration factor that was applied retrospectively to the raw sensor data, 
rather than standard calibration (1 hour, 2 hours, 10 hours, 3, 5, 7, 9, 11 and 
13 days since sensor insertion), resulted in improvement of sensor accuracy 
with a MARD of 12.2%. Without recalibration, there was no significant 
difference in MARD between days of sensor wear. Analysis using point-EGA 
showed that 88% of results were in zone A, 10.6% in zone B, 1.4% in zone C 
(Hoss et al., 2013). 
Evaluating the accuracy of the Medtronic Enlite Veo 6-day CGM system 
reported an overall MARD of 13.89% versus YSI glucose. System accuracy 
was worse on day 1 of sensor wear (MARD of 14.9%) and in glucose range 
between 2.2-4.4 mmol/L (MARD of 18.4%). MARD at day 1 of sensor wear in 
glucose range between 2.2-4.4 mmol/L was reported as 20% (Keenan et al., 
2012). 
However, comparison between different CGM systems, based on these 
studies, is made difficult by differences in experimental design between 
different studies. For example, the difference in the method of calculation of 
MARD (YSI venous blood versus capillary blood glucose), number and 
frequency of paired CGM-reference blood points, number of participants or 
whether the study was conducted as an inpatient or in ambulatory settings. A 
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head-to-head comparison between three CGM systems was performed in six 
subjects with type 1 diabetes under closed-loop blood glucose control. Each 
subject wore the FreeStyle Navigator (FSN), Dexcom Seven Plus (DSP) and 
Medtronic Guardian-sofsensor system simultaneously in two 48-hour 
experiments in the hospital. Results from the 12 experiments showed that the 
FSN had the best overall accuracy with an average MARD of 11.8 ± 3.8%. In 
comparison, the DSP and Guardian produced an average MARD of 16.5 ± 
6.7% and 20.2 ± 6.8%, respectively. Similarly, the FSN showed the best 
performance across different ranges of glycaemia, except in glucose level 
>13.9 mmol/L (> 250 mg/dL) (Damiano et al., 2013). 
More recently, the same group has reported the results of their head-to-head 
comparison study including new generations of CGM systems. In a similar 
study design of 24 experiments, subjects simultaneously wore FSN, G4 
PLATINUM and Medtronic Enlite Veo CGM systems. Results revealed that 
G4 PLATINUM had the best accuracy and precision, followed closely by FSN. 
The two CGM systems significantly outperformed the Enlite Veo system. The 
mean (SD) of all 24 individual 48-hour MARDs were 12.3 ± 4.7%, 10.8 ± 2.8% 
and 18.3 ± 8% for the FSN, G4 PLATINUM and Enlite, respectively. As the 
data were collected as part of a closed-loop study, there were relatively few 
points <3.9 and >13.9 mmol/L (<70 and >250 mg/dL). Aggregate MARDs 
reported for glucose range between 2.8-3.9 mmol/L (50-70 mg/dL) were 36%, 
19% and 23% for the FSN, G4 PLATINUM and Enlite, respectively. 
Frequencies of very large errors (MARD ≥ 50%) were 1.4% for the FSN, 0.5% 
for G4 PLATINUM and 4.4% Enlite. Most of these very large errors were due 
to reduced sensitivity for detection of hypoglycaemia. Similar to the previous 
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study, the FSN showed tendency to underestimate glucose values at the 
hyperglycaemia range (plasma glucose >13.9 mmol/L). CGM reliability 
(defined as the percentage of glucose values reported by the CGM relative to 
the total number possible) were 99.7% for the FSN, 99.5% for G4 PLATINUM 
and 97.1% for the enlite (Damiano et al., 2014). This study highlights the 
progress of CGM technology resulting in improvement in accuracy, precision 
and reliability of current CGM systems. It also highlights the rapid pace of 
technology development. Currently, there are two more recent CGM 
generations that have not yet been assessed in head-to-head comparison 
(FSN II and G4AP). Similarly, Abbott’s Freestyle Libre glucose monitoring 
system has not been evaluated so far in a head-to-head comparison. 
 
1.2.5. Evidence for the use of CGM: 
Research evaluating the effectiveness of CGM technology is extensive. It has 
studied the effect of CGM on several glycaemic outcomes including effect on 
HbA1c, hypoglycaemia measures and glycaemic variability measures. It has 
also studied non-glycaemic outcomes including effect on quality of life. The 
effectiveness of CGM has been evaluated in different settings (ambulatory, 
inpatient and in intensive therapeutic unit (ITU)) and in different types and 
subgroups of diabetes. However, several confounding factors need to be 
considered while evaluating the CGM evidence. As the CGM is a diagnostic 
tool, its effectiveness relies on effective translation of the CGM data into an 
effective therapeutic intervention that will eventually impact the outcome. This 
effective translation depends on patient’s training, skills and compliance. It 
also depends on the experience of the diabetes team and the level of support 
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provided to patients. Therefore, some of the CGM studies might not only 
evaluate the use of CGM and its accuracy, but also evaluate factors related to 
patient and diabetes team interaction with the CGM. Furthermore, CGM 
cannot be investigated in a double-blind manner. Therefore, the best possible 
evidence can be obtained from large-scale open-label randomised controlled 
crossover studies, where subjects act as their own control. Another important 
factor to consider when evaluating the CGM evidence is the rapid 
development in CGM technology. The continuous development in CGM 
sensor fabrication and algorithms used for glucose data analysis has resulted 
in significant improvement in CGM accuracy. Therefore, studies conducted 
few years ago using older generations of CGM systems might have shown 
different results if they were conducted using newer generations of CGM with 
enhanced accuracy. 
The effectiveness of blinded CGM in guiding therapeutic interventions was 
assessed in a number of studies. In an open-label randomised controlled trial 
(RCT) of 71 pregnant women with type 1 and type 2 diabetes, the use of 
blinded-CGM (CGMS Gold – Medtronic) for up to 7 days at intervals of 4-6 
weeks between 8-32 weeks gestation was compared against standard 
antenatal care. Subjects in the intervention arm showed lower HbA1c 
between 32-36 weeks, lower mean infant birth weight and reduced risk of 
macrosomia, compared to the control group (Murphy et al., 2008).  
The effectiveness of RT-CGM devices has also been demonstrated in a 
number of studies. The landmark Juvenile Diabetes Research Foundation 
(JDRF) CGM study evaluated the use of RT-CGM in 322 subjects with type 1 
diabetes with baseline HbA1c ≥ 7%. Subjects were randomised to either 
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continuous RT-CGM or standard care and were offered the choice of 
Medtronic, Abbott or DexCom devices. At 26 weeks the HbA1c fell 
significantly only in subjects aged ≥25 years from 7.6 to 7.1% but not in those 
aged 8–14 years or 15–24 years (Tamborlane et al., 2008). In all three age 
groups, factors that were associated with a greater reduction in HbA1c from 
baseline to 6 months were sensor use of 6 days or more per week and higher 
baseline HbA1c (Beck et al., 2009a). The study has also demonstrated that 
reduction in HbA1c was not associated with increased risk of hypoglycaemia, 
which did not change at 26 weeks. The JDRF CGM study also evaluated the 
potential benefits of RT-CGM use in subjects with HbA1c<7%. Although the 
reduction in time spent with glucose levels <3.9 mmol/L was not significantly 
different between the CGM and control groups at 26 weeks, total time out of 
range (<3.9mmol/L or >10mmol/L) was significantly lower in the CGM group 
and between-group difference in HbA1c was 0.34% favoring the CGM group 
(Beck et al., 2009b). The 26-week extension of the JDRF study in the adult 
group, combining subjects with HbA1c<7% and those with HbA1c ≥ 7%, 
showed the added benefits of RT-CGM in reducing rates of severe 
hypoglycaemia, reducing time spent in hypoglycaemia and increasing time 
spent in glucose level between 4-10 mmol/L while sustaining reduction in 
HbA1c (Bode et al., 2009). 
These findings were supported by a meta-analysis, which showed an overall 
mean HbA1c reduction of 0.3% in type 1 diabetic subjects using RT-CGM in 
comparison to SMBG. This meta-analysis also highlighted the correlation 
between compliance with the frequency of CGM device use and its 
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effectiveness; for every one day increase in sensor usage per week there was 
an additional HbA1c reduction of 0.15% (Pickup et al., 2011).  
Combining the diagnostic benefits of CGM with the therapeutic benefits of 
subcutaneous continuous insulin pump therapy and the development of 
sensor augmented pump therapy (SAP) was evaluated in several studies. The 
STAR3 study was a 1-year RCT with 485 subjects who were randomised to 
either SAP or standard care (multiple daily injection and SMBG). At the end of 
the study there was HbA1c reduction from 8.3% to 7.5% in the intervention 
group with significant between-group difference in HbA1c of 0.6% favoring the 
intervention group. There was no statistically significant difference in the rate 
of severe hypoglycaemia between the two groups. However, the study failed 
to demonstrate the effect of CGM or insulin pump therapy alone compared to 
SAP therapy to determine the beneficial contribution of each component of 
the system (Bergenstal et al., 2010). At the end of 1-year in the STAR3 study, 
subjects from the control group were crossed over to SAP group for 6 months. 
This resulted in reduction of HbA1c from 8% to 7.6%. Subjects already in the 
intervention group who continued with SAP therapy showed sustained 
reduction in HbA1c. The study also highlighted the role of compliance with 
sensor use in the effectiveness in SAP therapy. Subjects in the SAP group 
were able to maintain HbA1c if they used the sensor >40% of the time, 
whereas in the crossover cohort the maximum reduction in HbA1c was 
observed with sensor wear times>60% (Bergenstal et al., 2011).  
To evaluate the contribution of CGM to SAP therapy, the SWITCH study was 
conducted with 153 children and adults already on insulin pump therapy. In 
this randomised controlled crossover study, subjects were randomised to 
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CGM “sensor on” or “sensor off” groups for six months before washout period 
of four months followed by crossover for another six months. The study 
showed HbA1c reduction from 8.47% to 8.04% (difference of 0.43%, 
P<0.001) in the SAP group. The study also demonstrated that the SAP group 
spent less time in hypoglycaemia and that stopping CGM led HbA1c to revert 
back to baseline (Battelino et al., 2012). 
While SAP still relies on appropriate therapeutic interventions from patients 
and/or physicians to impact outcomes, it represents an important step towards 
realisation of the closed loop insulin delivery system. Another important step 
in this direction was the development of SAP with low glucose suspend (LGS) 
feature by Medtronic. The Paradigm Veo System with the LGS feature allows 
suspension of insulin delivery for 2 hours when a prespecified glucose 
threshold setting is reached by the associated continuous glucose monitoring. 
The ASPIRE In-Clinic study evaluated this LGS feature in 50 subjects with 
type1 diabetes. In this randomised crossover study subjects fasted overnight 
and exercised whilst using SAP, with LGS feature either turned on or turned 
off, until their sensor glucose value was <4.7 mmol/L. LGS feature was set to 
suspend insulin therapy when CGM-detected glucose concentration 
<3.9mmol/L. The mean hypoglycaemia duration was lower and mean nadir 
glucose value was higher in the LGS-On sessions, compared to LGS-Off 
sessions, without causing rebound hyperglycaemia (Garg et al., 2012). 
Similarly, the ASPIRE In-Home study evaluated the ambulatory use of LGS 
feature over three months in 121 subjects with documented nocturnal 
hypoglycaemia. The study showed that use of LGS feature resulted in 
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reduction in nocturnal hypoglycaemia without increasing HbA1c and was not 
associated with ketoacidosis (Bergenstal et al., 2013b). 
Evidence for the benefit of CGM technology in subjects with type 2 diabetes is 
relatively limited by paucity of data. In an RCT of 100 subjects with type 2 
diabetes not treated with prandial insulin, subjects were randomised to either 
RT-CGM or SMBG for 3 months before they were follow-up for 40 weeks. 
During the intervention phase, RT-CGM occurred in the intervention group in 
four cycles (2 weeks on /1 week off). At 12 weeks, there was significant 
reduction in HbA1c by 1% in the intervention group compared with 0.5% in the 
control group (P = 0.04) without increasing incidence of hypoglycaemia. This 
reduction in HbA1c was sustained, in contrast to the subjects with type 1 
diabetes in the SWITCH study. As in type 1 diabetes, the study also 
demonstrated the positive correlation between compliance with the frequency 
of CGM device use and effectiveness (Vigersky et al., 2012, Ehrhardt et al., 
2011).  
Glycaemic variability has also been the focus of interest in several CGM 
studies (this is discussed in chapter 6 – Glycaemic Variability and The Effect 
of RT-CGM). 
An evolving area for research is the use of CGM in the ITU setting. CGM can 
potentially allow the use of intensive insulin therapy to achieve tight glycaemic 
control in critically ill patients without increasing the risk of hypoglycaemia. It 
may also reduce the need for frequent blood sampling for glucose estimation 
with subsequent reduction in ITU staff workload. However, the alteration in 
blood flow, metabolic rate and capillary permeability in the subcutaneous 
tissue in critically ill patients represents a concern with regards to accuracy 
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and reliability of ISF glucose measurement using a subcutaneous implanted 
glucose sensor. This was assessed in a study of 50 critically ill subjects on 
intensive insulin therapy. The study demonstrated that circulatory shock 
requiring epinephrine did not affect the accuracy and reliability of 
subcutaneous CGM systems (Holzinger et al., 2009). Another study that 
evaluated two subcutaneous CGM systems in postoperative cardiac surgery 
patients during ITU stay reported numerical accuracy of the sensors that is 
better compared to reported data for outpatient use. The median ARD was 
11% and 14% with a lag of 0-4 minutes compared to reference arterial blood 
glucose values (Siegelaar et al., 2011a). In an RCT with 124 critically ill 
subjects, the effect of RT-CGM (Guardian CGMS) use on glycaemic control 
and risk of hypoglycaemia was compared to standard care. Glucose data 
were used to feed an algorithm to guide insulin infusion rate in the two groups. 
The control group also had a blinded CGM. The study demonstrated that RT-
CGM reduced risk of severe hypoglycaemia by 9.9% in the intervention group 
but had no effect on mean glycaemia (Holzinger et al., 2010). A recent RCT of 
177 subjects in a mixed ITU was conducted to compare subcutaneous CGM 
(FreeStyle Navigator) to intermitted capillary blood glucose (CBG) testing to 
guide insulin treatment. In the intervention group, glucose data were obtained 
every 10 minutes from CGM and used to feed a computerised glucose 
regulation algorithm to guide IV insulin infusion rate, with a target glucose of 
5-9 mmol/L. Subjects in the control group had blinded CGM and the same 
algorithm was fed by intermittent CBG measurement every two hours. In both 
groups, arterial reference blood glucose samples were collected six times 
daily and used for calibration. The study demonstrated significant reduction in 
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ITU staff workload in the intervention group but no difference in incidence of 
severe hypoglycaemia or percentage of time within target range between the 
two groups. The study highlighted the reduced accuracy of subcutaneous 
CGM in comparison to CBG testing device, with a median ARD of 13.7% vs 
7.1% respectively, which is comparable to published data on ambulatory 
CGM. There were also technical difficulties with CGM device use (related to 
calibration and temporary signal loss) despite training of all ITU nurses. 
Furthermore, CGM device failure occurred in 21 subjects (Boom et al., 2014). 
Further studies are required for full assessment of the effect of CGM on 
different glycaemic measures, morbidity and mortality in ITU setting.  
Despite the extensive research in the field of CGM technology, there remain 
important gaps in our knowledge. The impact of CGM use on risk of severe 
hypoglycaemia remains unclear (Choudhary et al., 2013). This is largely 
secondary to the lack of RCTs that have been specifically designed to 
evaluate CGM use in this population. Moreover, subjects with history of 
severe hypoglycaemia are often excluded from interventional studies. Another 
area of controversy in this field is the impact of CGM use on quality of life, 
with conflicting evidence emerging from different RCTs (Langendam et al., 
2012, Hommel et al., 2014, Polonsky and Hessler, 2013). The cost-
effectiveness of CGM use in patients with type 1 diabetes is another important 
area for future research (McQueen et al., 2011). The National Institute for 
Health and Care Excellence has conducted a de novo cost-effective analysis 
for its recent updated guidelines, which has found that existing CGM systems 
are not cost-effective even in people with type 1 diabetes who suffer from 
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impaired awareness of hypoglycaemia. However, these systems could be of 
some value in adults with type 1 diabetes with elevated HbA1c (NICE, 2015). 
However, despite the clear benefits of continuous glucose monitoring, it has 
not been widely implemented in the routine management of type 1 diabetes 
due to several challenges. This is evident from T1D exchange data 
demonstrating that CGM technology is being used by only 6.5% of people 
with type 1 diabetes in United States, despite reimbursement (Miller et al., 
2013b). The devices remain invasive and are associated with discomfort. This 
can negatively affect compliance and therefore the effectiveness of CGM, and 
is a potential limitation to continuous use. This is corroborated by the high 
dropout rate in clinical studies (Hermanides et al., 2011) and in routine clinical 
practice, as demonstrated in the T1D exchange data showing that among 
individuals who have used a CGM, two-thirds stopped using it (Miller et al., 
2013b). Moreover, data for CGM sensor accuracy has demonstrated clinically 
relevant reduced accuracy in the critical hypoglycaemic range (Mader et al., 
2010, Keenan et al., 2012, Weinstein et al., 2007, Mastrototaro et al., 2008). 
The complexity of CGM devices, the need for ongoing calibration against 
blood glucose values and the limited life span of glucose sensors can 
negatively impact patient’s experience when using CGM (Voskerician and 
Anderson, 2006). Other important limitations to CGM use could be related to 
high cost and clinicians’ reluctance due to either lack of experience or lack of 
resources required for effective management of patients on CGM. To 
overcome some of the challenges facing CGM, emerging technologies, 
including microneedles, aim to minimise the level of invasiveness and 
enhance sensor’s accuracy. 
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1.3.   USE OF MICRONEEDLE-ARRAY TECHNOLOGY IN CGM: 
1.3.1. Background 
Microneedle use was first suggested in 1976 by Gestel and Place who 
proposed the use of multiple needle shaped projections with a needle length 
of 5-100 µm to penetrate the stratum corneum layer for drug delivery. Thanks 
to advances in microfabrication in 1990s, microneedle manufacture was 
feasible. In 1998, Henry et al showed that using microneedles of 150 µm 
length to penetrate the stratum corneum can dramatically increase skin 
permeability to a model drug, calcein (Henry et al., 1998). Since then, 
research in microneedle array technology has developed rapidly, particularly 
in the field of transdermal drug delivery. Microneedles can be manufactured 
as in-plane or out-of-plane where the needles are either parallel or 
perpendicular to the fabrication surface respectively. Out-of-plane 
microneedles can be either solid or hollow. Microneedles of different 
geometries, designs and materials (including polymers, metals, glass, 
carbohydrates or silicon) have been manufactured and microneedle 
technology has been extensively investigated as a therapeutic tool for 
transdermal drug delivery. Other applications for microneedle technology 
have been investigated including for biopsy (Byun et al., 2005), light delivery 
to deeper skin layers for diagnosis and treatment of epithelial cancers 
(Kosoglu et al., 2010) and for measurement of electrical potentials (for 
example in electrocardiography) (Yu et al., 2009). Several research groups 
have investigated the use of microneedle technology as a diagnostic tool 
allowing access to biofluids (ISF or blood) for analysis of variable analytes 
including glucose. For CGM using ISF, an array containing several 
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microneedles can be employed to penetrate the stratum corneum and access 
ISF without impinging on the dermal nerve fibers or blood vessels. ISF can 
then be either extracted to the surface (using hollow microneedles) or 
analysed in situ using microneedle sensors.  
 
Figure 1.5: A scanning electron microscopy image of a 500 µm tall microneedle 
next to the tip of a 27-gauge hypodermic needle. 
“Reprinted from Davis, S.P., et al., Insertion of microneedles into skin: measurement 
and prediction of insertion force and needle fracture force. J Biomech, 2004. 37(8): 
p.1155-63, Copyright (2004), with permission from Elsevier”. 
 http://www.sciencedirect.com/science/article/pii/S0021929003004731 
 
1.3.2. Potential advantages of microneedle technology for CGM: 
1.3.2.1 Minimal invasiveness 
Human skin comprises the epidermis, dermis and subcutaneous tissue. The 
outermost layer of epidermis, called stratum corneum, is primarily made of 
dead tissue and is responsible for skin barrier characteristics. The viable 
epidermis, below the stratum corneum, contains living cells, but is devoid of 
blood vessels and contains few nerves. Below the viable epidermis lies the 
dermis, 800–1500 µm in thickness, which contains nerves and blood vessels 
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at approximately 400 µm depth from skin surface (Khanna et al., 2008). 
(Figure 1.6) 
 
Figure 1.6: A schematic diagram showing a cross section of skin layers and a 
microprobe array applied to skin surface with the microprobes’ tips in the 
upper dermis.  
One of the main aims of microneedles accessing the dermal ISF 
compartment, to measure its glucose content, is to penetrate the layer of 
stratum corneum without impinging on dermal microcirculation or dermal 
nerve fibers. 
The stratum corneum represents the main mechanical barrier to microneedle 
insertion (Park et al., 2005). Knowledge of stratum corneum thickness is 
therefore essential to determine microneedle length and ensure adequate 
penetration. There is a marked site variation in mean stratum corneum 
thickness; ranging from 22.6+/-4.33 µm for volar forearm, 29.3+/-6.84 µm for 
back of the hand, and 173.0+/-36.96 µm for palm. The stratum corneum 
thickness tends to become age-dependently thicker at the forearm (Egawa et 
al., 2007). Similarly, variation in the total epidermal thickness largely depends 
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on body sites, with no correlation to either age or skin type (Sandby-Moller et 
al., 2003). 
In comparison to the smallest needle-type glucose sensor used in clinical 
practice for CGM which has a length of 9mm and a width of 420 µm (27-
gauge), microneedles employed for the same purpose have a length of less 
than 2000 µm and a tip diameter of less than 50 µm. Thanks to its minimally 
invasive nature, microneedles’ application results in less skin inflammation, 
less pain, reduced risk of infection or bleeding and rapid skin recovery 
following removal. 
1.3.2.1.1. Skin reaction 
Skin irritation is a reversible local inflammatory reaction that leads to erythema 
and oedema. It can also be associated with local heat and pain and may be 
immediate or delayed. The ISO, responsible for setting the requirement for 
medical device manufacture and design, defines irritation as a "localised 
inflammatory response to single, repeated, or continuous application of the 
test substance, without involvement of an immunological mechanism."  If 
irritation occurs, the resulting erythema can be assessed clinically or 
measured by different methods including chromametry or laser doppler 
imaging methods. Chromametry measures superficial colour change while 
laser doppler measures blood flow deeper in the skin (Noh et al., 2010).  
The minimally invasive nature of microneedle arrays suggests that they are 
likely to be associated with less skin irritation when compared to invasive 
devices provided that a biocompatible material is used. The safety of 
microneedles with regards to skin irritation has been demonstrated in a 
double-blinded, sham-controlled, randomised study in 54 human subjects. An 
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8-point skin reaction score was employed to assess skin irritation following 
application of 35, pyramidal, 700 µm long, solid microneedle to facial skin or a 
sham device. Microneedle application was associated with minimal self-
limiting facial skin irritation that rapidly resolved in less than 1 hour (Hoesly et 
al., 2012). 
The relationship between different variables of microneedle array manufacture 
and skin irritation has been evaluated in a number of studies. The relationship 
between microneedle geometry and skin redness was investigated using 
metal microneedles of variable length (200 – 550 µm) and shapes in eighteen 
human subjects. Skin redness was measured by assessment of skin colour 
and laser Doppler imaging. This showed that microneedles with sharper tips 
resulted in less skin irritation compared to solid ones and that skin blood flow 
increased with longer microneedles. For all microneedles studied, irritation 
was minimal and lasted less than 2 hours (Bal et al., 2008). 
To study the effect of microneedle application time on skin irritation, polymer 
microneedles of 500 µm length were inserted for 2, 10, 60, 120 and 240 
minutes in five human subjects. Skin redness was measured by reflectance 
spectrophotometer as a determinant of the degree of skin irritation. Redness 
score increased for all microneedles with the highest initial value noted for 
microneedles applied only for 2 minutes, and was maintained for 30 minutes 
indicating that redness was greater when application time was shorter. 
Regardless of the duration of microneedle application, redness was 
maintained for 30 minutes then rapidly resolved between 30 minutes and 2 
hours after removal (Noh et al., 2010, Bal et al., 2008) (table 1.3). 
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1.3.2.1.2. Pain 
Needle insertion, whether for drug administration or diagnostic fluid sampling 
can cause undesirable pain and trauma. This is particularly relevant in 
diabetes where frequent needle use is part of the daily routine for people with 
diabetes for either insulin administration or for monitoring. This can result in 
declining treatment adherence and is particularly challenging in people with 
needle phobia and in children. Microneedle array technology represents a 
minimally invasive alternative to traditional needles and lancets, resulting in 
reduced pain and tissue trauma. 
The first study to evaluate pain related to microneedle application was carried 
out in 12 healthy human subjects challenged by silicon microneedle arrays 
containing 400 solid microneedles (length of 150 µm, base diameter of 80µm 
and tip radius of 1 µm). A 26-gauge hypodermic needle was used as a 
positive control (inserted to 2 mm) and a smooth silicon surface as a negative 
control. Pain was assessed using a 100 mm visual analogue scale (VAS). The 
mean score was 0.67 mm for microneedles compared to that of 0.42 mm for 
the negative control (P=0.09) and 23.9 mm for the positive control (P=0.001) 
(Kaushik et al., 2001). 
The relationship between microneedle geometry and the degree of pain 
resulting from microneedle insertion has also been evaluated. An expected 
positive correlation between pain and microneedle length was demonstrated 
in a number of studies (Kaushik et al., 2001, Gill et al., 2008, Gupta et al., 
2011). As microneedle length increases, the chances of stimulating dermal 
nerve fibers lying at an approximate penetration depth of 400 µm increases. 
However, even with long microneedles, the resulting pain seems to be 
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minimal, presumably due to the small diameter of the microneedles. In a study 
using 2 mm long microneedle to extract blood for glucose monitoring, the 
insertion was described as barely noticeable by the majority of subjects 
(Smart and Subramanian, 2000). In another study, single microneedles with 
variable geometry (variable tip angles, thickness, width and lengths that 
ranged from 480–1450 µm) and arrays containing 5 or 50 microneedles were 
compared to a negative control Teflon rod and a 5 mm insertion of a 26-gauge 
hypodermic needle as a positive control in ten human subjects. Pain intensity 
was assessed using a 100mm VAS. The study showed that all microneedle 
arrays were significantly less painful than the hypodermic needle with a pain 
score varying from 5-40% of the pain from the hypodermic needle use. 
Microneedle length has the strongest effect on pain with a three-fold increase 
in length increasing pain score seven-fold. The number of microneedles also 
affects pain score but to a lesser extent, with a ten-fold increase in number of 
microneedles increasing pain score 2.5 fold (Gill et al., 2008). 
Pain and sensation were assessed in twelve human subjects in response to 
microneedle platinum-coated silicon arrays of two different lengths (180 µm 
and 280 µm microneedle) and a 25-gauge hypodermic needle. Pain intensity 
was assessed using VAS and sensory perception was determined by using 
the McGill Pain Questionnaire short form. Microneedles were perceived to be 
significantly less painful compared to hypodermic needles. Subjects described 
a pressing and heavy sensation rather than a sharp or stabbing one in 
response to microneedle application (Haq et al., 2009). 
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1.3.2.1.3. Infection 
The skin acts as the main barrier against environmental organisms and any 
breach in the skin barrier carries an infection risk. Because of the advantage 
of being minimally invasive, microneedles may be expected to be associated 
with less damage to skin barrier characteristics and therefore lower risk of 
local infection.  
The ability of three different microorganisms to traverse microneedle-induced 
holes was investigated in vitro using porcine skin and using a silicon 
membrane that mimics the stratum corneum. A 21-gauge hypodermic needle 
was used as a positive control. The study showed that microorganisms could 
traverse microchannels created following microneedle application. However, 
microbial penetration was significantly less in the microneedle created holes 
and no microorganism crossed the viable epidermis. The study also 
demonstrated that microorganisms could adhere to microneedle arrays, which 
reflects the importance of microneedle sterilization during manufacturing and 
safe disposal after use (Donnelly et al., 2009). 
Fabrication of antimicrobial microneedles has been demonstrated by the use 
of composite materials that contain biocompatible polymer and gentamicin 
(Gittard et al., 2010) or by coating microneedles with a thin film of silver 
(Gittard et al., 2009). 
Despite the lack of studies that were designed to investigate the risk of 
infection in subjects with diabetes or those who are immunocompromised, 
none of the animal or human studies investigating microneedles has reported 
microneedle-related infection. 
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1.3.2.1.4. Bleeding 
The most superficial skin microcapillaries are located in the dermis at a depth 
of approximately 400 µm from skin surface. Therefore, microneedle arrays 
resulting in penetration below 400µm can impinge on cutaneous 
microcirculation and cause bleeding. However, despite the use of longer 
microneedles, bleeding is rarely observed in human studies (Prausnitz et al., 
2009). 
In one study, tiny droplets of blood (e.g. 1 µl) were observed at the insertion 
site of 1450 µm long microneedle. Shorter needles (400 µm and 700 µm) did 
not result in bleeding (Gill et al., 2008). 
 
1.3.2.1.5. Skin recovery 
Disruption of skin barrier characteristics following microneedle application can 
be assessed by several markers including optical imaging. Since disruption of 
skin barrier results in increased epidermal water loss, measurement of 
transepidermal water loss (TEWL) can also be used as a marker of successful 
microneedle penetration of stratum corneum. Markers used to assess 
disruption of skin barrier characteristics can be also employed to assess 
recovery of those characteristics. In general, recovery of the barrier 
characteristics of the stratum corneum is rapid following its disruption (Fluhr et 
al., 2002).  
Several studies have assessed skin recovery following microneedle 
application. In 12 human subjects, TEWL increased significantly following 
insertion of microneedles of 180 µm and 280 µm length and a 25-gauge 
hypodermic needle. In each case, TEWL recovered to baseline within 24 
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hours with no significant difference between devices(Haq et al., 2009). Similar 
results were obtained in animal studies (Yan et al., 2010). 
The relationship between skin recovery and microneedle length was also 
demonstrated using TEWL measurement in human subjects. TEWL declined 
rapidly to reach baseline in 30 and 60 minutes following application of solid 
microneedle arrays of 300 µm and 400 µm length respectively (Bal et al., 
2008). 
Electrical impedance spectroscopy has been employed to analyse the 
resealing of skin barrier characteristics following microneedle insertion in 
human subjects. Stainless steel microneedles of five different geometries 
were used in the absence and presence of occlusive covering to the 
microneedle-treated areas. In the absence of occlusion, skin barrier 
characteristics recovered within 2 hours for all insertion sites regardless of 
microneedle geometry. This extended up to 40 hours in the presence of 
occlusion (Gupta et al., 2011). Optical coherence tomography (OCT) was 
used to assess microchannel closure rate. Silicon microneedle arrays of 280 
µm length were manually inserted in human subjects in the forearm and 
fingernail folds, after 85 minutes of microneedle removal the microchannel 
depth had reduced from 158+/-20 µm down to a depth of 76+/-13 µm (Enfield 
et al., 2010). 
 
1.3.2.2. Enhanced accuracy: 
Microneedle technology also provides the potential to enhance accuracy of 
electrochemical sensing of ISF glucose through different strategies. In vivo 
analysis of ISF using multiple microsensors compared to one macrosensor 
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provides a larger surface area for the enzymatic electrochemical reaction 
resulting in increased current with potential to improve accuracy of glucose 
sensing even in the hypoglycaemic range by improving the signal:noise ratio. 
This was demonstrated in an in vitro study that showed that the current 
generated from an array of solid microneedles was in the microampere 
domain (100 times larger than the current generated from gold disc electrode 
of comparable “footprint”) (Radomska-Botelho Moniz et al., 2012).  
It has been demonstrated that the simultaneous use of multiple glucose 
sensors improves accuracy and precision of continuous glucose monitoring 
(Castle et al., 2012). Partitioning a microneedle array (designed for non-
extractive in vivo measurement) into separately addressable electrodes allows 
for multiple glucose oxidase sensors, as well as providing a reference 
electrode. Other than allowing simultaneous multiple glucose sensing, this 
important feature provides redundancy for technical failure of single sensors 
as a single malfunctioning sensor can be “voted out” on the basis of divergent 
results. 
Another avenue for potential enhancement of accuracy of ISF glucose 
sensing using microneedle technology is related to the measurement of 
glucose concentration in dermal ISF rather than subcutaneous ISF. Using 
microdialysis technique to compare dermal and subcutaneous ISF glucose 
against blood glucose showed that dermal ISF glucose concentration is 
similar to that of the blood (99.1%), while subcutaneous ISF glucose 
concentration is only 50% in comparison to blood glucose. It also 
demonstrated that dermal ISF glucose has identical peak concentration to 
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blood glucose and suffers from less lag in comparison to subcutaneous ISF 
glucose (Petersen et al., 1992, Boschmann et al., 2001). 
 
1.3.2.3. Reduced biofouling and FBR: 
Sensor size and geometry are important factors that affect FBR to implanted 
biosensors with less significant FBR to smaller sensors. This was supported 
by a study that demonstrated that subcutaneous implantation of 300 µm thick 
polyurethane substrate in rats for seven weeks resulted in capsule formation 
that is 20% thinner in comparison to the one that surrounded a 2000 µm thick 
implant (Ward et al., 2002). Another study, investigating the effect of needle 
size on tissue inflammation in pigs, has demonstrated that reduction in needle 
size significantly reduced hemorrhage, fibrin exudation, cell infiltration and 
FBR (Kvist et al., 2006)  
1.3.2.4. Multi-analyte sensing: 
Partitioning of a microneedle array (designed for non-extractive in vivo 
measurement) can also permit continuous multi-analyte sensing by 
immobilisation of different enzymes across multiple sensing areas sharing a 
common reference electrode. Simultaneous continuous monitoring of lactate, 
glycerol, bicarbonate and ß-hydroxybutyrate could, in theory, be beneficial in 
daily management of type 1 diabetes. 
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1.3.3. Use of microneedle technology for glucose sensing: 
As previously discussed, glucose sensors vary with regards to degree of 
invasiveness, sensing technique and type of analysed biofluid (blood or ISF) 
(Oliver et al., 2009). 
Microneedle technology has been investigated for detection of physiologically 
relevant analytes such as glucose, lactic acid, hydrogen peroxide or 
glutamate in biological fluids (Windmiller et al., 2011a, Trzebinski et al., 2012, 
Windmiller et al., 2011b). Microneedle arrays can be employed for either 
extraction of biological fluid followed by offline analysis or as sensors for in 
situ analysis. This will impact microneedle array geometry, material and 
therefore mechanics of insertion. For example, microneedle array-based 
sensors that target ISF should be able to penetrate the stratum corneum layer 
and achieve a penetration depth of less than 400 µm to access ISF without 
impinging on cutaneous microcirculation or nerve fibers. Those targeting 
blood for analysis of its glucose content should be able to achieve penetration 
depth of 400–900 µm (Khanna et al., 2008, Moon et al., 2006). Microneedle 
arrays used for biofluid extraction will also need to have a specific design to 
allow for this.  
 
1.3.3.1. Microneedles for blood extraction: 
The concept of "e-Mosquito" blood sampling system consisting of silicon 
hollow microneedles, microactuators and microsensors has been described 
(Gattiker et al., 2005). A mechanism for biofluid extraction depending on 
volume change of a copolymerised gel caused by temperature and pH 
changes has been described. This resulted in a pressure change in a flow 
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channel connected to a hollow microneedle to withdraw fluid for analysis by a 
glucose micro-sensor. The system was not upgraded to a practical level due 
to challenges in miniaturisation and system integration (Suzuki et al., 2002, 
Suzuki et al., 2004). Another blood extraction system incorporates titanium 
hollow microneedles (1 mm long, 25 µm internal diameter and 60 µm external 
diameter), micropumping system and glucose sensor. The system has not 
been tested in vivo (Tsuchiya et al., 2005). A 2 mm microneedle blood 
extraction system operated using a microprocessor to advance the 
microneedle into the skin has been assessed with blood drawn from the 
dermal microcirculation by capillary force to fill a microcuvette containing 
glucose assay reagent allowing one-step testing without the need to transfer 
blood from skin surface to a testing machine. Challenges to the system 
include the reagent formulation, sterilisation procedure, shelf life and 
integration of an electrochemical glucose sensor into their system (Smart and 
Subramanian, 2000). 
 
1.3.3.2. Microneedles for ISF extraction: 
The use of microneedle arrays has also been demonstrated for ISF extraction. 
Single microneedles manufactured from glass (700-1500 µm in length, 15-40 
µm tip radii) were inserted and removed 10 times in a 1 cm2 area of the skin 
of 15 rats and 6 human subjects before applying a vacuum to extract ISF and 
measure glucose concentration compared to that of capillary blood. 
Penetration was confirmed by the mean of confocal microscopy and histology. 
Analysis of extracted ISF glucose showed good correlation to capillary blood 
glucose with a lag time of less than 20 minutes following an insulin injection 
77
! 78!
(Wang et al., 2005). In another study, a device containing an array of hollow 
silicon microneedles with internal diameter of 10-15 µm and length of 200-350 
µm and microfluidic channels was used for ISF extraction and subsequent 
glucose measurement from human skin (Mukerjee et al., 2004). The 
complexity in obtaining the ISF sample, extraction time, erythema at the 
treated skin site, biocompatibility of glass or silicon and possibility of tip 
clogging when using hollow microneedles represent challenges to clinical use 
of these extraction systems.  
A novel microneedle based system for ISF extraction has been demonstrated 
in vivo for measurement of glucose area under the curve (AUC) 2 hours 
following a glucose load. Two hydrogel patches were applied for 2 hours to 
microneedle-treated skin area to extract ISF. The hydrogel was then placed in 
water overnight for glucose extraction. The study showed a good correlation 
between ISF and plasma glucose AUC. The complex procedure of ISF 
collection and glucose measurement represent a challenge for this system to 
be used clinically. Moreover, glucose AUC has not been widely used as an 
index for hyperglycaemia and does not replace the need for glucose 
monitoring (Sakaguchi et al., 2012). 
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Figure 1.7:Scanning electron microscopy image showing a 500 µm high 
microneedle array. “Reprinted from El-Laboudi et al., Use of microneedle array 
devices for continuous glucose monitoring: a review. Diabetes(Technol(Ther.(2013 
Jan;15(1):101-15. Copyright (2013), with permission from Mary Ann Liebert, Inc” 
1.3.3.3. Microneedles for CGM: 
To employ microneedle array technology for continuous monitoring of biofluid 
analytes including CGM, microneedles need to be incorporated in a system 
that extracts ISF continuously for subsequent in vitro analysis or to be 
modified for use as sensors for non-extractive in situ analysis. 
Microdialysis techniques used for CGM involves the use of a semipermeable 
microdialysis membrane inserted into the subcutaneous tissue, allowing 
diffusion of glucose from ISF into a dialysate that is collected for glucose 
analysis.  The use of microdialysis-based microneedles for CGM has been 
reported (Zahn et al., 2005, Zimmermann et al., 2003). In one study, the 
microdialysis system consisted of an array of eight 200 µm hollow silicon 
microneedles, an integrated porous poly-silicon dialysis membrane and an 
integrated GOx-based flow-through glucose sensor. Following penetration of 
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stratum corneum, the microneedles fill with ISF by capillary force. Glucose 
diffuses through the integrated dialysis membrane into a dialysate that is 
pumped past the integrated glucose sensor for glucose measurement. The 
system recalibrates automatically through periodic pumping of reference 
glucose solution past the sensor avoiding the need for finger-prick testing. 
The estimated sensor operation time was 72 hours with an instrumental lag of 
only 2 minutes. However, device assessment showed capillary forces are not 
sufficient to maintain a constant flow of ISF past the sensor (Zimmermann et 
al., 2003). 
Several in vitro studies into the use of microneedle-based sensors for sensing 
of ISF analytes in situ have been recently published. In one study, the use of 
microneedle array-based carbon paste amperometric sensors was 
demonstrated for simultaneous detection of pH, glucose and lactate. An 
acrylate-based polymer hollow microneedle array was aligned with wells 
placed on a flexible flat cable. Each well had been filled with carbon paste 
material that was tailored to detect pH, glucose or lactate. The microneedle 
sensors were able to selectively detect changes in any of those analytes 
when tested in complex solutions and showed suitable performance when 
tested over physiologically relevant concentration range for each analyte 
(Miller et al., 2012). Our group has also demonstrated the performance of our 
microneedle array based glucose and lactate biosensors in vitro. Using 
covalent coupling chemistry, solid microneedle arrays were modified with 
glucose oxidase or lactate oxidase. An epoxy-polyurethane based membrane 
was used to extend the linear working range of the biosensors. Glucose 
biosensors performance was optimum over glucose concentrations ranging 
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from 0-25 mmol/L and was consistent for over 48 hours. The study has 
highlighted the potential to improve sensor accuracy by demonstrating that a 
glucose-dependent signal over one hundred times that of commercially 
available CGM, even in the hypoglycaemic range. This in turn improves 
signal:noise ratio and therefore sensor accuracy (Radomska-Botelho Moniz et 
al., 2012). Safety and performance (including accuracy, precision and life 
span) of these systems are yet to be demonstrated in vivo in human studies, 
which is an objective of this project.  
Recently, in vivo assessment of a microneedle-based CGM system was 
described (Jina et al., 2014). The system consists of an array of 200 hollow 
microneedles that, upon application to skin surface and penetration of stratum 
corneum, allows passive diffusion of ISF to a glucose collection chamber. 
Glucose level is measured using an external amperometric first generation 
glucose sensor. The clinical study involved 10 subjects with diabetes wearing 
four devices simultaneously for 48 - 72 hours. Comparison of the system’s 
performance and calibration were made using capillary blood glucose 
measured using FreeStyle blood glucose meter (Abbott Diabetes Care, 
Alameda, CA, USA). The microneedle CGM systems were calibrated using a 
reference blood glucose value after an initial 2-hour warm-up period and then 
once daily with a morning finger-stick glucose value. The authors concluded 
that the device is accurate with MARD of 15% and 98.4% of paired points in 
the A+B region of the Clarke error grid. However, comparative capillary blood 
glucose testing (done every 20 minutes) was only done when subjects 
reported to the study site. Graphs published in the paper demonstrate that 
microneedle CGM glucose measurements reached as high as 33.3 mmol/L 
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(600 mg/dL) without having a comparative capillary blood glucose 
measurement at the time. Lag time was estimated as 17 minutes and minimal 
skin reaction that resolved completely without treatment in several days was 
reported. 
1.4.   RESEARCH MOTIVATION: 
The growing evidence from CGM studies correlating compliance with 
frequency of device use and effectiveness has highlighted the need for a 
painless, non-invasive (or minimally invasive), accurate continuous glucose 
monitor. This is particularly important in view of recent advances in diabetes 
technology, including the use of sensor-augmented pump therapy and rapid 
progress in closed-loop research.  
The use of microneedles as biosensors for continuous glucose monitoring 
shows great potential, overcoming a number of disadvantages related to the 
currently available sensors. The minimally invasive nature of the technology 
allows for pain-free continuous monitoring with minimal tissue trauma and 
inflammation, and allows for rapid skin recovery. By providing a large surface 
area for the enzymatic electrochemical reaction and measuring dermal (rather 
than subcutaneous) ISF glucose, functionalised microneedles provide the 
potential to improve the accuracy of glucose sensing, even in the 
hypoglycaemic range. It is also possible to partition microneedle arrays, that 
are designed for non-extractive sensing, into multiple subarrays to sense 
glucose simultaneously or providing a multiple analyte platform. The use of 
multiple simultaneous glucose sensors improves accuracy and precision of 
glucose monitoring (Castle et al., 2012). Advances in microfabrication allow 
mass production of microneedles at low cost with economies of scale. This is 
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particularly important as the high cost of clinically available CGM devices may 
represent one of the important limitations in approved clinical uses (Burge et 
al., 2008). 
To be considered for clinical use, electrochemical glucose biosensors need to 
fulfill several requirements including specificity, accuracy, wide linear range, 
sensitivity, rapid response, resistance to interferents, biocompatibility and 
stability. Therefore design and optimisation of an electrochemical glucose 
biosensor requires careful choice of working electrode material, enzyme load 
and its immobilisation method, electron acceptor, type and thickness of the 
coating membrane and the operating potential. Despite the large efforts 
invested by various academic teams and the industry in the field of 
electrochemical continuous glucose sensors, there are several technical 
challenges and important barriers facing this technology.  
The growing interest in microneedle-array technology for continuous analyte 
sensing is promising. However, further work is required before microneedle-
based sensors are embedded in clinical practice. Despite the description of 
several microneedle-based glucose monitoring systems in the literature, only 
few systems have managed to reach human studies (El-Laboudi et al., 2012). 
Apart from general technical challenges facing electrochemical glucose 
sensors, microneedle-based electrochemical glucose sensors also face the 
challenges of miniaturisation, system integration and lifespan extension.  
This research aims to complete the work that started in Cass’s group on 
microprobe array sensors (Trzebinski et al., 2012, Radomska-Botelho Moniz 
et al., 2012) and move it from bench side to bedside through optimisation, 
pre-clinical characterisation and clinical assessment of the novel microprobe 
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array continuous glucose sensor. In this work, we have optimised sensor 
design for clinical use from mechanical and functional aspects. At an early 
stage of this project, we have established a patient and public involvement 
group to help in identifying users’ requirements with regards to the device’s 
design and functionality and in gauging the problems that patients feel affect 
them day-to-day. We have also designed a questionnaire aimed at people 
with diabetes to find out their views on different aspects of existing diabetes 
technology and how it can help them in diabetes management.  
 To describe our solid microneedle array that are designed for non-extractive 
in vivo measurement of dermal ISF glucose, we have adopted the term 
“microprobes” to distinguish it from hollow microneedles that are usually 
employed for ISF extraction for in vitro glucose measurement. We have 
characterised the device mechanically by assessing the force required to 
penetrate the stratum corneum skin barrier and the force required to fracture 
microprobes in the axial and transverse planes. This is to ensure that 
microprobes are capable of reaching the dermal skin compartment to perform 
its intended function in measuring ISF glucose and to ensure that the risk of 
microprobes failing mechanically as they are penetrating skin layers is 
minimum. The work also includes electrochemical validation of the sensor in 
vitro and ex vivo and data on eight subjects from the first phase of the clinical 
study to assess safety of the device in healthy volunteers. Finally, we present 
retrospective analysis of the JDRF CGM randomised controlled study dataset 
to evaluate different measures of glycaemic variability in subjects with type 1 
diabetes and the effect of RT-CGM on these measures. 
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CHAPTER 2 
CONTINUOUS GLUCOSE MONITORING: 
PATIENTS’ PERSPECTIVE 
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2.1.    INTRODUCTION: 
Despite the extensive research in the field of diabetes technology, research 
conducted to capture the views of the eventual end-users (patients or 
caregivers) is relatively limited. In recent years, there has been increasing 
awareness of the importance of patient and public involvement (PPI) in 
healthcare and healthcare research. In the UK, PPI is a core component in 
transforming health services towards patient-centered, collaborative and 
individualised care (NICE, 2012). Similarly, academic researchers, funding 
bodies and the pharmaceutical industry now consider PPI as an essential part 
of clinical research for the several benefits it brings throughout the different 
stages of the research process (Staley, 2009). By providing a different 
perspective to that of the researchers, a patient and public perspective offers 
a unique and invaluable insight that can help to correctly set research 
priorities, enhance research strategy and improve research outcome. It also 
helps in reaching potential subjects for recruitment and in dissemination and 
implementation of research findings. In diabetes technology research, active 
involvement of patients at an early stage of the research can correctly identify 
users! priorities and reveal potential limitations of the technology from users!
perspectives. This will help to ensure that the end product is more acceptable 
to patients. 
2.2.    AIM: 
This chapter describes the work conducted to capture patients' and public 
views and concerns in relation to continuous glucose monitoring (CGM) and 
the use of microprobe technology in CGM. It also describes PPI in our project 
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to develop a novel continuous glucose monitoring system based on 
microprobe technology.!
2.3.    METHOD: 
2.3.1. Microprobe Glucose Sensor focus group: 
A partnership was created with the North West London Diabetes Clinical 
Research Network. A focus group of people with type 1 diabetes, their family 
members or caregivers, was convened at Imperial College London. As a 
moderator, I briefly presented: a) advantages and challenges facing existing 
CGM technology; and b) described microprobe technology and the potential 
advantage of using microprobe arrays to access interstitial fluid compartment 
in a less invasive manner, compared to existing needle-type sensors. Images 
were shown to participants, to illustrate microprobe arrays and show the 
difference between microprobes and needle-type sensors.  Also, a prototype 
of the microprobe glucose sensor (36 microprobes in 6x6 rows) was passed 
around the group.  Discussions were transcribed and open-ended questions 
were used to facilitate the 2 hours session.  The aim of the focus group was to 
capture patients' and public views on CGM technology and the potential 
benefits or concerns related to the use of microprobe technology in CGM. We 
also aimed to invite interested participants to establish the Microprobe 
Continuous Glucose Monitoring PPI Advisory Group! to present patients' and 
public perspectives throughout the different stages of the research project. 
2.3.2. Diabetes Technology Questionnaire: 
With help from the PPI group, an online questionnaire was designed to 
explore views and concerns of people with type 1 diabetes regarding diabetes 
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technology. The questionnaire covered the two main areas in diabetes 
technology: glucose monitoring (intermittent and continuous) and Insulin 
delivery (using insulin pens and subcutaneous insulin pump). It also 
addressed sensor augment pump therapy. Each area of diabetes technology 
was assessed using ranking questions (quantitative) related to potential 
advantages, potential challenges and features that should be added to make 
the technology more acceptable for patients. As subjects were allowed to 
choose more than one answer as the top priority, some of the results can add 
up to more than 100%. At the end of each section and at the end of the whole 
questionnaire, participants were asked an open-ended question to elaborate 
on their views and the reasons behind these views and their answers to the 
ranking questions. The questionnaire was designed using Google Forms and 
was distributed electronically, using social media and emails, by members of 
the PPI group, North West London Diabetes Clinical Research Network and 
Imperial Clinical Research Facility.  
Questionnaire analysis of CGM data is presented in this chapter. Quantitative 
data were analysed using the Excel software (Microsoft Office Excel 2011 for 
Mac) and SPSS 21.0 for Mac (SPSS Inc., Chicago, IL). Qualitative data were 
analysed according to the principles of thematic analysis using Atlas.ti 
software (ATLAS.ti Scientific Software Development GmbH, London, UK) 
(Kitzinger, 1995, Pope et al., 2000). 
2.4.   RESULTS: 
2.4.1 Focus Group: 
The group consisted of 9 participants; 4 females and 5 males with an age 
range of 23 – 70 years. The group comprised 7 participants with type 1 
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diabetes and 2 family members. 3 participants were current users of insulin 
pump therapy and 1 participant was a current user of a continuous glucose 
monitor as part of sensor augment pump therapy.  
We identified the following themes: 
1-Advantages of CGM technology: 
The group members identified benefits related to CGM use. Continuous 
knowledge of glucose fluctuations and how glucose levels are impacted by 
daily activities (e.g. diet and exercise), improvement in glycaemic control, 
“peace of mind” and the possibility of reducing the frequency of finger prick 
testing were all cited as advantages for using RT-CGM. 
• “I would like to know constantly what my BG [blood glucose] is to help 
maintain control” 
• “….Finger prick testing only lets me know what my BG [blood glucose] 
is for a segment of time….” 
• “…I am tired of pricking my fingers so anything that helps me avoid 
finger prick testing would be good….” 
2- Limitations to CGM use: 
Cost was identified as the main reason for preventing CGM being widely 
available through the NHS.  
• “ ….The cost of these devices needs to come down significantly before 
they can be funded by the NHS.” 
The need to carry the device was also recognised as a limitation to 
continuous CGM use 
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• “My only concern would be that it would constantly be in me.” 
One participant, who was a current user of a CGM system, highlighted the 
issue of lack of CGM accuracy and reliability.!
• “…The problem is that it [CGM] doesn’t recognise whether I am high or 
low ….” 
Important features for further development of CGM systems that participants 
identified, were related to; sensor life span, pain related to sensor application, 
data transmission, display and accessibility by healthcare professionals: !
• “What size would the screen be?  Where would you look for a 
reading?” 
• “I would prefer to have the reading transmitted to my mobile phone.  I’d 
also like my consultant to be able to access the data online.” 
•  “What is the range of readings on the device?” 
•  “If it is not painful then I don’t mind changing it every day.” 
• “Will it be affected by extremes in temperature?” 
•  “Will it be waterproof?” 
3- The potential advantages for the use of microprobe arrays in continuous 
glucose monitoring were identified from comments raised by the participants. 
These were mainly related to the small size and painless application. 
•  “Sounds excellent....I like the idea of it being small and not too 
invasive”   
•  “The new sensor sounds to be small enough not to be noticeable or a 
hindrance”  
• “Brilliant idea....very useful for needle phobics” 
•  “The size is so much better – I would be able to take up rugby again” 
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4- Potential limitations to microprobe technology in CGM: 
However, participants also raised a number of concerns related to microprobe 
arrays. These were related to cost, life span and the method of sensor 
application.  
•  “It’s a lovely idea but I hope it is not too expensive.” 
• “How would you ensure that the company that will eventually buy this 
technology, if your research proofs [proves] it works, won’t market it at 
a very high price similar to current continuous glucose monitors?” 
• “What is the lifespan of the patch?  How often would you need to 
replace it?” 
• “How would you apply the patch?  Would you need a device to put it 
on?” 
Interestingly, all group members expressed the importance of designing an 
appropriate applicator for microprobe insertion. Since microprobe application 
is likely to be painless, the user will have no indication to know that the 
microprobes have been applied correctly. This might prompt some users to 
unnecessarily continue applying large force on the device, if applied manually, 
which can carry higher risk of microprobes fracture. 
2.4.2 Microprobe Glucose Sensor PPI Advisory group: 
Following the focus group meeting, an advisory group was established with 
membership of 8 participants (6 participants with type 1 diabetes and 2 family 
members of people with type 1 diabetes). Communication between group 
members and the research group was through email communication and 
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regular meetings (2-3 annually). The group participated in the development of 
research protocols and participant information leaflets for the clinical study, to 
evaluate safety and performance of a microprobe array continuous glucose 
sensor. They also participated in reviewing and editing grant applications. 
Furthermore, the group also helped in design and dissemination of the 
diabetes technology questionnaire. This active partnership between the 
research team and the patient and public group that was established at an 
early stage of research had many positive impacts. Other than improving the 
research design, protocol and clarifying participant information material, it was 
also positively viewed by funding bodies and proved pertinent in the success 
of obtaining a grant from the National institute for Health Research (NIHR) – 
Invention for Innovation (i4i) programme.  
PPI also had a clear impact on participants. It resulted in the promotion of a 
well-informed and motivated group who developed a sense of ownership of 
the project and gained new skills in diabetes management. An example was a 
participant who found her participation in the PPI advisory group as a 
motivation to explore diabetes technology. She was suffering from frequent 
hypoglycaemia and impaired awareness, and therefore qualified for NHS 
funding for an insulin pump and she self-funded a Dexcom CGM system. She 
has also become actively involved in diabetes technology and education in 
her local community and through different online forums. For the research 
team, the interaction with the group members was useful in understanding 
patients’ priorities in diabetes management.  
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2.4.3 Diabetes Technology Questionnaire: 
Participation in the online questionnaire was open for a period of 8 weeks to 
people with diabetes or their caregivers, regardless of diabetes type or 
geographical location. Social media was a very useful tool in disseminating 
the questionnaire to potential participants. Figure 1 demonstrates the 
interaction of potential subjects to reminders sent through social media by one 
of the members of the microprobe glucose sensor advisory PPI group who 
helped in dissemination of the questionnaire. 
 
 
Figure 2.1: The number of daily responses to the survey and the effect of the 
use of social media on increasing response rate (arrows represent points of 
interaction with the social media to invite potential participants to take part in 
the questionnaire). 
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geographical location. Social media was a very useful tool in disseminating 
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Figure 2.1: The number of daily responses to the survey and the effect of the 
use of social media on increasing  rate. 
2.4.3.1 Participants’ charact ristics:  
A total of 214 responses were received. As shown in tables 1 and 2, the 
majority of responses were from patients or caregivers of people with type 1 
diabetes (92.5%), living in the UK (74.8%), treated with insulin pump therapy 
(69.6%) and either current or previous CGM users (57%). 
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2.4.3.1 Participants’ characteristics:  
A total of 214 responses were received. As shown in tables 1 and 2, the 
majority of responses were from patients or caregivers of people with type 1 
diabetes (92.5%), living in the UK (74.8%), treated with insulin pump therapy 
(69.6%) and either current or previous CGM users (57%). 
 
Table 2.1: Characteristics of the 214 respondents to the diabetes technology 
questionnaire (divided according to age group). 
 
Adults ChildrenNumber 178*(83%) 36*(17%)CGM*use 93*(52%) 29*(80%)Current*CGM*user 53*(30%) 22*(61%)Previous*CGM*user 40*(22%) 7*(19%)CSII*treatment 117*(65%) 32*(89%)SAP*treatment 46*(26%) 21*(58%)Gender*(females) 126*(71%) 20*(56%)*Age*Groups*(%*of*total*participants) 16I25*years:*****9% 0I5*years*:***********1%26I40*years:***27% 6I15*years*:*******16%41I65*years:***42%>65*years:********5%Location UK 140*(79%) 20*(56%)North*America 29*(16%) 14*(39%)rest*of*Europe 2*(1%) 2*(6%)Other 7*(4%) IType*of*diabetesType*1 162*(93%) 36*(100%)Type*2 10*(6%) IOther 2*(1%) IDuration*of*diabetes<1*year 5*(3%) 3*(8%)1I5*years 23(13%) 21*(58%)6I10*years 18*(10%) 9*(25%)>10*years 132*(74%) 3*(8%)SMBG*frequency1I5*times/week 10*(6%) I2I4*times*per*day 42*(24%) 4*(11%)>5*times*per*day 125*(70%) 32*(89%)
95
! 96!
 
Table 2.2: Characteristics of the 214 respondents to the diabetes technology 
questionnaire (divided according to age group and CGM use). 
The ability to monitor fluctuations and trends in glucose levels, in response to 
various daily activities, was cited as the indication for CGM use by 50% of 
respondents. Other indications included: improving glycaemic control (32%), 
prevention of hypoglycaemia (25%), monitoring glycaemic fluctuations 
overnight (21%), hypoglycaemic unawareness (16%), reassurance (11%), 
flexible lifestyle (mainly around exercise and children’s activities) (10%). In 2 
subjects “the need to avoid frequent finger pricking” was reported as the 
indication for CGM use.  
CGM$$users No$CGM$use CGM$users No$CGM$use
Number 93 85 29 7
CGM$useCurrent-user 53-(57%) 2 22-(76%) 2Ex2user 40-(43%) 2 7-(24%) 2
CSII$treatment 76-(82%) 41-(48%) 28-(97%) 5-(71%)
SAP$treatment 46-(50%) 2 21-(72%) 2
Gender Female 65-(70%) 61-(72%) 15-(52%) 5-(71%)Male 28-(30%) 24-(28%) 14-(48%) 2-(29%)
Age$Group 025 2 2 2-(7%) 06210-years 2 2 25-(86%) 7-(100%)Over-15-years-old 2 2 2-(7%) 016225 9-(10%) 10-(12%) 2 226240 34-(37%) 25-(30%) 2 241265 48-(52%) 42-(49%) 2 2over-65 2-(2%) 8-(9%) 2 2
Location UK 62-(67%) 79-(93%) 14-(48%) 6-(86%)North-America 27-(29%) 2-(2%) 13-(45%) 1-(14%)Others 4-(4%) 4-(5%) 2-(7%) 0
Diabetes$typeType-1-diabetes 93-(100%) 73-(86%) 29-(100%) 7-(100%)Type-2-diabetes 0 10-(12%) 0 0Others 0 2-(2%) 0 0
Diabetes$Durationless-than-1-year 1-(1%) 4-(5%) 1-(3%) 2-(29%)125-years 9-(10%) 14-(16%) 17-(59%) 4-(57%)6210-years 6-(6%) 12-(14%) 8-(28%) 1-(14%)more-than-10-years 77-(83%) 55-(65%) 3-(10%) 0
SMBG$frequencymore-than-5-times-daily 69-(74%) 56-(67%) 25-(86%) 7-(100%)2-2-4-times-per-day 21-(23%) 21-(25%) 4-(14%) 01-2-5-times-per-week 3-(3%) 7-(8%) 0 0Never 2 1-(1%) 2 2
Adults Children
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When asked to rank potential advantages obtained from CGM use, the two 
groups ranked the ability to monitor glucose fluctuations and detects trends as 
the most important advantage for CGM use. The value of CGM in improving 
metabolic control was less important compared to the ability to gather 
information about glucose fluctuations when unable to test CBG (e.g. night 
time) in the adult group. Similarly, it was less important compared to 
prevention of hypoglycaemic events in the children group (table 2.3). 
 
Table 2.3: Advantage of CGM as viewed by respondents. 
 
With regards to limitations to CGM use, the majority of adult patients with 
current or previous experience in CGM (64%) ranked cost as the top 
challenge facing CGM technology. This was followed by lack of accuracy 
(21%). The order was reversed for the children group, where CGM inaccuracy 
was ranked as the most important challenge (43%) followed by cost (28%). As 
expected, pain related to the use of CGM was more important for the children 
n % n %
Provides info on glucose fluctuation 119 67 26 72
Provides info at time when unable to check 109 61 22 61
Helps in improving control 107 60 22 61
Helps in avoiding hypos 91 51 25 69
Reassurance by alarm function 87 49 21 58
Helps with hypo awareness 79 44 19 53
Flexibility with daily activity 70 39 18 50
Reduces the need for repeated SMBG 61 34 14 39
Helps in modifying behavior around food 55 31 13 36
Response
Adults Children
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group (ranked the forth) compared to the adult group (ranked the 13th). 10% of 
participants in the children group considered pain as the biggest challenge 
facing the use of CGM. 
Out of respondents with current or previous experience in CGM use, 89% had 
positive views about CGM technology. Only 4 subjects (3 adults and one 
child) stated that they would not use CGM in the future. Lack of accuracy was 
cited by the three adult respondents, while the child cited pain as the reason. 
Other reasons were the bulky size of current CGM devices (in comparison to 
insulin pumps), false alarms, discomfort and lag time. 
 
Figure 2.2: Limitations to the use of continuous glucose monitoring 
technology from participants’ perspectives. 
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Table 2.4: limitations to continuous glucose monitoring use. 
 
Consistent with responses to limitations of current CGM technology, the 
majority of adult respondents ranked improved accuracy and affordability as 
the most important features for future development of CGM technology and to 
improve its acceptance. Longer sensor life, which could have an impact on 
the overall cost of CGM and also minimises the frequency of exposure to pain 
related to sensor insertion, was ranked third for both groups. 
The majority of respondents (96% of adults and 94% of children) expressed a 
preference for RT-CGM compared to blinded CGM. Similarly, 73% of adults 
and 81% of children preferred the use of continuous CGM compared to 
intermittent CGM use.  
n % n %
Cost 57 64 8 28
Inaccuracy 19 21 12 43
Lag.time 18 20 4 14
Need.for.calibration 13 14 2 7
Another.electronic.device.to.manage 9 10 3 10
Disturbance.by.alarms 8 7.5 2 7
Access.to.training.&.support 8 7.5 2 7
Interference.with.daily.activity 7 6.5 1 3.5
Visible 7 6.5 2 7
Too.much.data 6 5.4 2 7
Difficult.to.use 5 4.3 1 3.5
Increasing.anxiety 5 4.3 2 7
Pain 3 3 3 10
Response
Adults Children
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Table 2.5: important features for development of CGM technology. 
 
Almost 80% of respondents expressed positive views to CGM use. However, 
3% felt negative about CGM: 
• “Found it inaccurate and too stressful” 
• “I didn't like having to insert and wear another thing on my abdomen 
and having to change it so frequently “ 
• “Thought it would aid in meter accuracy and cut back on testing “ 
Analysing respondents’ narratives (169 responses) identified several themes 
and subthemes (table 2.6). To enhance the reader’s understanding of each 
subtheme, some quotations were selected based on clarity. 
1- Limitations to CGM use: 
a. Cost: 32.5% of respondents identified cost as the main barrier to 
the use or continuous use of CGM.  87% of those who 
mentioned cost as a barrier to CGM use were from the UK. One 
participant stated:  
n % n %
Improved)accuracy 144 81 32 89
affordable 107 60 19 53
Longer)sensor)life 94 53 20 56
Alarm)function 84 47 23 64
Easy)data)interpretation 81 46 15 42
Readability)of)the)screen 75 42 15 42
Water<resistance 74 42 20 56
User<friendly)PC)software 63 35 15 42
Ability)to)suspend)insulin)delivery))(SAP) 55 31 14 39
Discrete 52 29 11 31
Painless 47 26 12 33
Ability)to)integrate)with)mobile)phones 35 20 14 39
Response
Adults Children
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• “….CGM needs to be funded by the NHS. I now eat once a 
day or sometimes every other day so I can afford the 
sensors”.  
 
A. Limitations to CGM use: 
1 Cost 
2 Accuracy and reliability including impact of lag time and the importance 
of proper calibration 
3 Pain/discomfort 
4 Education and support by healthcare professionals 
5 Others: 
 Adhesion problems 
 Sensor life 
 More devices to carry around 
 Data interpretation 
B. Benefits of CGM 
1 Ability to see fluctuations and trends in glycaemia  
2 Metabolic control 
3 Quality of life and the value of CGM in empowering and motivating 
patients 
4 Hypoglycaemia 
C. Features for future development of CGM 
1 Improved accuracy 
2 Integration with insulin pumps 
3 Integration with smartphones and remote monitoring 
4 User-friendly and compatible PC software 
5 Waterproof CGM 
6 Smaller size 
7 Improved look and display. 
 
Table 2.6: themes and subthemes of participants’ responses 
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b. Accuracy and reliability of CGM. The issue of sensor accuracy 
was highlighted by 20% of participants. In the majority of cases, 
poor accuracy resulting in increased frequency of false alarms 
was considered as a barrier to CGM system’s use and an 
important area for future development of CGM technology, as 
highlighted in this response:  
• “……I have totally disabled the Low suspend feature on my 
pump because of lack of accuracy. Particular problems with 
pump thinking I am hypo overnight when I am in target (e.g. 
5 [mmol/L] but pump thinks I am 4[mmol/L]) - sometimes this 
leads me to turn off alarms overnight in order to avoid 
continued alarms disturbing sleep - but this kind of defeats 
point of CGM!” 
However, four responses have highlighted difference of 
accuracy between different sensors: 
• “My daughter loves it when it is accurate, but is easily 
frustrated when it is out of sync. She knows they are 
expensive and doesn’t feel they are accurate enough for her – 
she is using medtronic/enlites. I would like to try Dexcom now 
because they seem to be more accurate and last longer. The 
accuracy is the biggest thing that is stopping us using the 
enlite, cost of restarting on dexcom is stopping us going that 
route. When she was using sensors full time her HBA1c was 
around 6.5 [%], Now it is creeping to 6.9 [%] and will be higher 
still next time, She is 11.” 
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c. Pain: pain or discomfort related to sensor insertion was 
highlighted by 2 adults and 3 children: 
•  “I want insertion to be less painful and less damaging to skin 
- ideally entirely non-invasive - so that we do not have tears 
at bedtime every third day” 
• “My daughter found CGM painful to wear and due to this will 
not wear one again”. 
d. Few respondents highlighted issues related to lack of education 
and support from healthcare professionals: 
• ”New users should ALWAYS get support in first weeks of use 
(should be mandatory) and on going education to ensure it's 
being used effectively. Seen far to many users online who 
don't understand even basic principles…..”. 
 
2- Benefits of CGM: 
a. Glycaemic control was mentioned by 15%. This was almost 
always linking the use of CGM to good control. However, few 
respondents added that good control was not adequate and the 
technology needs to develop further to reduce disease burden. 
• “ I want a safe, effective technology that will fit in with life 
while ensuring good control”. 
b. Improved quality of life (QoL) and reducing disease burden was 
mentioned by 21% of respondents as the most important benefit 
for CGM use. Improved QoL resulted from effect of CGM on 
providing “peace of mind”, reassurance and sense of safety 
103
! 104!
related to help in detection and prevention of hypoglycaemia 
and flexible lifestyle related to diet and exercise. Words like 
“love” and “importance” of CGM was mentioned by 22% of the 
respondents: 
• “In my opinion CGMs are an essential tool for managing 
diabetes. Even more important than a pump. Once you have 
become used to monitoring blood glucose in real time it is 
very difficult to go back to finger stick tests alone. Rather like 
driving a car with no speedo or fuel gauge….” 
• “….we have both an insulin pump (Animas Ping) and a CGM.  
As parents of a young (9 yr old) active boy, we would give up 
the pump before the CGM.  The CGM gives him the ability to 
be a child, to play, to do sports and to 'forget' about diabetes 
for even a short while.  We don't need to be constantly 
bugging him, we have the information at our fingertips...”  
Nevertheless, few responses reflected the frustration that can result 
from CGM use and how it can negatively impact QoL and increase 
stress: 
• “I find the CGM isn't super accurate. I calibrated it but found 
that the CGM was telling me I was hypo and I was actually 
high when I checked on my glucometer. This was quite 
alarming and frustrating….”. 
• “The alarms drove me mad - I ripped out CGM in middle of 
night due to waking me repeatedly w/false highs or lows-not 
acceptable! It was like having a baby crying and waking you 
104
! 105!
up off & on at night- didn't work well enough for me to want 
this on 24/7.” 
Further developments were suggested by some participants to 
further reduce disease burden …….“I need a system that takes all 
the maths from my diabetes control”. 
c. The value of CGM in visualising glycaemic fluctuations, trends, 
showing effect of life activities on glycaemia and guiding insulin 
adjustments was important for 12%: 
• “I thank the big guy upstairs for the CGMS daily.  It's a no 
brainer IMO [in my opinion] that every diabetic should have 
one.  Finger pokes are like driving in the dark and turning 
your lights on every 10 miles, the CGMS is having the lights 
on always.  With children it's a must!” 
d. Prevention and reducing risk of hypoglycaemia especially at 
nighttime was reported by 8% of respondents: 
• “CGM would give my family peace of mind as well as myself.  
I do tend to run low in my sleep and an alarm would give my 
husband peace of mind as he checks I'm ok during the 
night.” 
 
3- Requirements for future development of CGM: 
a. 25% of respondents wanted CGM to be integrated with insulin 
pumps. Other than providing the advantage of carrying less 
devices, interaction between the CGM and pump to allow low 
glucose suspend was also highlighted: 
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• I am very angry that open loop and closed loop integration is 
not already available for my Animas Vibe plus Dexcom G4. It 
is insulting and patronising and a wasted opportunity 
because the technical capability is there.  I am really angry 
about this. The pump has a Chinese wall [firewall] to pretend 
it doesn't know the CGM readings. I have to enter them 
manually, I don't even get prompted with the sensor 
values….”. 
• “…At work, I have to carry a cell phone, and an oxygen 
monitor in my pocket, and with a pump and CGM besides, 
my hips look three miles wide!” 
b. 12% of responses addressed the issue of smartphone 
integration and ability for remote monitoring. 
• “Better integration between multiple devices and 
compatibility with Macintosh computers, or even smartphone 
apps is important”.  
However, potential challenges to the use of smartphone, as an 
alternative to a dedicated CGM display unit, was highlighted by 
some respondents:  
• “Please don't make mobile phones the default receiving 
device.  This would mean students taking exams could not 
wear their CGM (unable to have mobile phone in exam hall).  
There is also a greater risk of a phone being lost/stolen than 
another receiving device. Data integrated on the pump 
screen (for insulin pump users) is by far the best option”. 
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• “If parents or other nominated carer could remotely view the 
pump and sensor screen it would be hugely helpful both in 
terms of peace of mind and allowing more independence for 
my son. Ideally the system would involve text alerts to 
parents/carers of impending lows/highs and if a GPS location 
were incorporated I would be much less worried about my 
son being out on his own as I could remotely view glucose 
trends to flag up potential problems and be able to locate him 
quickly in an emergency”. 
c. Alarms were mentioned by 8%. This included the need for 
louder alarms, ability to customise alarms and false alarm: 
• “ability to personalise alarms, cycle different alarms as after 
a while brain gets used to alarms and you don't hear them 
as they become familiar background noise. Different alarms 
for different things, really annoying if driving and alarm goes, 
is it hypo alarm or too high alarm. One needs dealing with 
more urgently than the other”. 
d. Other important themes included: the need for smaller CGM 
devices; the need for waterproof CGM devices; the need for 
better looking CGM devices; the need for sensors with longer 
life; and the importance of user-friendly compatible PC software. 
 
2.5.   DISCUSSION: 
There is a gap between our knowledge of the potential benefits of CGM 
technology, and the implementation of this technology in the general 
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management of people with diabetes. Identifying the reason(s) for this gap is 
particularly important, since research evidence has linked CGM effectiveness 
to compliance with the frequency of its use (Tamborlane et al., 2008, Pickup 
et al., 2011). Moreover, evidence from RCTs showed that CGM use was not 
associated with improved QoL (Langendam et al., 2012, Hommel et al., 
2014). Capturing patients’ views will not only help to identify limitations related 
to diabetes technology, but could also help assessing the psychological 
aspects of the technology and help to improve patient selection and training in 
the use of this technology. This in turn could lead to improvement in patient 
satisfaction, QoL, compliance and glycaemic control. For CGM technology, 
which is the focus of this project, cost has always been cited as the major 
culprit for this gap. However, data from the T1D exchange demonstrate that, 
despite reimbursement, CGM technology is being used by only 6.5% of 
people with type 1 diabetes in the United States and that among individuals 
who have used CGM, up to two-thirds stopped using it (Miller et al., 2013b). 
The high drop out rate among subjects recruited to blinded, as well as real-
time, CGM clinical studies suggest that reduced accuracy and reliability of 
existing CGM systems might not be the only reason for reduced tolerability to 
CGM (Hermanides et al., 2011).  
By capturing the views of patients, qualitative research and PPI can provide 
invaluable insights to researchers prior to conducting quantitative research 
and helps to improve users’ acceptability of the end product (Kitzinger, 1995).  
In the field of diabetes research, the value of PPI in setting research priorities 
was highlighted through setting up a partnership of patients, carers, health 
professionals and diabetes organisations to develop a top 10 list of priorities 
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in type 1 diabetes research.  The James Lind Alliance Type 1 Diabetes 
Priority Setting Partnership (including Juvenile Diabetes Research 
Foundation, Insulin Dependent Diabetes Trust, Diabetes Research Network, 
Diabetes UK, Scottish Diabetes Research Network, UK Database of 
Uncertainties in the Effects of Treatments and NHS Evidence - Diabetes) has 
identified that the ability to constantly and accurately monitor blood glucose 
levels, in people with type 1 diabetes, with a discrete device represents the 
top research priority for both patients and clinicians (Gadsby et al., 2012). 
Aiming to identify the reasons for the existence of the gap between CGM 
technology and its adoption by end-users, we conducted this mixed-method 
study to capture the views and concerns of patients with diabetes and their 
family members or caregivers in relation to CGM.  
As shown, participation was from highly motivated subjects with the majority 
having current or previous exposure to diabetes technology. This might be 
considered as one of the study limitations, since the sample does not 
represent the general population with diabetes, for whom exposure to the 
diabetes technology might be relatively limited, and therefore does not 
address potential misconceptions related to the use of diabetes technology. 
However, it can also be considered as one of the strengths of this study 
having obtained its results from those with real life experience with diabetes 
technology. Another limitation is relying exclusively on electronic method of 
distribution. This excludes a significant proportion of people with diabetes 
(target population) who are not regular users of Internet or social media. 
The study shows that respondents had overwhelmingly positive views and 
experience related to the use of CGM. They have identified the positive 
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impact on their QoL, reassurance by the alarm function, the ability to monitor 
glucose fluctuations and trends through day and night, detection of 
hypoglycaemia and impact in improving glycaemic control as important 
advantages of CGM. “Peace of mind” related to the use of CGM has been 
frequently cited as a key CGM benefit.  
Concerns related to existing CGM technology were mainly related to cost, 
lack of accuracy, the sensor life span and having to carry another electronic 
device. Despite these concerns, 80% of participants viewed existing CGM 
technology positively. Also, most of the participants (96%) had positive views 
in relation to overall diabetes technology and what it can provide to them to 
reduce the burden of their, or their children’s, disease.  
Enhancement in CGM accuracy with subsequent reduction in false alarms, 
alarm fatigue and improvement in reliability could result in improvement in 
QoL, satisfaction related to sensor use, compliance and glycaemic control 
(Polonsky and Hessler, 2013). Reducing the cost has also been identified as 
a key issue in future development in CGM technology.  
Further development in CGM should also consider CGM-pump integration, 
enhancement of user interface, improving alarm function, data display, ease 
of data interpretation, user friendly PC software and smartphone integration. 
Smartphone integration could help in reducing the number of devices carried 
by the patient (by mitigating the need to carry a dedicated CGM display unit) 
and might enhance interaction with the CGM through the use of a more 
familiar user-friendly interface provided by the smartphone. Integration 
between CGM systems and other devices (pump or smartphones) can also 
reduce the initial cost of a CGM system by mitigating the need to buy a 
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dedicated CGM display unit. Furthermore, smartphone integration can allow 
remote monitoring, which was shown to reduce the risk of prolonged nocturnal 
hypoglycaemia (DeSalvo et al., 2014). Another important development in 
CGM, from patients’ perspective, would include longer sensor life. 
Results from our survey are consistent with results of recent qualitative 
research that used framework analysis of narratives of 100 adults with type 1 
diabetes using RT-CGM. Lack of sensor accuracy and reliability was 
highlighted by most of the participants. Issues related to lag time, calibration 
and sensor life were also highlighted. Other barriers to CGM use included 
insertion discomfort or pain, sensitivity to tape, more kit to wear, difficulty in 
interpreting data, cost and issues related to support by healthcare 
professionals (Pickup et al., 2014). Participants in our survey had different 
background with regards to age group and exposure to CGM. 
Our results are also consistent with those of a study that evaluated views of 
children and young adults (mean age 15+/- 4.8 years) in relation to CGM use. 
58 responses from subjects with type 1 diabetes showed that providing 
continuous data on glucose level and improvement in glycaemic control were 
the top two reported beneficial features for RT-CGM use. Pain was the most 
disliked aspect of RT-CGM use with 14% of subjects discontinuing RT-CGM 
as a result. In subjects who stopped using RT-CGM, problematic equipment 
and inaccuracy accounted for 64% of reasons for discontinuation of RT-CGM 
use. This was followed by intrusion in life and insurance issues. Despite the 
reported problems 52% of subjects continued to use RT-CGM (Ramchandani 
et al., 2011). 
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Another limitation to this study is that it did not address views or concerns of 
healthcare professionals in relation to CGM or other aspects of diabetes 
technology. The reluctance of clinicians to adopt CGM devices is another 
important challenge preventing widespread implementation of the CGM 
technology. This can be related to lack of the necessary skills required to 
identify patients who are likely to benefit from CGM or for interpretation of 
CGM data (Bergenstal et al., 2013a). It could also be related to lack of 
resources or due to inadequate accuracy of existing CGM systems affecting 
its acceptance by clinicians (Christiansen et al., 2013). Including the views of 
healthcare professionals in this study or in a parallel study would have been 
useful to find out the reasons, views, concerns or misconceptions contributing 
to the gap between diabetes technology and its adoption by clinicians. This is 
particularly important as patients and clinicians might have different reasons 
for adopting CGM technology. While clinicians might mainly focus on 
reduction in HbA1c and risk of hypoglycaemia, patients’ top priority, as shown 
in the result of this survey, seems to largely focus on reduction of disease 
burden.  
The use of microprobe technology in CGM was assessed through a focus 
group. The potential benefits identified by the participants included reduced 
pain and the small size of the sensor. However, concerns raised included the 
need for a method to ensure proper application and the potential cost. A 
qualitative study that assessed public and healthcare professionals views in 
relation to the use of microneedle technology for transdermal drug delivery 
demonstrated the potential advantages of this technology in comparison to 
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conventional needles. These included reduced pain, tissue damage, and risk 
of infection (Birchall et al., 2011). 
This study also highlights the value of social media in healthcare research and 
as an important platform to reach potential participants.  
It also highlights the impact of social networking on diabetes management. 
Not only does it provide a platform to gain knowledge and exchange 
experiences, it can also be an important motivational tool through online peer 
support and engagement. Furthermore, It can serve as a method to 
disseminate information, improve doctor-patient communication or as a 
valuable research tool (Chretien and Kind, 2013). A qualitative analysis of 
posts and discussion forum topics on the 10 largest Facebook groups focused 
on diabetes management revealed that patients, as well as family members 
and friends, share personal clinical information, receive emotional support, 
and request diabetes management guidance from other group members. 
However, the study has also highlighted that promotional activity and requests 
for personal data collection were also common (Greene et al., 2011). A clear 
example highlighting the impact of social networking and the importance of 
communication with patients to capture their views and demands in relation to 
CGM technology is “The Nightscout Project”. The project aims at allowing 
real-time remote monitoring of the CGM data for Dexcom users. It requires a 
cable to connect the Dexcom receiver to an android smartphone and an open 
source software that transmits the CGM data to the smartphone and then to a 
server (cloud platform), where it can be accessed remotely 
(http://www.nightscout.info/).  
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Finally, this chapter highlights the positive impact of PPI on the research 
project, participants and researchers and the value of establishing this 
involvement at an early stage of the project. 
 
 
2.6.   CONCLUSION: 
This study provides important insight into patients’ views, concerns and 
demands in relation to CGM technology. Cost and reduced accuracy 
represent important barriers to adoption and widespread implementation of 
this technology in general management of people with diabetes. Efforts to 
enhance CGM accuracy and reduce cost could have a significant impact in 
users’ perception of CGM technology with subsequent improvement in 
satisfaction, QoL, cost effectiveness, compliance and glycaemic control. 
PPI in diabetes technology research can play an important role throughout the 
different stages of the research and can potentially positively impact research 
design, conduct and outcome and has the potential to help in enhancing 
users’ acceptability to the end product.  !
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CHAPTER 3 
FABRICATION AND MECHANICAL 
CHARACTERISATION OF A NOVEL 
MICROPROBE ARRAY CONTINUOUS 
GLUCOSE SENSOR 
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3.1 INTRODUCTION 
3.1.1 Skin microanatomy: 
As previously highlighted, human skin comprises the epidermis, dermis and 
subcutaneous tissue. The outermost layer of epidermis, stratum corneum, is 
primarily made of dead keratinocytes and is responsible for skin barrier 
characteristics. The viable epidermis, below the stratum corneum, is around 
100 µm and mainly consists of living cells, but is devoid of blood vessels and 
contains few nerves. Below the viable epidermis lies the dermis, 800 – 1500 
µm in thickness, which contains nerves and blood vessels at approximately 
400 µm depth from skin surface (Khanna et al., 2008).  
One of the main aims of microneedles accessing the dermal interstitial fluid 
(ISF) compartment is to penetrate the layer of stratum corneum without 
impinging on dermal microcirculation or dermal nerve fibers.  
The stratum corneum represents the main mechanical barrier to microneedle 
insertion (Park et al., 2005). Knowledge of stratum corneum thickness is 
therefore essential to determine microneedle length and ensure adequate 
penetration. There is a marked site variation in mean stratum corneum 
thickness; ranging from 22.6 +/-4.33 µm for volar forearm, 29.3 +/- 6.84 µm 
for back of the hand, and 173.0 +/- 36.96 µm for palm. The stratum corneum 
thickness tends to become age-dependently thicker at the forearm (Egawa et 
al., 2007). 
3.1.2 Mechanics of microneedle insertion: 
The mechanics of microneedle insertion into skin is of paramount importance 
to device performance and safety. The mechanics of microneedle insertion 
were first investigated by Davis et al (Davis et al., 2004) who measured the 
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force required for fracture, the force required for insertion, and their ratio 
(termed the margin of safety). To determine the effect of microneedle 
geometry on the force of insertion, individual hollow metal microneedles with 
tip radii of 30 – 80 µm, wall thicknesses of 5 – 58 µm and a constant length of 
720 µm were pressed against human subjects’ skin using a displacement-
force test station until a preset maximum load was reached. Measured 
insertion forces ranged from 0.1 – 3 N, which is sufficiently low to permit 
insertion by hand. Forces of insertion showed an approximately linear 
dependence on the interfacial area of the needle tip but are independent of 
wall thickness. To determine the effect of microneedle geometry on the force 
of fracture, individual hollow microneedles were pressed against a hard 
surface using an axial load test station until a preset maximum displacement 
of 500 µm was reached. Fracture force increased significantly with increasing 
wall thickness and increased modestly with increasing wall angle and tip 
radius. The ratio of the fracture force to the insertion force was described as 
“the margin of safety”; values greater than one identify needles that will insert 
into the skin without breaking. The largest margin of safety was achieved 
using needles with small tip radius to reduce insertion force and large wall 
thickness to provide strength and increase fracture force. A similar method 
has been used to determine the margin of safety of microneedle arrays, rather 
than individual microneedles, has shown a safety margin of 6 - 9 when arrays 
of silicon solid microneedles, pyramidal in shape, with a tip radius of 5.5 µm, a 
base diameter of 250 µm and 308 µm high are assessed (Forvi et al., 2010). 
In another study to evaluate the relationship between microneedle geometry 
and fracture force, the force required to cause microneedle failure by axial 
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loading increased with decreasing microneedle length, increasing base 
diameter or using microneedles of larger Young’s modulus (a measure of 
stiffness of materials). The force required to cause microneedle failure by a 
transverse load was also measured. This showed that the transverse-load 
failure force is smaller than the axial-load failure force for microneedles of the 
same geometry and material. This indicates that if microneedles experience 
significant transverse load due to incorrect axial insertion, microneedles could 
fail by bending (Park et al., 2005). Microneedles with geometry below a 12:1 
aspect ratio of length-to-equivalent diameter and a polymer with more than 3 
GPa of Young’s modulus were recommended to avoid microneedle 
mechanical failure by axial force (Park and Prausnitz, 2010). 
The effect of microneedles’ distribution on skin insertion was evaluated by 
Donnelly’s group. The study has demonstrated that microneedle interspacing 
only begins to increase insertion force at low interspacing (<150 µm 
interspacing at microneedle base) (Olatunji et al., 2013). 
3.1.3 Skin penetration: 
Several methods have been employed to assess the ability of microneedles to 
successfully penetrate stratum corneum (micropore formation) and to further 
penetrate the underlying tissue (microchannels formation). Application of a 
staining dye to the insertion site allows en face visualisation of the created 
micropores. Alternatively, as intact stratum corneum is a barrier against water 
diffusion, interruption of this layer results in increased water loss and 
measurement of transepidermal water loss (TEWL) can be used as a 
measure of successful skin penetration by microneedles. Infra-red 
spectroscopy and electrical impedance spectroscopy have also been used 
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(Gupta et al., 2011). Although those techniques confirm whether the stratum 
corneum has been penetrated, they do not provide information on 
microchannel characteristics. Assessment of depth of penetration and its 
relation to microneedle array geometry require transverse visualisation of 
microchannels, which can be obtained by biopsy of the microneedle-
penetrated skin for histological examination. However, this may alter the 
biomechanical characteristics of the punctured skin and alter macro- or 
microscopic appearance. The use of confocal laser scanning microcopy for in 
vivo imaging is limited to a penetration depth of only 200 µm (Enfield et al., 
2010, Coulman et al., 2011). Optical coherence tomography (OCT) has 
emerged as a powerful tool to obtain in vivo transverse images of 
microneedles in situ and of the created microchannels after device removal. 
OCT is a non-invasive optical imaging technique analogous to ultrasound, 
mapping the variations of reflected light rather than sound from biological 
samples. The major advantage of OCT is that it is capable of penetrating to a 
depth of 2 mm, providing cross-section imaging of epidermis and upper 
dermis for accurate in vivo assessment of microneedle penetration and of the 
created microchannels without the need for skin biopsy. Furthermore, no prior 
sample preparation is needed as with histological examination. When 
compared to histology, OCT images showed that the histological techniques 
overestimate the dimensions of the created microchannels (Coulman et al., 
2011).  
Apart from microneedle geometry, skin resistance is another factor influencing 
the mechanics of microneedle insertion. Due to the elasticity of skin, 
application of microneedles results in skin indentation at the insertion site prior 
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to penetration of the stratum corneum layer which may result in incomplete or 
even failure of penetration (Martanto et al., 2006, Verbaan et al., 2007, 
Verbaan et al., 2008). The effect of skin elasticity and deflection on 
microneedle insertion was shown in a study that used tryptan blue staining 
and TEWL to evaluate the relationship between microneedle length and skin 
penetration. It showed that manual application of short microneedles (300 µm 
long) was not successful in penetrating the stratum corneum and 
microneedles of 550 µm or more are needed to overcome skin elasticity and 
resistance (Verbaan et al., 2007). Subsequently, the use of an electrical 
applicator at a velocity of 1 or 3 m/s showed successful insertion of the short 
microneedles (300 µm long) (Verbaan et al., 2008). 
Skin resistance to microneedle insertion was also demonstrated by OCT 
images showing stratified skin tissue is compressed during microneedle 
application leading to partial penetration (700 µm long microneedles created 
300 µm long microchannels when inserted in palmar skin of human subjects). 
This skin resistance to microneedle insertion seems to increase as 
microneedle length increases, as shown in data demonstrating that the 
distance between the lower microneedle array base plate and stratum 
corneum was significantly lower with microneedle arrays of relatively short 
length (250 and 350 µm) compared to those of greater length (600 and 900 
µm) (Donnelly et al., 2010a). 
Various approaches have been used to reduce skin deformation at the 
microneedle insertion site and to overcome skin resistance including insertion 
using rotation (Martanto et al., 2006), vibration (Yang and Zahn, 2004) or at 
high velocity (Verbaan et al., 2008).  
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3.1.4 Microchannel characteristics: 
Assessment of the characteristics of the resulting microchannels following 
successful insertion and establishing the relationship to microneedle geometry 
and insertion mechanics is equally important. For example, with the use of 
microneedles as biosensors for in situ monitoring of ISF glucose, the larger 
the surface area in contact with ISF, the better signal:noise ratio and this can 
lead to more accurate results being obtained. 
OCT has been employed to evaluate the effect of microneedle geometry and 
force of application on skin penetration characteristics. A spring activated 
applicator has been used to insert silicon microneedle arrays into neonatal 
porcine skin in vitro using defined insertion forces showing that increasing the 
microneedle length or the force of application results in a significant increase 
in the depth of penetration. Moreover, alteration of the microneedle 
interspacing (density) had no effect on penetration depth achieved at a 
constant microneedle length and force of application (Donnelly et al., 2010a). 
OCT was also used to evaluate the diameter of the created microchannels. It 
showed that following removal of microneedles, the created microchannels 
collapsed secondary to the elastic properties of human skin suggesting that 
microneedles are possibly even less invasive than previously suggested 
(Coulman et al., 2011). 
Previous studies employing TEWL to evaluate the relationship between 
microneedle geometry and skin penetration characteristics show a positive 
correlation between microneedle length and TEWL (Badran et al., 2009, 
Verbaan et al., 2007). Measuring the TEWL of rat skin before and after 
treatment with silicon microneedles of variable length and density showed that 
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TEWL increased when arrays with longer microneedles and lower 
microneedle density were employed (Yan et al., 2010). This supports the 
hypothesis that increasing microneedle density reduces their skin piercing 
capacity, due to proportional pressure reduction at the tips of individual 
microneedles, referred to as the “bed of nails” effect (Stoeber and Liepmann, 
2005). However, other studies showed no relation between microneedle array 
density and skin penetration characteristics (Donnelly et al., 2010a, Verbaan 
et al., 2008). Subsequently, the relationship between microneedle 
interspacing and skin penetration was evaluated suggesting that force 
required to insert microneedles starts to increase when interspacing distance 
at the base is <150 µm (Olatunji et al., 2013). 
 
3.2 DESCRIPTION OF THE IMPERIAL COLLEGE MICROPROBE ARRAY 
CONTINUOUS GLUCOSE SENSOR: 
The microprobe array continuous glucose sensor consists of a three 
dimensional out-of-plane microprobe arrays, with 64 microprobes (solid 
microneedles) perpendicular to the base plate and arranged as 8x8 arrays. 
The pyramidal-shaped microprobes are 1000 µm in length with a base of 600 
µm, a tip diameter of 25 µm and pitch (distance between 2 adjacent 
microprobes) of 1200 µm (centre to centre). The microprobe arrays are made 
of SU-8, a biocompatible (Voskerician et al., 2003) negative photoresist epoxy 
material, coated with gold and are functionalised with glucose oxidase (GOx) 
enzyme (EC 1.1.3.4) to detect glucose electrochemically. Subsequently these 
microprobes were coated with a biocompatible (Wang et al., 2013) epoxy-
polyurethane (epoxy-PU) membrane to prolong their linear working range 
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(figures 3.1 and 3.2). The epoxy-PU membrane is known to limit mass 
transport, reduce biofouling and increase resistance to interfering agents such 
as dopamine, ascorbic acid, acetaminophen, or uric acid (Yu et al., 2007, 
Wang et al., 2013). 
This device is intended to be applied to the skin surface and inserted using 
thumb pressure or a specially-designed applicator allowing its microprobes to 
penetrate through the epidermis and access the dermal ISF and sense its 
glucose content electrochemically. 
 
Figure 3.1: A scanning electron microscopy image of the Imperial College 
microprobe array continuous glucose sensor. 
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Figure 3.2: A schematic of the functionalised microprobe array demonstrating 
different layers of the glucose sensor. 
 
3.3 AIM:  
The aim of this chapter is to describe process and methods for optimisation 
of sensor fabrication and mechanical characterisation of the sensor to 
assess its ability to access dermal ISF without microprobes’ fracture. 
Mechanical characterisation of the sensor aimed at assessing the force 
required to penetrate stratum corneum (insertion force) and the force 
required to fracture microprobes (fracture force) in the axial and transverse 
planes. 
3.4 METHOD: 
3.4.1 Materials:   
SU-8 photoresist was obtained from Chestech Ltd, UK. Methylene blue was 
obtained from VWR International Ltd, UK. Masters used for fabrication of 
Polydimethoxy Siloxane (PDMS) moulds were initially obtained through 
collaboration with Centre for NanoHealth, Swansea University and 
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subsequently fabricated at Imperial College London. PDMS was obtained 
from Sigma-Aldrich, UK. 
3.4.2 Fabrication of the microprobe array glucose sensor: 
Several methods for microneedle/microprobe array fabrication have been 
described in the literature (Donnelly et al., 2010b). In our attempt to obtain a 
device with the correct geometry, we have explored two fabrication 
techniques (photolithography and micromoulding) using SU-8. SU-8 is a 
biocompatible negative photoresist viscous epoxy polymer (Voskerician et al., 
2003).  On exposure to ultraviolet (UV) rays, SU-8's long molecular 
chains cross-link leading to the solidification of the material. SU-8 is available 
in several varieties with different densities and viscosities. Examples include 
SU-8 2, SU-8 25, SU-8 50 and SU-8 100 (higher numbers indicating higher 
viscosity). 
3.4.2.1 Photolithography: 
The Imperial College microprobe arrays were first fabricated using method 
reported by Kim et al (Kabseog Kim, 2004). An SU-8 mesa was formed on a 
Pyrex glass substrate. A second SU-8 layer was then deposited on to the first 
SU-8 and exposed to UV rays through the backside of the glass substrate 
using a mask that has circular openings of a preset diameter. When exposed 
to UV, SU-8's long molecular chains cross-link, causing the solidification of 
the material and formation of an array of SU-8 tapered pillar structures (figure 
3.3). Geometry of microneedles is controlled by the thickness of SU-8 layers 
and the diameter of the mask’s circular openings. 
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Figure 3.3: Fabrication of microprobe array using photolithography (Kabseog 
Kim, 2004). 
“© IOP Publishing. Reproduced by permission of IOP Publishing.  All rights reserved” 
 
Apart from the high technical complexity and the high cost of the 
photolithography fabrication technique, it was difficult to obtain reproducible 
microprobe arrays of the correct geometry (figure 3.4). Therefore, we moved 
towards micromoulding technique for device fabrication. 
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Figure 3.4: A scanning electron microscopy image of an attempted fabrication 
of a microprobe array using photolithography. 
 
3.4.2.2 Micromoulding technique: 
This manufacturing method involves the use of a metal masters. The masters 
are used to create moulds of PDMS. Alternatively, moulds can be created 
from PDMS casts by directly punching holes into the cast using a laser 
ablation system.  
To create PDMS moulds, masters were initially obtained through collaboration 
with Centre of NanoHealth, Swansea University. As the geometry obtained 
was suboptimal (as shown from initial skin insertion studies that will be 
discussed later in this chapter), we replaced these masters with aluminium 
masters, fabricated using an Electrical Discharge Milling (EDM) technique at 
Imperial College London. 
The PDMS moulds were cast with SU-8 (50) using vacuum and spinning to 
ensure SU-8 is filling mould’s microcavities. The PDMS casts were subjected 
to 10 mm Hg vacuum pressure for 2 minutes and spun in petri dish at 4000 
rpm for 30 minutes in a centrifuge (Eppendorf). The SU-8 was then cross-
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linked by exposure to UV light at 365 nm for 30 - 60 minutes (figure 3.5). The 
samples were cooled at 4° C and the PDMS layer peeled off to obtain the 
cross-linked epoxy microprobe arrays. Bare microprobe arrays were then 
coated with an adhesion layer of titanium (15 nm) followed by gold (135 nm) 
using conformal sputtering (DC sputter system, JLS MPS 500) in a clean 
room. 
 
 
 
 
Figure 3.5: Fabrication of microprobe array using micromoulding. 
 
3.4.3. Mechanical validation 
3.4.3.1. Measurement of insertion force in human skin ex vivo : 
Insertion force, (the force required to insert microprobes into human skin ex 
vivo), was determined using an Instron 5866 instrument with a 50 N load cell 
and Bluehill software (Norwood, MA). Full thickness human skin samples 
(breast or abdomen) were obtained from elective surgery at Imperial College 
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Healthcare NHS Trust after approval from Imperial College Human Tissue 
Bank (ICHTB) and patients’ consent.  ICHTB is approved by National 
Research Ethics Service in England to give “deemed ethics” for research 
projects to use extra samples of anonymised tissue and fluids collected 
specifically for research. Skin was either transported immediately in 
physiological saline solution, to the laboratory for mechanical testing or stored 
at – 20° C. All skin samples were used within two weeks from date of surgery. 
The subcutaneous fat was removed, using sharp dissection, and the skin 
stretched and mounted, dermis side down, on a cork dissection board 
covered with parafilm. The skin surface was wiped with a 70% ethanol swab 
to remove any subcutaneous fat remnants. Microprobe arrays were attached 
to the Instron’s movable probe, face down, using double-sided adhesive tape. 
The probe was lowered onto the skin at a speed of 3 mm/s until the required 
force was exerted. Forces of 7, 10, 15, 20 and 25 Newton (N) were applied 
(figure 3.6). Once reached, the target force was maintained for duration of 60 
seconds. Following removal of the device, methylene blue solution, which 
selectively stains the sites of stratum corneum penetration, was applied to the 
upper surface of the skin for 20 minutes to visualise created micropores 
(Donnelly et al., 2011). Methylene blue dye was then carefully wiped using 
alcohol swap before skin examination using digital microscopy (Leica EZ4D) 
to count created micropores and determine insertion ratio (number of created 
micropores : number of microprobes) (Donnelly et al., 2011). Skin was then 
fixed in formaldehyde for 24 hours at room temperature. Skin samples were 
subsequently examined by the histology department (Imperial College 
Healthcare NHS Trust). This involved the skin being sectioned into 4 µm 
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sections. Sections were then stained with haematoxylin and eosin and 
examined by light microscopy to confirm penetration of stratum corneum 
layer.  
 
Figure 3.6: A schematic showing method of measurement of insertion force in 
human skin ex vivo. 
 
3.4.3.2. Measurement of microprobe axial compression force in vitro: 
The effect of applying axial compression load (Donnelly et al., 2011) to the 
microprobe array was assessed using an Instron 5866 instrument with a 500 
N load cell and Bluehill software (Norwood, MA). Microprobe arrays were 
placed on a fixed metal plate with the microprobes facing upwards before 
applying the desired force through the movable probe of the Instron 
compression system. The Instron instrument pressed the microprobe arrays 
using an axial force (parallel to the microprobes’ axes) at a rate of 1mm/s until 
the required force was exerted. Forces ranging from 50N to 400 N (50, 50 
repeated, 100, 200, 300 and 400 N) were tested (figure 3.7). Microprobe 
arrays were examined before and after application of the compression load 
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using scanning electron microscopy (SEM) (JEOL JSM 5610 SEM) to detect 
the presence and mode of any mechanical failure.  The height of each 
microprobe was measured after testing and the percentage change in 
microprobe height calculated.  
 
Figure 3.7: A schematic showing method of measurement of microprobes’ 
axial compression force. 
 
3.4.3.3. Measurement of transverse fracture force of microprobes In 
vitro: 
The transverse failure forces of microprobe arrays were measured with the 
same force station as described above. A T-slot was used to clamp a thin 
probe (Agar Scientific) (0.5 mm thickness at the tip). The probe was adjusted 
to ensure that it pressed orthogonally against a row of eight microprobes 
(figure 3.8). The probe was moved at a speed of 1 mm/min. The force 
required to fracture a single microprobe was determined by dividing the 
transverse force required to fracture one row by the number of microprobes in 
each row (eight). The microprobe arrays were examined by SEM prior to and 
after fracture testing to assess mechanical failure. 
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Figure 3.8: A schematic showing method of measurement of microprobes’ 
transverse fracture force. 
 
3.5 RESULTS 
3.5.1 Insertion tests - ex vivo: 
Initially, six ex vivo tests were performed using devices fabricated using 
masters obtained from Swansea University. Histological examination revealed 
that none of the tests have shown consistent penetration of stratum corneum. 
Examination of the device using SEM revealed that microprobes had large tip 
diameter. Although the microprobes' target tip diameter is 10 - 50 µm, 
microprobes used for ex vivo tests had a tip diameter in the range of 100 - 
140 µm (figure 3.9(a)). As discussed in the introduction, the efficiency of 
penetration depends inversely on microneedles’ tip diameter (Davis et al., 
2004), which is probably the reason for failure of microprobes with larger tips 
to perform adequately. 
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Figure 3.9(a): A scanning electron microscopy image of one microprobe with 
tip diameter of 100 µm in a device fabricated using master obtained from 
University of Swansea. 9(b) A scanning electron microscopy image of 
aluminum master fabricated using electrical discharge milling at Imperial 
College London showing the pyramidal shaped microprobes with tip diameter 
of 25 µm. 
 
 
Figure 3.10: Histological examination of microprobe array treated skin area 
showing indentation (a) and penetration (b) of stratum corneum. 
 
b"a"
a" b"
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Following the replacement of these masters with masters fabricated at 
Imperial College London using EDM, we managed to fabricate devices with 
pyramidal shaped microprobes that had tip diameter of 25 µm (figure 3.9(b)).  
Testing devices fabricated using new masters, the insertion ratio, as 
determined from the tests (n=10) on excised human skin, was 83% for 
moderate forces (7 N). Using forces of 10 N or above resulted in insertion 
ratio of over 90%. Above this threshold, the insertion ratio was proportional to 
force used (slope 0.5N-1, R2 = 0.93) (table 3.1). SEM images of the 
microprobe arrays following insertion tests confirmed the structural integrity of 
the device.  
 
  
 
Figure 3.11(a): A digital microscopy image of a microprobe array treated human 
skin (ex vivo) following application of methylene blue dye to confirm successful 
penetration. This shows extravasation of the dye in deeper skin layer after 
penetration of stratum corneum. Figure 11(b): Histological examination of 
microprobe array treated skin area showing penetration of stratum corneum 
(arrow) with microchannels (penetration depth of 300 microns) created by 
microprobes. 
 
 
 
300"µm"a" b"
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Axial Force Mean insertion ratio (%) Standard Deviation 
7N 83 11.64 
10N 90.36 8.25 
15N 91.68 8.44 
20N 93.83 8.91 
25N  98.22 2.14 
 
Table 3.1: Relationship between axial compression force tested and insertion 
ratio. 
 
3.5.2 Axial compression tests 
Axial compression tests (n=10) have demonstrated the ability of microprobes 
to tolerate large forces without fracture of microprobes or base plate. The 
reduction of microprobe height was proportional to the applied force. This 
ranged between 4.1% for 50 N and 18 % for 400 N axial pressures (figures 
3.12 and 3.13 - table 3.2). 
  
Figure 3.12(a): A scanning electron microscopy image of a microprobe array 
following successful skin penetration using force of 20 N. Figure 12(b): A 
scanning electron microscopy image of a microprobe array after applying 
axial force of 400 N.  
a" b"
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Table 3.2: Relationship between axial compression force tested and 
microprobes’ final height. 
  
Figure 3.13: Graph showing the relationship between axial compression force 
and mean final microprobes’ height [bars represent standard errors]. 
 
3.5.3 Transverse fracture tests 
Transverse fracture tests (n=10) showed that the force required to fracture 
one row of eight microprobes was 25.18 ± 2.81 N (≈ 3 N per microprobe) 
(figures 3.14 and 3.15). 
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Figure 3.14: A scanning electron microscopy image showing effect of 
transverse force application on the first row of microprobes. 
 
Figure 3.15: Instron generated graphs of 10 transverse fracture tests [as the 
Instron’s probe gets in contact with the shaft of microprobes, the force starts 
to increase. This continues until the microprobes fracture, which is identified 
by the drop in the recorded compressive force]. 
 
3.6 DISCUSSION: 
Mechanical characterisation is an important step in pre-clinical validation of 
microneedle-based devices to assess the ability of microneedles to reach 
target compartment without mechanical failure. Successful insertion depends 
on microneedles’ geometry (microneedle length, wall thickness, tip radius, 
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base diameter, wall angle) and distribution. It also depends on the mechanical 
properties of the skin and its resistance to penetration (Olatunji et al., 2013). 
All these factors, together with type of microneedles’ material, determine the 
force needed for insertion or fracture of microneedles. Microneedles of the 
correct geometry and physical properties allow for a small insertion force. If 
the force required for insertion exceeds fracture force, needles will break or 
bend before insertion occurs. 
The term “safety margin” has been used in microneedle literature to describe 
the device’s mechanical safety (Davis et al., 2004). It describes the 
relationship between the force required to fracture microneedles and that 
required for skin insertion, by dividing the fracture force by insertion force. The 
higher the safety margin, the lower the risk of mechanical failure and the safer 
the device. To ensure successful skin insertion of microneedles without 
breaking, appropriate microneedle geometry, distribution and materials are 
required to minimise insertion force and to maximise fracture force achieving 
the largest possible safety margin. Insertion is best achieved by small tip 
radius, interspacing of >150 µm at the base and sufficient microneedle length 
to overcome skin resistance, while mechanical strength is increased by 
increasing wall thickness (for hollow microneedles), base diameter and using 
materials of larger Young’s modulus (a measure of stiffness of materials) 
(Davis et al., 2004, Park et al., 2005, Olatunji et al., 2013). Examples of safety 
margins reported in the microneedle literature include a safety margin (for 
axial load) of up to five for a single hollow polymer microneedle with small tip 
and large wall thickness (Davis et al., 2004) and up to 23 for solid 
microneedle array fabricated from dissolvable polymer (Donnelly et al., 2011).  
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Mechanical characterisation of our sensor has demonstrated a safety margin, 
when an insertion force of 15 - 25 N is used, to range between 16 - 26 for 
axial load and 8 - 13 for transverse load, implying a high safety margin of the 
device (table 3.3). The higher safety margin for our device compared to typical 
microneedles is likely related to the microprobes’ geometry (low aspect ratio), 
being solid and the pyramidal shape, which was shown to have stronger 
mechanical properties than conical microneedles of comparable geometry 
(Hoa et al., 2014, Lee et al., 2008). It also reflects the relatively small insertion 
force achieved by small tip radius and microprobes’ height that is sufficient to 
overcome resistance of the stratum corneum without compromising 
microprobes’ fracture force. 
Insertion force 
(N) 
Mean insertion 
ratio (%) 
Safety margin 
(Axial load) 
Safety margin 
(Transverse load) 
7 83 56 29 
10 90.36 40 20 
15 91.68 26 13 
20 93.83 20 11 
25 98.22 16 8 
 
Table 3.3: Relationship between insertion force, insertion ratio, safety margin 
for axial compression force [obtained by dividing 400 N (which was the 
maximum axial force tested and only resulted in 18% reduction in 
microprobes’ height) by insertion force] and safety margin for transverse 
fracture force [obtained by dividing 192 N (transverse fracture force was 3N 
per microprobe X total number of microprobes (64)) by insertion force]. 
 
Another important factor for successful stratum corneum penetration by 
microneedles (apart from microneedle geometry and distribution) is the 
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application force. This can be delivered by using either a manual pressure or 
an applicator.  In a recent study, the mean force delivered by human 
volunteers to insert microneedles, when they were asked to use the force they 
would use to press an elevator button or a press a stamp on an envelope, 
was estimated to be 20 N (Larraneta et al., 2014). The use of an applicator 
enables the delivery of a defined insertion force or velocity to microneedle 
arrays. Several studies have highlighted the importance of the application 
method in microneedle insertion (Donnelly et al., 2010a). The use of manual 
self-application of microneedles simplifies the application processes and 
avoids the cost and training related to the use of applicators. However, the 
use of an applicator allows for reproducible skin penetration by limiting inter- 
and intra-individual variability in skin resistance to penetration and force 
applied for insertion (Singh et al., 2011). It can also result in reduction of 
insertion force with subsequent increase in the device’s safety margin 
(Olatunji et al., 2013). Another potential advantage to the use of a 
microneedle applicator device is that it provides the user (and the healthcare 
professional) with the assurance that a successful penetration has occurred, 
even in the absence of any associated pain or sensation, by producing a 
marker such as an audible click (Singh et al., 2011). 
3.7 CONCLUSION: 
Mechanical characterisation studies have demonstrated the ability of 
microprobes to penetrate the stratum corneum layer to reach its target dermal 
compartment for ISF glucose measurement. This was achieved using small 
insertion force with low risk of fracture either at the axial or transverse planes.  
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4.1. INTRODUCTION:  
4.1.1  Sensor functionalisation 
As discussed in chapter one, amperometric electrochemical glucose 
biosensors based on glucose oxidase (GOx) enzyme has been widely used 
for continuous glucose monitoring (CGM) systems. In these systems, the 
sensor consists of a three-electrode system, where a potential is applied 
between the working and reference electrodes and the generated current is 
measured between the working and counter electrodes. GOx enzyme is used 
as a biorecognition element to catalyse the reaction with glucose, with 
subsequent production of electroactive hydrogen peroxide. Application of a 
specific potential between working electrode and reference electrodes (which 
is typically +700 mV in first generation sensors) oxidise hydrogen peroxide. 
This results in generation of a current that is proportional to glucose 
concentration. This process requires an electron acceptor, which can be 
either oxygen (as in first-generation sensors) or synthetic mediators (in 
second generation sensors). The latter have the advantages of avoiding the 
issues of oxygen depletion following in vivo sensor implantation and the ability 
to use a lower potential to oxidise hydrogen peroxide, which reduces the risk 
of oxidising other electroactive analytes (interferents). However, a limitation to 
the use of mediators in implantable biosensors is lack of biocompatibility and 
the concern that leakage of mediators from the sensor to host tissues can be 
potentially harmful (Wang, 2008).  
Several factors need to be considered for the design of an enzymatic glucose 
biosensor including the detection element (electrode) material, the 
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biorecognition element (enzyme), the enzyme immobilisation technique, the 
redox couple and the permselective membrane.  
4.1.1.1 Glucose oxidase enzyme immobilisation 
Rendering the working electrode specific to glucose requires immobilisation of 
a glucose oxidoreductase enzyme such as GOx or glucose dehydrogenase 
(GDH). Enzyme immobilisation on an electrode surface may enhance the 
communication between the active site of the enzyme and the electrode and 
prevents enzyme leaching (Mani et al., 2014). 
Several strategies have been used for GOx enzyme immobilisation on the 
electrode surface. GOx can be physically entrapped between the electrode 
surface and the permselective membrane or it can be covalently coupled 
within a polymer film on top of the electrode surface (Arica and Hasirci, 1993). 
The advantage of the latter method is that it allows entrapping large quantities 
of GOx which results in higher current density and can enhance the enzyme 
activity. A commonly used method is to cross-link the enzyme to bovine 
serum albumin with gluteraldehyde (Crespilho et al., 2006). An alternative 
method is the deposition of an enzyme using self-assembly monolayer (SAM) 
technique. This involves functionalisation of gold electrode with thiomalic acid 
to provide a carboxylic group modified surface leading to an amide bond 
formation to amino groups on the GOx enzyme and its covalent attachment to 
the electrode surface (Li et al., 2007, Trzebinski et al., 2012). 
In this work, GOx sourced from Aspergillus niger (E.C.1.1.3.4) was used as 
the functional part of the biosensors and was immobilised to the gold 
electrode surface using the SAM technique. 
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4.1.1.2 Epoxy-polyurethane membrane 
An important step in the design of an enzymatic glucose biosensor is the 
choice of the permselective membrane (also referred to as mass transport 
limiting or flux limiting membranes) as it serves several important functions. Its 
primary function is to extend the glucose detection range of the sensor by 
limiting glucose flux to electrode surface and enzyme layer. This serves two 
functions. First, it prevents GOx saturation at high glucose concentrations. 
Secondly, it avoids the problem of oxygen deficit (in first generation glucose 
sensors) by maintaining a balance between oxygen and glucose fluxes. It also 
acts as a protective coating providing a biocompatible interface between the 
electrodes and the tissues enhancing sensor biocompatibility and protecting 
sensor components (e.g. electrode, enzyme or mediators) from degradation 
or leaching.  Furthermore, permselective membranes limit electroactive 
interferents from reaching the electrode. However, use of permselective 
membranes comes at the expense of sensor sensitivity. Also, small variations 
in steps of permselective membrane fabrication can lead to high variability in 
sensor performance (Trzebinski et al., 2011).  
Several materials such as Nafion, cellulose acetate, polycarbonate and 
polyurethane (PU) have been used as permselective membranes. Addition of 
epoxy resins reinforces the membrane with subsequent improvement in its 
mechanical integrity and durability (Wang et al., 2013).  In this work, PU 
membrane reinforced with epoxy has been chosen as a permselective 
membrane. 
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4.1.2 Electrochemical techniques 
Electrochemical evaluation of implantable electrochemical glucose sensors, 
both in vitro and in vivo, is an essential step in the design of a CGM system 
and a pre-requisite by regulatory bodies before approval for clinical studies 
(Agency, 2013). It aims at assessment of sensor functionality including 
glucose detection range and its linearity, sensitivity, effect of sterilisation, skin 
insertion and potential interferents on sensor performance. 
Several methods have been established to study electrochemical reactions. In 
this work, we have used cyclic voltammetry and chronoamperometry for 
electrochemical characterisation of the microprobe array sensor.   
4.1.2.1 Cyclic voltammetry 
Cyclic voltammetry (CV) is a potentio-dynamic technique that provides 
information about the electrode and the thermodynamics and kinetics of redox 
processes. It involves the measurement of the current of a sensor immersed 
in a redox solution.  In this technique, the potential applied between the 
working electrode and the reference electrode is swept linearly against time at 
a fixed rate until it reaches a set point, after which the potential is swept in the 
opposite direction to return to the initial potential. This cycle can be repeated 
several times (figure 4.1). Plotting the generated current (I) against the 
applied potential (E) gives the cyclic voltammogram trace (figure 4.2).  
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Figure 4.1: An example of potential versus time plot for a cyclic voltammetry 
experiment.  A full cycle potential triangular waveform consists of a forward 
scan and a reverse scan.  
 
The initial potential is usually chosen where no redox reactions occur. As the 
oxidation potential increases, the anodic current increases until a peak 
oxidation current (Ip ox) is reached, after which a steady state current is 
reached. At that point, the current is mass transport limited not potential 
limited. During the reverse scan (reducing potential), the accumulated 
oxidised species are reduced which results in a cathodic current until a peak 
reduction current is reached (Ip red), followed by a steady state current. 
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Figure 4.2: An example of a potential versus current plot for a cyclic 
voltammetry [Ip ox, peak oxidation current; Ip red, peak reduction current]. 
4.1.2.2 Chronoamperometry 
This technique is used to study the sensor response to a change of substrate 
concentration, which is referred to as titration. In chronoamperometry a 
constant potential is applied to the working electrode and the resulting current 
is measured as a function of time. The applied potential is usually chosen 
(based on the CV experiments) such that the resulting current is mass 
transport limited thus it reflects the concentration of the electroactive analyte 
of interest. Chronoamperometry involves measurements of the output current 
of a sensor under constant polarisation immersed in a buffer solution, while 
changing the analyte concentration (stepwise). The results are plotted on a 
current versus time curve (figure 4.3).  
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Figure 4.3: An example of chronoamperometry demonstrating current output 
of a sensor in relation to increasing analyte concentration. 
4.2. AIM: 
This chapter aims at a description of the process of functionalisation of the 
microprobe array sensor, the evaluation of its electrochemical characteristics, 
sterilisation validation and biocompatibility of sensor components. 
4.3. METHOD: 
4.3.1 Materials: 
SU-8 photoresist was obtained from Chestech Ltd, UK. Ferrocene carboxylic 
acid, Thiomalic acid (TMA), ethyl-dimethyl-aminopropylcarbodiimide (EDC), 
N-hydroxy-succinimide (NHS), glucose oxidase (GOx, EC 1.1.3.4), from 
Aspergillus niger, lyophilized, powder, ~200 units/mg), ATACS5104 epoxy 
adhesive, Brij 30, polyurethane (PU), tetrahydrofuran (THF) and potential 
interferents (ascorbic acid, acetaminophen and uric acid) were obtained from 
Sigma-Aldrich, UK. Methylene blue was obtained from VWR International Ltd, 
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UK. Silver conductive paint “RS 186-3600”, copper tape and PVC tape were 
obtained from RS Components Ltd, UK. 
4.3.2 Sensor fabrication and wire bonding: 
Following sensor fabrication and metallisation (as described in chapter 3), the 
microprobe array was wire bonded using silver paint and ATACS5104 epoxy 
adhesive to enable sensor functionalisation and electrochemical testing. The 
base of the metallised microprobe array was then encapsulated by spinning 
SU-8 photoresist followed by crosslinking using UV rays. The edges of the 
array were also encapsulated by applying a layer of SU-8 followed by 
crosslinking. Encapsulation is done to avoid electrochemical reactions 
occurring at the base or edges of the array. Subsequently, the wire 
connection and the electrode surface of the microprobe array were evaluated 
by CV using ferrocene carboxylic acid as a redox probe before starting the 
functionalisation protocol. Copper tape and PVC tapes were later also used 
as an alternative to silver paint and ATACS5104 epoxy adhesive for wire 
bonding. 
4.3.3 Functionalisation and membrane coating: 
Metallised microprobe arrays were functionalised with GOx enzyme to obtain 
the electrochemical glucose biosensors. Immobilisation of GOx on gold 
microprobe electrodes was achieved by employing self-assembled 
monolayers of TMA. Using drop coating, 40 mM TMA in deionised water was 
deposited on the microprobe array for 90 minutes. Subsequent treatment with 
EDC and NHS generates an activated ester coating, which immobilises the 
GOx through amide bond formation to amino groups on the enzyme. The 
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procedure involved deposition of an aqueous solution composed of 40 mM 
EDC and 100mM NHS in 10 mM phosphate buffered saline (PBS) solution, 
using drop coating, for 45 minutes at room temperature. This was followed by 
overnight incubation at 4 C ° in 0.1M PBS (pH 7.4) containing 10mg/ml of 
GOx (figure 4.4). Finally an epoxy-PU membrane was conformally deposited 
by dip coating in a solution of 17.8 mg each of Part A and Part B of 
ATACS5104 epoxy adhesive and 26.7 mg of PU in 4 ml of THF and 1 ml of 
Brij 30 (Wang et al., 2013). The sensors were stored at 4oC until further use.  
 
Figure 4.4: A schematic diagram showing steps of glucose oxidase (GOx) 
immobilisation using self-assembled monolayer (not to scale). 
 
4.3.4 In Vitro tests: 
4.3.4.1 Biosensor characteristics  
Electrochemical measurements were performed with a CHI 1003b 
potentiostat (CHI Instruments, Llanelli, UK) running a general-purpose 
electrochemical software (GPES v4). The microprobe array glucose 
biosensors acted as the working electrode with a commercially available 
Ag/AgCl reference/counter electrode (World Precision Instruments). Before 
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chronoamperometry measurements, the sensor was polarised at +700 mV 
versus the Ag/AgCl reference/counter electrode, unless otherwise stated, until 
a stable current was observed.  A magnetic stirrer (Fischer Scientific) was 
used to provide the convective transport for the electrochemical 
measurements. Calibration plots were obtained by measuring the current in 
10 mM PBS under constant stirring with stepwise glucose concentration 
increments of 2.5 mM every 125 seconds in the range of 0 – 20 mM. The 
resulting plot was used to evaluate linearity of the detection range and sensor 
sensitivity. All experiments were done at room temperature (22+/-0.5 C °). 
4.3.4.2 Interference studies 
Metallised microprobes were conformally covered with PU membrane of 
different thicknesses by adjusting the duration of dip coating (5,10, 20 
seconds). Using chronoamperometry, interference studies were performed by 
polarising the metallised sensors at either +700 mV or at +530 mV in the 
presence of uric acid, ascorbic acid or acetaminophen. The sensors were 
calibrated in 10 mM PBS under constant stirring by stepwise uric acid 
concentration increments of 0.1mM in the range of 0.1–1.0 mM. For ascorbic 
acid, the studied range was 0.02-0.2 mM using concentration increments of 
0.02 mM. For acetaminophen the tested range was 0.01-2.0 mM using 
concentration increments of 0.02 mM. 
4.3.4.3 Gamma ray sterilisation and its effect on sensor 
performance 
Functionalised sensors were packed in falcon tubes (VWR, Sussex, UK) and 
sent to TCM Associates (Essex, UK) for repackaging. Following repackaging, 
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they were sent to Synergy Health for Cobalt-60 gamma ray irradiation, assay 
of the bioburden levels on the microprobe arrays and subsequent estimation 
of the dose for sterilisation. (These studies were done in accordance with ISO 
11137-2:2012, Sterilisation of health care products -Radiation- Part 2: 
Establishing the Sterilisation dose). As described above, calibration curves 
were obtained before and after sensor sterilisation to assess the effect of 
gamma ray sterilisation on sensor performance. 
4.3.5 Ex vivo tests: 
4.3.5.1 Effect of skin insertion 
To evaluate the effect of skin insertion on sensor performance, the 
electrochemical response of one sensor was characterised before and after 
skin insertion. Full thickness human skin samples (breast or abdomen) were 
obtained from elective surgery at Imperial College Healthcare NHS Trust after 
approval from Imperial College Human Tissue Bank and patients’ consent. 
Skin insertion was achieved using an Instron 5866 instrument, running Bluehill 
software (Norwood, MA), with a 50 Newton (N) load cell to apply a force of 15 
N at a speed of 3 mm/s. Following device removal, methylene blue solution 
was applied to the microprobe array-treated skin area to confirm penetration.  
4.3.5.2 Comparison of generated current against a commercially 
available needle-type electrochemical sensor ex vivo 
Similarly, sensor performance was assessed ex vivo using fresh skin sample. 
In this experiment, full thickness human skin samples were transported 
immediately, after surgical removal, in physiological saline solution to the 
electrochemistry laboratory and were stretched and mounted, dermis side 
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down, on a cork dissection board covered with parafilm. An 8x8 solid 
microprobe array, metallised then functionalised with GOx and coated with 
epoxy-PU membrane (working electrode) and a 1x8 microprobe array of 
Ag/AgCl (reference/counter electrode) were inserted into the skin using a 
force of 15 N with an Instron compression system. A commercial needle-type 
sensor (Enlite, Medtronic, Northridge, CA) was inserted nearby using the 
sensor’s inserter device (figure 4.5). The current output from the sensors was 
then measured.  
 
Figure 4.5: A digital image showing 2 microprobe arrays (8x8), a reference 
electrode (1x8) and a needle-type sensor inserted in fresh full-thickness 
human skin ex vivo. 
4.4. RESULTS: 
4.4.1 Wire bonding: 
Difficulty in controlling the epoxy adhesive thickness and its hygroscopic 
nature, that leads to its swelling following exposure to water or moisture, 
resulted in the formation of a thick layer at the point of wire bonding (figure 
Needle-
type 
sensor 
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4.6). While wire bonding using epoxy adhesive enables sensor 
functionalisation and in vitro electrochemical testing, its thickness at the point 
of wire bonding raised concerns of interference with microprobes’ skin 
insertion during clinical studies (figure 4.6). 
 
 
Figure 4.6: showing the thick epoxy adhesive layer used to bond electrical 
wire to a microprobe array. 
 
Therefore, alternative methods for wire bonding were explored. These 
included replacing epoxy adhesive with either copper tapes or PVC tapes. 
Due to copper tape corrosion during the functionalisation process and poor 
adhesion of PVC tapes, wire bonding was finally achieved by drilling two 
holes in the edge of the array to allow threading of the wire into one hole, 
looping it back through the other hole before twisting the wire end around 
the wire to create a loop.  
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4.4.2 In Vitro tests: 
4.4.2.1 Biosensor characteristics 
Using 6x6 microprobe arrays, the current generated ranged from 20 – 150 
nanoampere (nA) with a sensitivity of 7 nA/mM. The response was linear in 
the glucose range tested (0-20 mM) (figure 4.7). 
 
 
Figure 4.7(a): Graph showing output current plotted against time to 
demonstrate the current response to a stepwise glucose concentration 
(calibration curve).   Figure 4.7 (b): Graph showing output current plotted 
against time to demonstrate linearity and sensitivity of glucose measurement. 
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4.4.2.2 Interference studies 
For metallised microprobes dip coated in PU for more than 10 seconds, 
interference was seen only at an applied potential of +700 mV with 
acetaminophen concentrations higher than 0.1 mM (therapeutic concentration 
0.03 - 0.13 mM) (figure 4.8). However, no interference was seen from uric 
acid or ascorbic acid using a potential of +700 mV. Also, no interference was 
seen from any of the three tested interferents when the metallised sensors 
were polarised with +530 mV (figure 4.9). 
 
 
Figure 4.8: A graph showing acetaminophen Interference in vitro study at an 
applied potential of +700 m V using microprobe arrays coated with variable 
thickness of PU obtained by dip coating for 15 seconds (blue) and 20 seconds 
(orange).  
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Figure 4.9: A graph showing acetaminophen Interference in vitro study at an 
applied potential of +530 mV using microprobe arrays coated with variable 
thickness of PU obtained by dip coating for 15 seconds (blue) and 20 seconds 
(orange).  
4.4.2.3 Gamma ray sterilisation and its effect on sensor 
performance 
Based on VDmax 25 study for sterilisation validation, a gamma irradiation dose 
of 25 kilogray (kGy) was accepted. Ten microprobe arrays were subjected to 
25 kGy of gamma ray irradiation and eight were used for subsequent 
bioburden measurements. Two microprobe arrays were used for functional 
and performance studies. The microprobe array sensor was calibrated before 
and after gamma ray sterilisation using a dose of 25 kGy. The electrochemical 
response of the microprobe sensor was the same before and after gamma ray 
sterilisation (figure 4.10).  
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Figure 4.10: A graph showing the effect of gamma irradiation (a dose of 25 
kGy) on sensor’s functionality. 
 
4.4.3 Ex vivo tests: 
4.4.3.1 Effect of skin insertion 
Similarly, chronoamperometry before and after skin insertion showed similar 
results, with no negative impact caused by skin insertion on sensor’s 
functionality (figure 4.11). 
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Figure 4.11: A graph showing the effect of skin insertion ex vivo on sensor’s 
functionality. 
4.4.3.2 Comparison of generated current against a commercially 
available needle-type electrochemical sensor ex vivo 
The relative currents from the microprobe sensor were initially at least 2 times 
higher than those from the enlite sensor. In both sensors the currents 
decreased over the duration of the study period likely reflecting the decline in 
glucose concentration in devitalised tissue (figure 4.12). Assessment of 
correlation between the outputs of the two sensors showed an R2 of 0.98 
(figure 4.13). 
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Figure 4.12: A graph showing relationship between output current from 
microprobe sensor and the enlite sensor in human skin ex vivo. 
 
 
Figure 4.13: A graph showing correlation between output current from 
microprobe array sensor and a commercially available needle-type-sensor. 
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4.5. DISCUSSION: 
In addition to in vitro mechanical evaluation of implantable glucose sensors, in 
vitro assessment of functionality, biocompatibility and sterilisation is required 
prior to in vivo evaluation of sensor’s performance and safety in clinical trials.  
Characterisation of performance of electrochemical sensors includes 
evaluation of linear range, sensor sensitivity, background current, response 
time and effect of potential interferents. Commercially available CGM systems 
have a working glucose range of 2.2 - 22.2 mmol/L (40 - 400 mg/dL). In this 
work, we have demonstrated that microprobe array sensors coated with 
epoxy-PU membrane demonstrated a linear response to changing glucose 
concentrations covering a glucose range similar to that of existing CGM 
systems. More importantly, the current generated and sensor sensitivity in 
vitro were higher than needle-type sensors (7 nA/mM compared to 0.96 
nA/mM for the latest needle-type sensor from Abbott’s diagnostics (Freestyle 
Libre) for example) (Hoss et al., 2014). This implies the potential of 
microprobe array sensors to have better signal: noise ratio and therefore 
better accuracy, particularly at the hypoglycaemic range. Furthermore, 
microprobe array sensors allow for further enhancement of the functional 
performance through adjustments of the microprobe array geometry by 
increasing the number of microprobes per array or increasing microprobes’ 
length or base diameter.  
Several exogenous and endogenous substances can interfere with 
electrochemical glucose sensor performance and compromise its accuracy. 
The ISO 15197:2013 standards and EP7-A2 guidelines from the Clinical & 
Laboratory Standards Institute list 22 potential interferents (McEnroe et al., 
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2005). Common electroactive interferents include acetaminophen, ascorbic 
acid and uric acid, which represent major specificity issues for CGM systems. 
One of the important functions of sensor’s coating membrane is to block 
interferents from reaching electrode surface by either electrostatic repulsion 
based on charge (e.g. Nafion) or mechanically based on interferents’ size 
(e.g. cellulose acetate film or PU). Interference from acetaminophen 
represents a challenge for most of electrochemical glucose sensors as the 
low oxidation potential of acetaminophen makes it electroactive during 
amperometric measurements of hydrogen peroxide. Furthermore, 
acetaminophen cannot be blocked based on electrostatic repulsion, as the 
molecule is uncharged (Lucarelli et al., 2012). Acetaminophen is reported to 
affect the enlite sensor and the G4 PLATINUM systems, while Ascorbic acid 
is reported to have minor effects on the FreeStyle Navigator and the enlite. 
Salicylate is reported to be the main interferent for FreeStyle Navigator (FDA, 
2008). In addition the coating membrane, current generated from electroactive 
interferents can be accounted for by the use of a non-functional electrode (not 
functionalised by GOx enzyme but coated with an outer membrane). 
Subtraction of the current measured by the non-functional electrode from that 
measured by the working electrode will account for background current and 
current resulting from interferents. Portioning of the microprobe array into 
several subarrays allows for integration of a “subtraction electrode” with the 
potential to further enhance device accuracy and specificity. In this work, we 
used metallised microprobe arrays (without functionalisation with GOx 
enzyme) coated with variable thickness of PU membrane. As GOx enzyme 
renders electrodes specific to glucose, use of non-functionalised electrodes 
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represents the worst-case scenario with the electrodes being more prone to 
the effect of electroactive interferents. Neither of ascorbic acid or uric acid 
showed interference in the tested range. However, acetaminophen showed 
interference at levels of ≥0.1 mM (therapeutic range 0.07 - 0.13 mM/L), 
regardless of PU membrane thickness, when a potential of +700 mV was 
used.  
In view of the labile nature and thermal instability of the GOx enzyme, the 
main challenge facing sterilisation of GOx-based glucose biosensors is the 
ability to ensure that sterility assurance is met without impacting the 
functionality of the sterilised sensor. Several methods have been evaluated 
for sterilisation of GOx-based sensors (Ahmed et al., 2000). Gamma radiation 
is frequently applied in medical sterilisation. The sterilising effect of gamma 
radiation is based on the generation of breaks in nucleic acid chains, 
preventing cell division and causing microorganism destruction. A dose of 25–
35 KGy irradiation is generally required to kill most commonly occurring 
microorganisms with an adequate safety factor and so achieve successful 
sterilisation of medical devices. Sensor evaluation is required post-sterilisation 
to ensure that sterility standards are met and sensor functionality is 
maintained. Sterilisation studies of the microprobe array sensor showed that a 
dose of 25 kGy was sufficient to meet sterility standards. Functional 
assessment showed that sensor functionality was maintained post-sterilisation 
using 25 kGy. This is consistent with the result of one study that evaluated the 
effect of two doses of gamma radiation (25 kGy and 30.6 kGy) on functionality 
of GOx-based biosensor and showed that sensor functionality was only 
maintained with the use of the smaller radiation dose (Ahmed et al., 2000). 
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The presence of the epoxy-PU membrane resulting in mass transport limited 
current, rather than enzyme kinetic limitations means that sensors should be 
less sensitive to loss of enzyme activity as a consequence of sterilisation. 
Similarly, skin insertion did not impact sensor functionality. The aim of this 
study was to ensure that the process of sensor insertion into the skin does not 
impact sensor layers, particularly the outer epoxy-PU membrane layer. 
However, this study does not provide information on the effect of duration of 
sensor implantation on sensor layers and performance. An attempt to assess 
this in another ex vivo study looked at the performance of the microprobe 
arrays over 15 hours of implantation in comparison to a commercially 
available needle type sensor. The performance of the microprobe sensors 
inserted into excised human skin was compared with that of a commercially 
available continuous glucose sensor. With a devitalised excised skin sample, 
glucose concentrations declines over time and this makes it difficult to 
separate the effects of longer-term implantation per se from those of declining 
glucose concentration. However, the study demonstrated that the current 
output from the microprobe array sensor was at least 2 times higher 
compared to output from the commercially available sensor and showed an 
excellent relationship (R2=0.98; y=1.93x-8x10-8) (figure 4.13). This study also 
does not provide information on the effect of the method of insertion 
(application speed or force) on the integrity of sensor layers. 
In vitro and in vivo assessment of the biocompatibility of sensor components 
is an essential step in sensor evaluation and is a requirement by regulatory 
bodies before evaluation in clinical studies. The standards specify that 
biocompatibility testing should be done on the end product after it has 
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undergone all washing, packaging and sterilisation steps (Koschwanez and 
Reichert, 2007). One method for in vitro evaluation of cytotoxicity of material 
used in sensor fabrication and functionalisation is examination of mouse 
fibroblast cells (L-929) after being exposed to sensor materials for several 
days. The cage implant system allows in vivo evaluation of sensor’s materials 
biocompatibility. In this method, the material of interest is inserted in a 
stainless steel mesh cage, which is then implanted into a test animal. Exudate 
from within the cage can be collected over the course of the experiment to 
examine for inflammatory and immune responses and cell-material 
interactions in comparison to an exudate from a control cage (Koschwanez 
and Reichert, 2007). In moving the microprobe array glucose sensor 
technology from bench side to bedside, several factors came into play 
including biocompatibility of components used in sensor fabrication and 
functionalisation. Initial work on the use of microprobe technology for CGM 
that was conducted in Cass’s group used tetrathiafulvalene (TTF) mediator 
(Trzebinski et al., 2012). As the biocompatibility of TTF has not been 
previously demonstrated for implantable glucose sensors, we decided to use 
unmediated first generation glucose sensors. The devices described in this 
chapter had already had their components assessed by this method and the 
results are available in the literature. The biocompatibility of SU-8 photoresist 
was evaluated in vivo using the cage implant method (Voskerician et al., 
2003). SU-8 was placed into a stainless steel cage and implanted 
subcutaneously in a rodent model. Exudates within the cage (sampled at 4, 7, 
14, and 21days) did not show any significant difference between the stages of 
inflammatory response elicited by SU-8 and the empty cage control over the 
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duration of the study. The biocompatibility of glucose oxidase and epoxy-PU 
has also been established (Wang et al., 2008), and these two components are 
routinely used in other commercially available CE-marked predicate devices.  
4.6. CONCLUSION: 
Functional evaluation of the microprobe array glucose biosensor, fabricated 
using biocompatible materials, showed high glucose-dependent current and 
sensitivity and that were not adversely affected by skin insertion or gamma 
ray sterilisation at a dose of 25 kGy. Interference studies showed that the 
device is liable to interference from acetaminophen at therapeutic 
concentration when the desired operating potential of +700 mV is used. These 
important observations, together with mechanical evaluation data showing the 
device mechanical robustness (chapter 3), were essential in obtaining 
regulatory bodies’ approval to proceed to clinical studies for evaluation of 
safety and efficacy of the sensor in human subjects. 
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CHAPTER 5 
CLINICAL EVALUATION OF SAFETY OF 
THE MICROPROBE ARRAY 
CONTINUOUS GLUCOSE SENSOR 
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5.1.  INTRODUCTION:  
For clinical evaluation of sensor’s safety and proof of concept of its 
performance, a non-randomised open-label prospective feasibility study has 
been planned to take place over four phases in healthy volunteers and in 
subjects with type 1 diabetes. The aim of this chapter is to describe the work 
done so far for clinical evaluation of device’s safety in non-diabetic subjects in 
phase 1 of the clinical study. 
 
5.2.  METHOD: 
Regulatory approval from the National Research Ethics Committee and 
Medicines and Healthcare Products Regulatory Agency (letter of no objection) 
were obtained. Non-diabetic subjects were recruited through poster adverts in 
Imperial College London campuses. Inclusion criteria were 18–75 years of 
age. Subjects were excluded if there was a history of upper limb neuropathy 
or radiculopathy, history of pre-existing skin condition, pregnant or planning 
pregnancy in next 12 months, breastfeeding, enrollment in other clinical trials, 
uncontrolled concurrent illness, have active malignancy or under investigation 
for malignancy. 
Subjects’ withdrawal from the study was in the case of loss of capacity to give 
informed consent, development of skin disease or upper limb neuropathy or 
radiculopathy or terminal illness. 
Participant information sheets were given to potential subjects and, after a 
minimum of 48 hours and following any questions, informed written consent 
was taken. Subjects were asked not to apply any cosmetic formulations on 
the non-dominant forearm for 7 days prior to the study. 
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Primary outcome was safety of the microprobe array glucose sensor (skin 
inflammation, pain score, bleeding, infection, fracture of microprobes). 
Secondary outcomes were presence of a detectable signal, magnitude of the 
generated current and correlation with venous blood glucose. 
5.2.1. Sensor design: 
Each microprobe array was partitioned into four subarrays. One subarray 
functioned as Ag/AgCl reference/counter electrode. The other three subarrays 
were metallised with gold, functionalised with glucose oxidase enzyme and 
coated with epoxy-PU membrane to function as three independent working 
electrodes allowing for multiple simultaneous glucose sensing (figure 5.1). 
The disposable sensor housings were sealed in foil package (TCM Associates 
Ltd, Essex, UK) and sterilised using gamma irradiation at a dose of 25 
kilogray (Synergy Health, Swindon, UK). The packaged, sterilised sensors 
were stored at +4C ° until use. 
 
 
 
Figure 5.1: A microprobe array partitioned into 4 subarrays (three gold 
working electrodes and one Ag/AgCl reference/counter electrode). 
 
RE1 WE1 
WE3 WE2 
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5.2.2. Study design: 
Subjects attended the NIHR/Wellcome Trust Imperial Clinical Research 
Facility at 09:30 am non-fasting. After revisiting inclusion and exclusion 
criteria and subject’s consent to start the clinical study, a 20-G intravenous 
cannula was inserted in the forearm for venous sampling.  
The microprobe sensor was applied to the upper part of the ventral aspect of 
the non-dominant forearm. Microprobe insertion was achieved by applying 
thumb pressure for 60 seconds. The sensor was secured in place with a 
transparent adhesive plaster (Elastoplast, Beiresdorf, Hamburg, Germany) for 
six hours. For measurement of output current, the sensor was directly 
connected to CHI 1003b potentiostat (CHI Instruments, Llanelli, UK) running a 
general-purpose electrochemical software (GPES v4) (figure 5.2). 
 
Figure 5.2: showing the microprobe array glucose sensor applied to subject’s 
forearm and connected to a potentiostat for measurement of the output current. 
 
Every 15 min throughout the six-hour study, a venous blood sample was 
taken and analysed for glucose using the YSI 2300 glucose and lactate 
analyser (Yellow Springs Instrument, Yellow Springs, OH). Subjects had one 
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main meal (lunch) during the six-hour study and were allowed to eat and drink 
throughout the study.  
5.2.3. Assessment of skin inflammation: 
The skin area around the microprobe array was inspected at 1 and 2 hours 
post-insertion and after device removal to determine degree of skin 
inflammation. Based on guidelines of the International Contact Dermatitis 
Research Group and the North American Contact Dermatitis Group, skin 
inflammation was rated as either: a negative reaction, a faint erythema 
(doubtful reaction), a mild erythema with possible papules (weak positive 
reaction), a moderate-intense erythema, papules or vesicles (strong positive 
reaction) or an intense erythema and infiltration and coalescing vesicles 
(extreme positive reaction) (Boone et al., 2015).  
In the case of persistent intense skin inflammation over 30 minutes following 
device removal, a 2 mm punch biopsy was planned.  
5.2.4. Assessment of integrity of microprobe arrays: 
Microprobe arrays were examined before and after application using scanning 
electron microscopy (SEM). This aimed at assessment of the structural 
integrity of microprobes and whether skin insertion has resulted in fracture of 
microprobe tips or resulted in damage to the epoxy-PU coating membrane. 
5.2.5. Visual analogue scale (VAS) pain scores: 
A 100mm-VAS was used to assess pain resulting from microprobe array (at 
insertion and throughout the six-hour study) in comparison to pain resulting 
from insertion of a 20-G intravenous cannula. The pain intensity score was 
measured immediately after sensor and intravenous cannula application at 
the beginning of the study, and immediately after sensor removal. The VAS 
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was determined by asking the participant to mark the degree of perceived 
pain on a 100 mm line. The line had word descriptors at each end (“No Pain 
= 0 mm” at one end and “Worst Pain = 100 mm” at the other end). The VAS 
score is determined by measuring in millimeters from the left hand end of the 
line to the point that the participant’s mark Participants were also asked to 
describe the sensation related to sensor application (e.g. sharp, pricking, 
heavy, pressure). 
5.2.6. Statistical analysis: 
Pain score data were analysed using Wilcoxon-Rank test. Spearman 
correlation was used to assess the relationship between sensor outputs 
whenever data on multiple simultaneous sensing where available. Similarly, 
the relationship between sensor output and venous blood glucose was 
evaluated using Spearman correlation. For this purpose, correlation was 
evaluated for each hour of the six-hour study. Analysis was performed using 
SPSS 21.0 for Mac (SPSS Inc., Chicago, IL). In all cases P < 0.05 indicated 
significance. 
 
5.3.   RESULTS: 
5.3.1. Subjects’ characteristics: 
Eight subjects (6 females, 2 males) were enrolled and studied at the 
NIHR/Wellcome Trust Imperial Clinical Research Facility at Hammersmith 
Hospital. 3 subjects were of White race, 3 of Asian race, 1 Middle Eastern and 
1 of mixed race. Subjects were 34.6 ± 6.9 years old (range 23-48 years).  
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5.3.2. Skin inflammation: 
None of the eight subjects had skin reaction in the area adjacent to the 
microprobe array when assessed at 1 and 2 hours post-insertion. The skin 
response at the microprobes’ insertion site, assessed immediately following 
sensor’s removal, was graded as barely noticeable (7 subjects) or mild 
erythema (in 1 subject). In comparison, none of the subjects had skin reaction 
to the adhesive plaster (Elastoplast, Beiresdorf, Hamburg, Germany) used to 
secure the microprobe array in place. In all subjects, skin reaction completely 
disappeared within 1 hour of device removal.    
 
Figure 5.3: A digital image of microprobe array treated skin area immediately 
following removal of the microprobe array.  
5.3.3. Pain scores: 
In only one subject, sensor insertion was described as painful. The remaining 
7 subjects reported insertion as painless. Sensation associated with sensor 
insertion was described as either “pricking” or “pressure” sensation. Median 
(interquartile range) pain scores for microprobe insertion on 100 mm VAS 
were 10 (1.25 – 17.5) compared to 30 (20 – 37.5) for the insertion of a 20-G 
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intravenous cannula. The difference between pain scores related to 
microprobe insertion in comparison to 20 G intravenous cannula insertion was 
statistically significant (P=0.017). Following sensor insertion, none of the 
subjects reported pain or sensation, in relation to the sensor, for the duration 
of the six-hour study. 
 
Figure 5.4: A box plot showing median and interquartile range of pain scores 
on 100 mm visual analogue scale for microprobe array insertion and the 
insertion of a 20 gauge intravenous cannula. 
 
5.3.4. Infection: 
Subjects were contacted the following day of the study to find out if there has 
been any delayed skin reaction or any signs of infection at the area that was 
treated with the microprobe array. None of the 8 subjects reported persistent 
or new dermatological symptoms/signs at the site of microprobe application.   
 
5.3.5. Bleeding: 
There was no evidence of bleeding at the site of microprobe array insertion in 
any of the 8 subjects. 
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5.3.6. Structural integrity of microprobes: 
SEM of microprobes following removal of the sensors, showed no evidence of 
fracture of microprobe tips as result of skin insertion. However, there was 
evidence of disruption of the epoxy-PU membrane (figure 5.5). 
 
Figure 5.5: A scanning electron microscopy image showing a top view of a 
microprobe following its removal from one of the subjects in phase 1.  This 
shows intact microprobe structure but the epoxy-PU coating membrane was 
disrupted. 
 
5.3.7. Sensor performance: 
A total of 189 paired YSI-sensor data points were available from the 8 
subjects. Mean glucose concentration (whole blood glucose estimated using 
YSI) was 5.19  ± 0.95 mmol/L (range 3.03 – 7.85 mmol/L). The average time 
between start of the study and lunch was 3:07 h ± 0.4h. 
From the total 8 microprobe array sensors (representing 24 working 
electrodes) placed, 9 working electrodes did not provide data. The main 
reason for this was malfunction of the electrical connection caused by 
SEM post insertion- Top view  
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corrosion at the point of contact between the electrical wire and the working 
electrode.  
In subjects where more than one glucose sensor (working electrode subarray) 
were functioning, significant correlation existed between the simultaneously 
functioning glucose sensors (table 5.1). 
Subject Number of functioning glucose sensors 
Spearman Correlation 
Correlation P 
1 1 - - 
2 1 - - 
3 3 
Sensor 1 vs 2: 0.71 
Sensor 1 vs 3: 0.92 
Sensor 2 vs 3: 0.85 
<0.001 
<0.001 
<0.001 
4 2 0.5 0.013 
5 2 0.97 <0.001 
6 2 0.6 0.002 
7 2 0.89 <0.001 
8 2 0.86 <0.001 
 
 Table 5.1: Number of functioning glucose sensors for each of the 8 
microprobe arrays used in phase 1 of the clinical study so far.  
 
However, there was no correlation between sensor output and YSI venous 
blood glucose (Figure 5.6). 
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Figure 5.6: Graphs showing venous blood glucose measured by YSI and output 
current of microprobe sensors for each of the eight subjects in phase 1 of the 
clinical study.  
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5.4.   DISCUSSION: 
Initial results of the phase 1 of the clinical study, obtained from 8 subjects, 
demonstrate safety of the microprobe array glucose sensor. Skin inflammation 
was barely noticeable and transient. Pain scores related to sensor insertion 
were low. There was no evidence of bleeding or infection at the insertion 
sites. As discussed earlier (chapter 2), one of the barriers to the use of CGM 
technology is pain, particularly in children. In the DirectNet study, pain during 
sensor insertion was cited as one of the reasons for discontinuation of CGM in 
children with type 1 diabetes (Weinzimer et al., 2009). Thanks to the minimally 
invasive nature of the microprobes, their use is associated with less risk of 
pain, skin reaction, bleeding or infection (El-Laboudi et al., 2013).  
In our study, partitioning of the microprobe array, allowing simultaneous 
multiple glucose sensing, provides the potential to improve CGM system 
accuracy (Castle et al., 2012). However, sensor performance, the secondary 
outcome of this phase 1 clinical study, showed no correlation between sensor 
output current and venous blood glucose. Failure mode and effect analysis 
(table 5.2) has highlighted potential source(s) of failure and recommended 
action(s). Failure of penetration of stratum corneum layer could result from 
use of sensors with blunt microprobe tips secondary to error in fabrication. 
This can avoided by the use of fresh new PDMS micomolds on fabrication of 
each sensor patch and SEM examination of the fabricated microprobe 
sensors. Errors in steps of sensor metallisation, functionalisation or 
membrane coating could result in poor performance or non-functioning 
sensors. Electrochemical assessment of at least one sensor per patch 
following these steps could identify these errors and guide any necessary
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actions. Inactivation of the glucose oxidase layer could result from wrong 
storage, wrong shelf life or wrong dose of gamma ray. Electrochemical 
assessment of at least one sensor per patch following these steps and before 
immediately before starting clinical studies could identify these errors. Another 
potential failure mode is disruption of the epoxy-PU membrane (figure 5.5). 
Although previous ex vivo tests showed that skin insertion did not affect the 
integrity of the coating membrane, these tests were performed using an 
Instron machine that allowed the use of preset speed and force to insert the 
microprobe arrays. In the in vivo studies performed so far, sensor was inserted 
by the use of thumb pressure. The speed of sensor insertion into skin can 
allow skin insertion using minimal force and this is known to affect the amount 
of local tissue trauma (Schmelzeisen-Redeker et al., 2013). The need to apply 
larger force, when inserting the microprobes using thumb pressure, could 
result in larger friction between skin and the coating membrane resulting in its 
rupture. The risk of membrane disruption can be minimised by altering the 
ratio between epoxy and PU in the membrane to enhance its robustness.  The 
use of an applicator to use preset speed and force for sensor insertion could 
also minimise the risk of disruption of the coating membrane.  
While manual application of the sensor simplifies the insertion processes and 
avoids the cost and training related to the use of applicators, the use of an 
applicator allows for reproducible skin penetration by limiting inter- and intra-
individual variability in skin resistance to penetration and force applied for 
insertion (Singh et al., 2011). Another potential advantage to the use of an 
applicator device, which was highlighted by participants in the focus group, is 
that it can provide the user with the assurance that successful penetration has 
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occurred, even in the absence of any associated pain or sensation (Singh et 
al., 2011). 
Equally important to the use of an applicator is evaluation of characteristics of 
skin penetration following sensor application. Other than confirming 
penetration and establishing the insertion ratio (number of inserted 
microprobes in relation to the total number of microprobes), it can also help in 
evaluating the relationship between depth of insertion and sensor’s output 
current. As discussed earlier, several methods have been described in the 
microneedle literature to confirm penetration of the stratum corneum and study 
the characteristics of the created microchannels. Evaluation using non-
invasive optical imaging techniques, such as confocal microscopy or optical 
coherence tomography (OCT), avoids the need for skin biopsy that, other than 
being invasive, may alter the biomechanical characteristics of the punctured 
skin and alter macro- or microscopic appearance. In our efforts to pursue an 
optical imaging tool for in vivo in situ evaluation of effect of microprobe 
application to the skin, an OCT imaging system (Thorlabs Telesto II) was used 
to image transparent non-metallised and gold metallised microprobe arrays 
(figure 5.7). While OCT was able to image through the non-metallised arrays 
and visualise structures underneath it, it was not able to do the same with gold 
metallised arrays. This implies that the OCT system cannot be used for in vivo 
in situ imaging of the metallised sensor. Alternatively, it can be used to confirm 
skin penetration and study characteristics of the created microchannels 
following sensor removal. We are currently planning further studies using an 
applicator and an OCT machine. In the studies conducted so far, post-removal 
in vitro electrochemical evaluation of the sensors was considered. However, 
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because of corrosion of contacts in vitro calibration was not possible due to 
the high background current. In future studies, contacts will be isolated during 
fabrication to allow in vitro electrochemical evaluation of sensors before and 
after clinical studies if required. 
 
Figure 5.7: En face video and optical coherence tomography (OCT) images 
(cross section and 3D) showing microprobes of a non-metallised array (A) and 
of a microprobe array metallised with gold (B). OCT can only show the 
underlying structures when used to image the transparent microprobe array 
(A2, A3).  [OCT imaging was done at Thorlabs Laboratory using Thorlabs 
Telesto II OCT imaging system]. 
 
5.5.   CONCLUSION: 
The novel microprobe array glucose sensor has been tested in 8 subjects (out 
of 16 subjects planned for phase 1 of the clinical study). Initial results show 
that the sensor was well tolerated. Pain scores during sensor insertion were 
low and there was no sensation related to the sensor over the six-hour study 
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period. Similarly, skin inflammation was barely noticeable and transient. There 
was no evidence of bleeding at sensor site or infection. 
Further optimisation of sensor functionalisation is required to address the 
issue of disruption of the epoxy-PU membrane. Design of an applicator for 
sensor insertion should allow insertion without disrupting sensor layers. It will 
also allow delivering preset force and may reduce intra- and inter-subject 
variability in relation to percentage of microprobes penetrating stratum 
corneum and penetration depth. Assessment of skin insertion using optical 
imaging may help in evaluating the relationship between penetration depth, 
sensor output current and performance.  
Finally, further clinical studies in subjects with type 1 diabetes are required to 
assess sensor performance at different glycaemic ranges and at difference 
rates and directions of glucose change. 
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CHAPTER 6 
GLYCAEMIC VARIABILITY AND THE 
EFFECT OF REAL-TIME CONTINUOUS 
GLUCOSE MONITORING 
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6.1. INTRODUCTION 
6.1.1. Definition of glycaemic variability: 
There is growing interest, supported by evidence and the increased 
availability of CGM technology, in the role of glycaemic variability (GV) in the 
development of diabetes related complications, independent of HbA1c. 
However, there are many aspects related to GV that are potential source of 
confusion for both researchers and clinicians. This begins with the definition 
of GV. The term has been used to describe several concepts of variation in 
glycaemia. Based on studies evaluating different forms of glucose variations, 
the term GV has been used in the literature to describe (Frontoni et al., 
2013): 
1- Day to day variations in fasting glucose 
2- Post-prandial hyperglycaemia 
3- HbA1c variation 
4- Short-term Interday and intraday variability 
 
The confusion is further complicated by controversy related to the effect of 
GV on diabetes-related complications, the plethora of GV measures with the 
lack of a “gold standard” measure, and the limited accuracy of existing CGM 
systems, all of which may affect results obtained for GV measures.  
 
6.1.2. Measures of glycaemic variability: 
Glycated Haemoglobin (HbA1c) has been the gold standard for clinical 
assessment and monitoring of glycaemic status in people with diabetes. As 
several clinical studies (including the landmark Diabetes Control and 
Complications Trial (DCCT) and the United Kingdom Prospective Diabetes 
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Study (UKPDS)) have demonstrated the positive relationship between 
HbA1c level and the risk of vascular complications (UKPDS, 1998, DCCT, 
1993), HbA1c has been used by clinicians as a treatment target and for 
assessment of clinical response to therapeutic interventions. More recently, 
HbA1c has also been used for diagnosis of diabetes and impaired glucose 
tolerance . 
Despite its value being the glycaemic marker most linked to diabetes-related 
complications, HbA1c measures glycaemic exposure over 2-3 months, 
therefore it may not provide adequate information on frequency, duration or 
magnitude of short-term fluctuations in glycaemia and is limited in people 
with haemoglobinopathies, renal disease, and iron deficiency anemia. Two 
patients with the same HbA1c can have completely different daily glucose 
profiles with different patterns of glycaemic excursions and hypoglycaemia. 
Furthermore, HbA1c is a poor predictor of hypoglycaemic episodes 
accounting for only 8% of risk of future severe hypoglycaemia (Kovatchev et 
al., 2006). DCCT has also demonstrated that the three fold increased risk of 
hypoglycaemia in the intensive treatment group could not be completely 
explained by difference in HbA1c between the two groups (DCCT, 1997). 
With the growing interest in GV and its role in the pathogenesis of diabetes-
related complications, independent from HbA1c level, several measures 
have been proposed to describe GV (table 6.1). Some of these measures 
can be calculated from SMBG data, while others require CGM data. GV 
measures can be broadly subdivided into (Rodbard, 2009a, Rodbard, 2012): 
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A. Measures based on glucose distribution: examples include: 
• Standard deviation (SD) 
• Mean amplitude of glycaemic excursion (MAGE)  
• Continuous overlapping net glycaemic action (CONGA)  
• Mean of daily difference (MODD) 
• Lability index (LI) 
• Mean absolute glucose (MAG) 
B. Measures based on quality of glycaemic control that are also sensitive to 
GV: examples include: 
• M-value  
• J-index 
 C. Risk measures: examples include: 
• High blood glucose index (HBGI) 
• Low blood glucose index (LBGI) 
• Average daily risk range (ADRR)  
• Glycaemic risk assessment diabetes equation (GRADE) 
 
SD is the amount of spread around the mean. While it is easy to calculate 
and it is possibly the simplest tool to assess GV, the lack of Gaussianness of 
glucose profile data (being more skewed towards hyperglycaemic range) 
means that SD is more sensitive to hyperglycaemic excursions and not 
sensitive to hypoglycaemia. Furthermore, SD is dependent on mean glucose 
and there is a potential for widely different glycaemic curves having the 
identical numerical value of SD. However, SD remains a robust measure of 
GV because a linear relation has been established between interquartile 
range and SD (DeVries, 2013). 
Several methods to assess interday and intraday GV based on SD have 
been proposed (Rodbard, 2009a), such as total SD (SDT), SD within days 
(SDw), SD within corresponding time points of multiple days (SD hh:mm), SD 
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between multiple days within corresponding time points (SDb hh:mm) and SD 
between daily means (SDdm). 
Percentage coefficient of variation (%CV) is the ratio of SD to mean. This 
parameter allows for standardised comparisons between patients with 
different levels of mean glycaemia. It was proposed that %CV may be the 
best parameter to characterise GV since it avoids dependency of SD and 
GV measures on mean glucose and HbA1c (Rodbard, 2011). 
Measure Description Formulae 
SD Measure of spread around the 
mean SD = 
(!!!)!!!!  
G=glucose measured 
x= mean glucose 
N= number of observations 
CONGA It is the SD of the differences 
between glucose values that are n 
hour(s) apart (n can vary from 1 to 
24 hours).    
 
k=number of observations with an 
observationn×60"min ago 
m=n×60 
G=glucose measured 
LI Measure of severity of GV and 
hypoglycaemia. Was proposed for 
candidates of islet cell 
transplantation 
 
G=glucose measured 
N=total number of readings in a week 
t=time 
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Measure Description Formulae 
J-Index A measure of both variability and 
mean glycaemia. 
J=0.324×(MBG+SD)2 
MBG=mean glucose levels 
SD=SD of glucose levels 
GRADE A measure that provides the risk 
attributable to a certain glucose 
level (hypoglycaemia or 
hyperglycaemia and its degree of 
severity) 
GRADE=median (425×{log[log(Gn)]+0.16}2) 
G=glucose measured 
LBGI/HBGI Measures of hypoglycaemia and 
hyperglycaemia. The formulae 
convert glucose values into risk 
scores. If the risk score is below 0, 
then the measure is labelled as 
LBGI. If the risk score is above 0, 
the measure is labelled as HBGI. 
 
N=number of readings 
rl=risk value associated with a low glucose (if x<0) 
rh=risk value associated with a high glucose (if x>0) 
x=nonlinear transformation of glucose measured 
MODD A measure of inter-day variability. 
It is the mean of the absolute 
difference between paired glucose 
values from consecutive 24-hour 
periods. 
 
k=number of observations with an observation 24"h 
ago 
G=glucose measured 
t=time (in min) 
MAGE A Measure of major glucose 
fluctuations, by measuring 
average amplitude of upwards or 
downwards glucose fluctuations 
with magnitudes greater than1SD. 
 
λ=blood glucose changes from peak to nadir 
x=number of valid observations 
v=1 SD of mean glucose for a 24-h period 
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Measure Description Formulae 
ADRR A measure that combines 
information from both LBGI and 
HBGI. 
 
N=total number of readings 
LR=risk value attributed to low glucose 
HR=risk value attributed to high glucose 
M-value A measure of both variability and 
mean glycaemia. The formula 
incorporates a reference value, 
representing ideal glucose level, 
that is typically set to 6.67 mmol/L. 
 
G=glucose measured 
IGV=ideal glucose value 
k=total number of observations 
N=total number of readings 
MAG A measure for assessment of 
intraday GV. It calculates the sum 
of the differences between 
successive glucose values 
(typically 60 minutes apart) divided 
by the total time measured in 
hours 
 
G=glucose measured 
N=number of glucose measurements 
T=total time (in h) 
 
Table 6.1: Description and formulae of evaluated glycaemic variability 
measures (adopted from (Hill et al., 2011)). 
 
MAGE was first described by Service et al (Service et al., 1970) using 
SMBG data of 48 hours to assess major glucose swings and exclude minor 
ones. It is calculated by estimation of the SD before identifying the direction 
of the first glycaemic excursion that exceeds 1SD. Subsequent qualifying 
excursions (exceeds 1SD and in the same direction of the first excursion) 
are then identified and the arithmetic mean of glucose changes from peak to 
nadir is calculated. Despite its popularity as a measure of GV, MAGE has 
several limitations. It discards minor excursions (smaller than 1SD), which 
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can potentially be clinically relevant. It does not take frequency of excursions 
or the absolute value of each excursion into account.  There is also a 
difference in outcome when upwards or downwards excursions are used for 
calculation of MAGE. Moreover, its analysis is time-consuming and operator 
dependent. Four computer algorithms have been described to standardise 
MAGE calculation but they show poor correlation (Sechterberger et al., 
2014).  A modified method (MAGE-CGM) has been proposed to select a 
peak or trough based on direction of change (rising or falling) of the 
preceding and succeeding data points. The MAGE-CGM formula also 
contains a 15-min lag window for the direction of change based on the delay 
between interstitial fluid glucose measurement and plasma glucose 
concentrations. It also contains an algorithm that eliminates short-term 
fluctuations related to sensor inaccuracies (Hill et al., 2011). 
CONGA is a GV measure that was developed for CGM (McDonnell et al., 
2005). It is the SD of the differences between glucose values that are n 
hour(s) apart. n can vary from 1 to 24 hours.  Analysis requires at least 24 
hours CGM trace. Comparison between subjects with type 1 diabetes and 
non-diabetic subjects showed mean CONGA1 value in the group with 
diabetes of 2.5 (range 1.7–3.2) compared with 0.7 (range 0.4–1.2) in the 
control non-diabetic group. The mean CONGA4 value in the diabetes group 
was 4.6, compared with 1.0 in the control group (McDonnell et al., 2005). 
MODD is a measure of inter-day variability. It is the mean of the absolute 
difference between paired glucose values from consecutive 24 hour periods. 
Therefore, it requires at least 48 hours of CGM (Molnar et al., 1972). 
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MAG is a measure for assessment of intraday GV. It was originally 
developed to assess the impact of GV on mortality in intensive care unit. It 
calculates the sum of the differences between successive glucose values 
(typically 60 minutes apart) divided by the total time measured in hours 
(Hermanides et al., 2010). 
LI was proposed to assess the severity of GV and hypoglycaemia before 
and after islet cell transplantation (Ryan et al., 2004). The LI is calculated 
based on the change in glucose level over a four-week period using SMBG 
with glucose measurements 1-12 hours apart. It was reported that a LI≥24 
mmol/L2/h.week-1 indicates high risk of hypoglycaemia. A modified LI was 
proposed since LI is dependent on the number of glucose measurements 
used (Kim et al., 2011, Rodbard, 2009b). In a study using four glucose 
measurements daily, correlation between LI and modified LI (LI divided by 
number of daily glucose measurements) was strong (r= 0.87, P <0.01) (Kim 
et al., 2011). 
M-value is a hybrid measure of both variability and mean glycaemia. It is 
calculated on each glucose value using a formula and then is divided by the 
total number of values to produce a mean. The formula incorporates a 
reference value that is typically set to 6.67 mmol/L (120 mg/dL). The formula 
gives greater emphasis to hypoglycaemia than hyperglycaemia. To use M-
value for comparison between studies, the same reference value needs to 
be used (Service, 2013). 
The J-index is also a measure of both variability and mean glycaemia. It was 
originally derived from SMBG but has been adapted for CGM data. It is 
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calculated from the equation: J = 0.324 (mean blood glucose + SD)2 . J-
index > 30 indicates poor control, while J-index between 10-20 indicates 
optimum control (Hill et al., 2011).  
Hypoglycaemia has been identified as a significant barrier to optimisation of 
glycaemic control and has been linked to morbidity and mortality in people 
with diabetes (Seaquist et al., 2013).  Various approaches have been 
adopted to assess risk and severity of hypoglycaemia including low HbA1C, 
history of severe hypoglycaemia, hypoglycaemic awareness questionnaires, 
and HYPO score, which is a score based on the frequency, severity, and 
degree of unawareness of hypoglycaemia recorded over a four-week 
glucose monitoring period and from self-reported episodes over the previous 
year (Ryan et al., 2004). However, HbA1c is a poor predictor of 
hypoglycaemic episodes accounting for around 8% of risk of future severe 
hypoglycaemia (Kovatchev et al., 2006). On the other hand, measures of GV 
like SD are less sensitive to hypoglycaemia because of the skewness of 
glucose data towards the hyperglycaemic range.  
Several measures of GV have been proposed to assess future risks of 
hypoglycaemia, hyperglycaemia or both. As glucose profile is skewed 
towards the hyperglycaemic range, the numerical centre of glucose data (17 
mmol/L) is different from the clinical one (6-7 mmol/L). Three risk measures 
were proposed based on log transformation of the glucose profile to give 
equal weights to hypoglycaemic and hyperglycaemic ranges. By 
symmetrisation of glucose data around zero (equivalent to 6.25 mmol/L), 
HBGI and LBGI were computed to assess the risk of hyperglycaemic and 
hypoglycaemic excursions, respectively (Kovatchev et al., 1997). HBGI and 
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LBGI were originally computed from SMBG but have been adapted for use 
with CGM. HBGI>15 indicates high risk of hyperglycaemic excursions, while 
HBGI≤4.5 indicates low risk. Correlation between HBGI and HbA1c has 
been reported (Kovatchev et al., 1997). On the other hand, LBGI>5 indicates 
high risk of hypoglycaemia, while LBGI<2.5 indicates low risk. In a study 
evaluating LBGI in adults with type 1 diabetes, the frequency of future 
severe hypoglycaemia was predicted by the LBGI and history of severe 
hypoglycaemia, while HbA1, age, duration of diabetes, and BG variability 
were not significant predictors (Kovatchev et al., 1998).  
ADRR was proposed to give a predictive value of both hypoglycaemic and 
hyperglycaemic excursions. It is computed from SMBG data collected 
typically over one month (at least 14 days) with a typical frequency of 3-5 
glucose measurements per day. An ADRR > 40 indicates high risk for GV, 
while ADRR<20 indicates low risk (Kovatchev et al., 2006).  
Another GV measure that assesses the risk of hypoglycaemia and 
hyperglycaemia is GRADE. It was created based on 50 questionnaires 
completed by healthcare professionals, who were asked to assign a risk 
value to each glucose concentration. The lowest score was assigned to 
glucose value of 5 mmol/L and a logarithmic formula was used to transform 
every glucose value into a GRADE value. GRADE score is then obtained by 
calculating the mean of all GRADE values (Hill et al., 2009).  GRADE score 
is reported as overall score, GRADEhypo, GRADEhyper and GRADEeu to 
express the contribution of hypoglycaemia, hyperglycaemia and 
euglycaemia in the assessed glucose profile, respectively. 
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6.1.3. Tools to calculate glycaemic variability: 
SD is usually reported as a measure of GV in CGM reports, however 
calculation of other measures of GV is a complicated and time-consuming 
task, representing another barrier to the use of these GV measures in 
clinical practice. Several computer programs are currently available to 
compute several GV parameters. EasyGV is an excel-enabled workbook 
that is available free for non-commercial use at www.easygv.co.uk. It allows 
calculation of SD, mean, M-Value, MAGE, LI, ADRR, J-Index, LBGI, HBGI, 
CONGA, MODD, GRADE and MAG. The main excel sheet has a number of 
options that allows the user to set up the sampling interval, CONGA length, 
LI interval, reference value of M-value and whether SMBG or CGM is used 
for MAGE calculation (Hill et al., 2011).  
Glyculator is another tool for calculation of GV measures. It is available as a 
web-based application or as a more complex Windows-based programme. 
In both versions available, variability parameters are mean, median, SD, 
SDw, SDb hh:mm, SDdm, %CV, M-Value, J-index, MAGE, MODD, CONGA (for 
1, 2, 4, 6, and 24 h time intervals), and percentage of hyperglycaemia (levels 
between 7 and 10 mmol/L) and hypoglycaemia (levels below 3.9 mmol/L) 
episodes (Czerwoniuk et al., 2011). 
Two tools were specifically developed for computation of MAGE aiming to 
replace the time-consuming graphical estimation method (Fritzsche et al., 
2011, Baghurst, 2011). However, a study that compared MAGE values 
obtained from these two tools, EasyGV and Glyculator, showed poor 
correlation (Sechterberger et al., 2014). 
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6.1.4. Impact of GV: 
6.4.1. Impact of GV on hypoglycaemia: 
The DCCT study has demonstrated that the three fold increase in the risk of 
severe hypoglycaemia in the intensive treatment group compared to the 
conventional treatment group could not be simply explained by the 
difference in HbA1c between the two groups, with HbA1c accounting for only 
8% of risk of severe hypoglycaemia (Kilpatrick et al., 2007). To study the 
relationship between GV and hypoglycaemia, a re-analysis of the DCCT 
study has demonstrated that HbA1c, mean blood glucose, and GV 
measurements (assessed as SD) each have an independent role in 
determining an individual’s risk of severe hypoglycaemia in type 1 diabetes 
(Kilpatrick et al., 2007). The Diabetes Outcomes in Veterans Study 
assessed hypoglycaemia risk in 195 stable, insulin-treated subjects with 
type 2 diabetes, and found that mean blood glucose and SD were stronger 
predictors of hypoglycaemia than HbA1c (Murata et al., 2004). Similarly, a 
retrospective analysis of data from 24 week insulin trials including more than 
2000 subjects with type 2 diabetes (who only started insulin therapy in the 
trial), demonstrated that intraday and interday GV are significantly 
associated with the risk of hypoglycaemia, independent of mean glycaemia. 
In this study, out of all the evaluated GV measure, intraday % CV at baseline 
and interday % CV at 24 weeks were the strongest predictors of risk of 
hypoglycaemia between 12 and 24 weeks (Qu et al., 2012). In a study 
aiming to define the relative contribution of GV and mean glycaemia to the 
incidence of asymptomatic hypoglycaemia in 222 adults with type 2 
diabetes, GV (assessed by SD and MAGE using CGM) and the 48 hour 
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mean glucose were significant independent predictors of frequency of 
asymptomatic hypoglycaemia. Whereas HbA1, age, gender, duration of 
diabetes and treatment modality were not (Monnier et al., 2011). In this 
study, the analysis was limited to asymptomatic hypoglycaemia to exclude 
the rebound effect resulting from correction of symptomatic hypoglycaemia 
on both glucose concentration and GV. This suggests that high GV is the 
cause rather than the consequence of hypoglycaemia.  
6.4.2. Impact of GV on mortality in ITU: 
It was also demonstrated that GV is a significant independent predictor of 
ITU and hospital mortality in diabetic and non-diabetic adults. In a 
retrospective analysis that evaluated the relationship between GV 
(measured as SD and %CV) and ITU or hospital mortality in more than 7000 
critically ill subjects, both mean glucose and GV were significant 
independent predictors of ITU and hospital mortality (Egi et al., 2006, 
Krinsley, 2008). Similarly, a retrospective analysis of 5728 subjects (12.2% 
known to suffer from diabetes) showed that high GV (measured as MAG and 
SD) was a significant predictor of ITU and hospital mortality, independent of 
mean glycaemia (Hermanides et al., 2010). 
6.4.3. Impact on micro- and macro-vascular complications: 
As discussed earlier, the term “glycaemic variability” has been used to 
describe different forms of glucose variation, particularly when evaluating the 
effect of glucose variation on diabetes-related vascular complications. 
The relationship between variation in fasting plasma glucose (FPG) and 
diabetes-related microvascular complication, was evaluated in several 
studies. In a study of 170 subjects with type 2 diabetes (treated with either 
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diet, oral hypoglycaemic agents or insulin) and mean follow-up of 33 years, 
the SD of FPG was reported to be a significant risk factor for the 
development of proliferative diabetic retinopathy, independent of mean FPG 
or HbA1c (Takao et al., 2011). Post-prandial glucose (PPG) and its 
relationship to cardiovascular disease and mortality was also evaluated in 
several studies. The San Luigi Gonzaga Diabetes Study reported that post-
prandial hyperglycaemia is a strong predictor of cardiovascular disease and 
mortality, independent of HbA1c. In this study, the relationship between 5 
glycaemic control parameters (fasting blood glucose, blood glucose 2 h after 
breakfast, blood glucose 2 h after lunch, blood glucose before dinner, and 
HbA1c), and cardio-vascular events and all-cause mortality were examined 
in 505 subjects with type 2 diabetes with mean follow up of 14 years. Both 
HbA1c and blood glucose 2 hours post lunch, but not FPG, were strong 
independent predictors of cardio-vascular events and of all-cause mortality 
(Cavalot et al., 2006, Cavalot et al., 2011). This is supported by findings of 
the STOP-NIDDM study, a double-blind randomised controlled trial (RCT) 
that evaluated the effect of targeting PPG using acarbose on the risk of 
development of major cardiovascular events in more than 1000 subjects with 
impaired glucose tolerance, who were followed up for a mean of 3.3 years. 
Compared to placebo, targeting PPG using acarbose resulted in significant 
reduction in development of cardiovascular events (Chiasson et al., 2003). 
In contradiction, the HEART2D study has demonstrated that a significant 
difference in PPG values between two insulin regimens, while achieving 
comparable HbA1c and FPG values, was not associated with a difference in 
cardiovascular outcome. In this RCT, the effects of a prandial and a basal 
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insulin regimen with respect to cardiovascular outcomes was examined in 
more than 1000 subjects with insulin-treated type 2 diabetes after acute 
myocardial infarction who were followed for a mean of 963 days (Raz et al., 
2009).   
The role of HbA1c variability in the development of diabetes-related 
complications was also addressed in several studies. In type 1 diabetes, a 
re-analysis of the DCCT reported that HbA1c variability (after the first 6 
months to allow stabilisation in glycaemia) was an independent and stronger 
predictor, compared to mean HbA1c, of nephropathy or retinopathy, while 
short-term GV was not (Kilpatrick et al., 2008). This was supported by a 
more recent study that evaluated the relationship between HbA1c variability 
(measured as SD of HbA1c) and proliferative diabetic retinopathy in more 
than 2000 subjects with type 1 diabetes (Hietala et al., 2013).  
The A1c-Derived Average Glucose (ADAG) study, a multi-centre study that 
was designed to assess the relationship between HbA1c and mean glucose 
in 507 subjects (268 subjects with type 1 diabetes, 159 subjects with type 2 
diabetes and 80 non-diabetic subjects) using periodic CGM and seven 
points SMBG over 16 weeks, evaluated the relationship between different 
indices of glycaemia. While measures of intraday GV (SD, MAGE and 
CONGA) showed strong intercorrelation, their correlation with indices of 
fasting, postprandial, mean glucose and HbA1c was relatively weaker. 
Therefore, authors suggested that measures of intraday GV may convey 
different information to other measures of glycaemia (Borg et al., 2010). 
Several studies were conducted using different measures of interday and 
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intraday GV to examine the relationship between short-term GV and diabetes-
related vascular complications. The relationship between oxidative stress, 
which is believed to be the putative mediator for diabetes-induced 
vasculopathy, and GV, has been demonstrated both in vitro and in vivo. 
Intermittent exposure to hyperglycaemia in vitro had more evident effect on 
increasing oxidative stress compared to sustained hyperglycaemia (Risso et 
al., 2001, Quagliaro et al., 2003, Quagliaro et al., 2005, Piconi et al., 2004, 
Schiekofer et al., 2003). In human studies, Monnier et al examined the 
relationship between oxidative stress, as measured by urine 8-iso 
prostaglandin F2α excretion, short-term GV (measured as MAGE), PPG 
(measured as mean postprandial incremental area under the curve), FPG and 
HbA1c levels in 21 subjects with poorly controlled type 2 diabetes, who were 
not insulin-treated. In this case-control study, only MAGE and PPG showed  
significant correlation with oxidative stress (Monnier et al., 2006). Consistent 
with this, Ceriello et al demonstrated that glucose oscillation between 5 and 
15 mmol/L every 6 hours for a period of 24 hours have more deleterious 
effect on endothelial function and oxidative stress compared to constant 
hyperglycaemia of 10 or 15 mmol/L. The study was conducted in 27 subjects 
with diet- controlled type 2 diabetes and 22 non-diabetic subjects. In this 
study, flow mediated dilatation was used as a marker for endothelial function, 
whereas plasma 3-nitrotyrosine and 24-h urinary excretion rates of free 8-iso 
prostaglandin F2α served as markers for oxidative stress. The effect of glucose 
oscillation on endothelial function and oxidative stress was counterbalanced 
by vitamin C infusion (Ceriello et al., 2008). 
In an 11-year follow up study, while HbA1c was an independent predictor of 
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nephropathy, GV (assessed as SD of blood glucose) was a predictor of 
peripheral neuropathy and a highly significant predictor of hypoglycaemic 
unawareness in subjects with type 1 diabetes (Bragd et al., 2008). GV has 
also been linked to coronary artery calcification in men with type 1 diabetes, 
independent of HbA1c (Snell-Bergeon et al., 2010). In 75 subjects with type 1 
diabetes, a gender-dependent significant relationship was noted between 
measures of intraday and interday GV and coronary artery calcification, a 
surrogate marker of cardiovascular disease.  
The relationship between GV (measured as MAGE) and severity of coronary 
artery disease (CAD) was investigated in 286 subjects who were referred for 
coronary angiogram following stable angina or angina-like chest pain and 
were found to have newly diagnosed type 2 diabetes. The study reported that 
MAGE was significantly higher in patients with CAD compared to those 
without and that high MAGE (≥3.4 mmol/L) was an independent predictor 
(and stronger predictor compared to HbA1c) of prevalence and severity of 
CAD (Mi et al., 2012). These findings are similar to those of a study 
conducted by the same research group in 344 subjects with type 2 diabetes. 
35-40% of subjects were on insulin and subjects who had their anti-
hyperglycaemic therapy changed between coronary angiogram and CGM 
were excluded from the study. While the study showed the significant 
relationship between intraday GV (expressed as MAGE) and prevalence and 
severity of CAD, interday GV (expressed as MODD) failed to show any 
significant relationship to CAD (Su et al., 2011). 
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Despite the above evidence, the effect of such a complex phenomenon as 
short-term interday and intraday GV on diabetes-related complications 
remains controversial. In contrast to the study by Monnier et al that showed 
correlation between GV and markers of oxidative stress, a similar study failed 
to establish this relationship in subjects with either type 1 diabetes or well-
controlled type 2 diabetes (Wentholt et al., 2008, Siegelaar et al., 2011b). The 
DCCT has demonstrated that HbA1c accounted for almost 96% of the 
variation in risk of retinopathy between the intensive and conventional control 
groups, concluding that GV may only have small contribution towards the risk 
of retinopathy between the two groups over time (Lachin et al., 2008). This 
was supported by another re-analysis of DCCT data, which reported that only 
variability in HbA1c, rather than that of GV (using SD or MAGE) predicted the 
development of retinopathy or nephropathy (Kilpatrick et al., 2006, Kilpatrick 
et al., 2008, Kilpatrick et al., 2009). An observational study aiming to evaluate 
the relationship between diabetic retinopathy and GV (assessed using SD, 
MAGE, CONGA2 and HBGI) was conducted in 35 subjects with type 1 
diabetes and 33 subjects with type 2 diabetes. Although univariate analysis 
showed significant relationship between diabetic retinopathy and each of SD, 
CONGA2 and HBGI, multivariate analysis showed that diabetes duration was 
the only significant parameter correlating with diabetic retinopathy (Sartore et 
al., 2013).  In a reanalysis of HEART2D, the effect of GV on cardiovascular 
disease was assessed using MAG, MAGE and SD. Despite an 18% reduction 
in MAG in the prandial insulin group, there was no difference between the two 
groups with regards to cardiovascular events (Siegelaar et al., 2011c). The 
ADAG study group reported that while mean glucose and HbA1c have 
207
! 208!
stronger associations with cardiovascular disease risk factors than fasting 
glucose or postprandial glucose in subjects with type 1 and type 2 diabetes, 
measures of intraday GV did not have a significant effect (Borg et al., 2011). 
Furthermore, a recent systematic review concluded that GV was associated 
with increased risk of development of microvascular complications only in 
type 2 diabetes and that the relationship between GV in type 1 diabetes and 
either microvascular or macrovascular complications was less clear (Smith-
Palmer et al., 2014).  
6.4.4. Impact of GV on psychological function: 
GV has also been linked to psychological function, quality of life (QoL) and 
patients’ satisfaction. In a randomised, controlled, crossover study, 388 
subjects with type 1 diabetes and insulin treated type 2 diabetes were 
randomised to either basal-bolus or twice-daily insulin regimens for 12 weeks 
before crossover. Reduction in GV (measured as SD using CGM) and 
improved mean glycaemia in the basal-bolus group were both independent 
predictors of patients’ satisfaction (Testa et al., 2012). In another study that 
examined the correlation between GV and health-related QoL in 23 women 
with type 2 diabetes, 24 hour SD and CONGA showed significant correlation 
with QoL after adjustment for age and weight (Penckofer et al., 2012). 
 
6.2. AIMS: 
The present analysis aims to describe several indices of GV and quality of 
glycaemic control in a large cohort of subjects with type 1 diabetes in 
comparison to normal reference ranges defined in people without diabetes. It 
also aims to examine the intercorrelation between these measures and the 
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correlation with HbA1c. Furthermore, It studies the effect of RT-CGM on these 
indices and the baseline factors predicting change, aiming to identify GV 
measures that are more sensitive to overall glycaemic status of people with 
type 1 diabetes.  
 
6.3. METHOD: 
We used data from the JDRF sponsored “Randomized Clinical Trial to Assess 
the Efficacy of RT-CGM in the Management of Type 1 Diabetes”. The 
publically accessible data obtained from “Jaeb Center for Health Research ” 
website (http://diabetes.jaeb.org/Dataset.aspx) were processed using Matlab 
(Mathworks) and EasyGV (v8.8.2.R2).  
 
Study design and intervention:   
The JDRF CGM study is a randomised, parallel group, efficacy and safety 
study (Group, 2008). The study included subjects meeting the following 
criteria: aged 8 years old or older with a diagnosis of type 1 diabetes for at 
least 1 year, HbA1c ≤10% and being able to use blinded RT-CGM during the 
assessment period. Exclusion criteria were the presence of a significant 
psychiatric or medical disorder that in the judgment of the investigator would 
adversely affect conduct of the study, home use of a RT-CGM systems in the 
preceding 6 months, participation in another intervention study in the 
preceding 6 weeks or pregnancy. 
 Subjects started to enroll in the study, that took place in 10 clinical centers, in 
early 2007. As shown in Figure 6.1, subjects with type 1 diabetes who meet 
eligibility criteria were randomised 1:1 to either standard SMBG alone or use 
of RT-CGM as a supplement to SMBG. At completion of the 6-month RCT, 
209
! 210!
subjects in the RT-CGM group continued to use RT-CGM for another 6 
months. In addition, subjects in the SMBG control group were offered use of 
RT-CGM for 6 months with less intensive contact than was provided at 
initiation of RT-CGM use in the RT-CGM group.  
On enrollment in the study, subjects were allowed to choose from the 
Medtronic (Northridge, CA), DexCom (San Diego, CA), or Abbott Diabetes 
Care (Alameda, CA) RT-CGM systems. 
To qualify for randomisation, subjects must have used the RT-CGM system 
for at least 6 out of the 7 days assessment period, have a total of at least 96 
hours of RT-CGM glucose values with at least 24 hours between the hours of 
10 p.m. and 6 a.m., and have performed at least three meter glucose tests 
each day. 
 
Figure 6.1: Diagram showing JDRF CGM study design. 
“Reprinted from Group, J.C.S., JDRF randomized clinical trial to assess the 
efficacy of real-time continuous glucose monitoring in the management of type 
1 diabetes: research design and methods. Diabetes Tech Ther, 2008. 10(4): p. 
310-21, Copyright (2008), with permission from Mary Ann Liebert, Inc” 
 
According to baseline HbA1c, the study cohort was separated into two 
different cohorts. The main study cohort included subjects with baseline 
were too difficult and u comfortable to use and not very ac-
curate (the GlucoWatch® Biographer™ [Animas Corp., West
Chester, PA]).9 More recently, several new, real-time (RT)
continuous glucose monitoring (CGM) systems have been
introduced that have improved accuracy, functionality, and
tolerance. However, sufficient evidence has not yet been ac-
cumulated to justify the widespread utilization of these de-
vices, even for children with T1D who are so difficult to treat
with standard methods of management. Clinical trials of RT-
CGM technology are also critically important to demonstrate
how this technology should be implemented and used.
In 2006, the Juvenile Diabetes Research Foundation (JDRF)
issued a Request for Applications from leading adult and pe-
diatric diabetes research centers in the United States to par-
ticipate in a consortium to develop a randomized clinical trial
to fill the gaps in knowledge related to the efficacy and ef-
fectiveness of the new RT-CGM systems. Ultimately, 10 clin-
ical centers, a coordinating center, and a health economics
follow-on team were selected, operating procedures for the
JDRF CGM Study Group were established, a randomized
clinical trial protocol was developed, and subjects began to
be enrolled in the study in early 2007. In this paper, we pres-
ent and discuss the research design and methods that are be-
ing employed in this large-scale, multicenter study.
Research Design and Methods
Study design
The JDRF CGM study is a randomized, parallel group, ef-
ficacy and safety study. As shown in Figure 1, subjects wit
T1D who meet eligibility criteria are randomized 1:1 to ei-
ther standard SMBG alone or use of RT-CGM as a supple-
ment to SMBG. At completion of the 6-month RCT, subjects
in the RT-CGM group continue to use RT-CGM for another
6 months to examine the durability of any beneficial effects
of RT-CGM that are seen in the first 6 months. In addition,
subjects in the SMBG control group are offered use of RT-
CGM for 6 months with less intensive contact than was pro-
vided at initiation of RT-CGM use in the RT-CGM group.
This crossover extension period is being offered to the SMBG
control group both as incentive to participate in the RCT and
as a means to examine whether RT-CGM is effective, even
in the fa e f less intense clinic follow-up. It should also be
noted that the JDRF CGM study actually includes two, sep-
arate study cohorts who differ with respect to baseline
HbA1c levels. The Main Study Cohort comprises patients
with T1D who have a baseline HbA1c of 7.0–10.0% inclusive.
The Exploratory Pilot Study Cohort includes subjects who
meet the same eligibility criteria but have a baseline HbA1c
of !7.0%.
The separation into two cohorts and two separate studies
according to baseline HbA1c level was done because the in-
vestigators concluded that there was no single widely ac-
cepted primary outcome that could be used across the full
range of HbA1c values. A difference in HbA1c levels be-
tween the two study groups at end point is a meaningful pri-
mary outcome for individuals who enter the study with
HbA1c "7.0% that would be acceptable to the scientific, clin-
ical, and insurance communities. On the other hand, change
in HbA1c is not a satisfactory primary outcome for individ-
uals with HbA1c !7.0% at baseline. In this group of patients,
successful use of RT-CGM to reduce the frequency of hypo-
glycemic events may be associated with either no change or
a small increase of HbA1c levels. Including such individu-
als in the Main Study (with HbA1c as the primary outcome)
would have reduced that study’s statistical power to lower
HbA1c and give the mistaken appearance of lack of effec-
tiveness.
Reduction in the frequency of severe hypoglycemia is per-
haps a plausible and appealing primary outcome in subjects
with HbA1c levels !7.0%. Fortunately, the frequency of se-
vere hypoglycemia, as defined by the DCCT, appears to be
decreasing with the more widespread use of insulin pumps
and insulin analogs.6,10–16 Since the RCT is relatively short
in duration, an impractically large sample size would be
needed to evaluate whether RT-CGM use can reduce the in-
cidence of severe hypoglycemic events in either cohort. A
definition of hypoglycemia that included less severe events
(such as confirmed symptomatic episodes in which assis-
tance was not needed) probably would be biased against the
RT-CGM group, since the use of the RT-CGM is likely to
identify more events merely because the sensor glucose level
is known. Therefore, subjects with baseline HbA1c !7.0%
are enrolled in an Exploratory Pilot Study that is examining
JDRF CGM RANDOMIZED TRIAL 311
Eligibility:
Single arm cross over
Able to use blinded
RT-CGM during
Baseline assessment
Randomization
0 month
Alone
SMBG
!RT-CGM
SMBG
6 months 12 months
• TID
• "8 yrs of age
• HbAlc # 10.0%
• Not Pregnant or
planning pregnancy
• Naïve to sensor use
FIG. 1. Study design.
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HbA1c between 7-10% inclusive. The other cohort included subjects with the 
same eligibility criteria but with baseline HbA1c <7%. 
Outcomes and measures of GV and quality of glycaemic control: 
The primary outcome of the JDRF CGM study was between group 
differences in HbA1c at 26 weeks. 
SMBG control group subjects were blinded to baseline CGM data, and 
subsequent blinded CGM profiles were obtained at 13 and 26 weeks post-
randomisation. These data were collected for comparison against unblinded 
sensor data obtained in the RT-CGM group at the same time points of study, 
to detect between group differences in GV indices at 26 weeks. 
Glucose profile data collected at 52 weeks from subjects in the control group 
who crossed-over to RT-CGM (unblinded control), were compared with data 
collected at 26 weeks in the same group (blinded control), to evaluate the 
effect of unmasking of CGM on changes of GV indices. 
Statistical analysis: 
Data were examined for normality. Non-normally distributed variables 
(baseline LI, baseline J-index, baseline LBGI, baseline M-value and baseline 
MAG) were logarithmically transformed with the use of geometric mean, SD 
and 95% CI for descriptive statistics of baseline data (n=448). Pearson 
correlation was used to examine the relationship between HbA1c and 
indices of GV and quality glycaemic control at baseline (n=448). 
Independent t-test was used to analyse the effect of RT-CGM in comparison 
to blinded control on the change of GV indices at 26 weeks. To study the 
effect of unmasking CGM in the control group, we used paired t-tests to 
compare GV indices at 52 weeks (unblinded CGM, n=207) with GV indices 
211
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at 26 weeks (blinded CGM, n=214). The associations of baseline 
demographic and clinical factors with change in GV indices from baseline to 
6 months were evaluated in the RT-CGM group (intervention, n=231) using 
regression models. The analysis was constructed using the following 
predictor variables: age, gender, race, education level of care giver, Insulin 
modality (pump or multiple daily injections (MDI)), frequency of daily self-
reported blood glucose monitoring, occurrence of one or more episodes of 
severe hypoglycaemia in the preceding 6 months, diabetes duration, 
baseline HbA1c and baseline GV. Categorical variables were included as 
dummy variables. Baseline factors with P≤0.2 in the univariate analysis were 
carried forward to multivariate analysis.  
Data are presented as means (SD), unless otherwise stated. Statistical tests 
were two tailed with statistical significance at P<0.05 and performed using 
SPSS 21.0 for Mac (SPSS Inc., Chicago, IL). 
6.4. RESULTS: 
6.4.1. Participants’ characteristics: 
CGM profile data were available for 448 subjects at baseline (54.9% 
females, 94.4% white race), following exclusion of 3 subjects due to missing 
HbA1c data at baseline. Mean age was 25.1years (SD 15.8) and mean 
diabetes duration 13.6years (SD 11.7). 231 subjects were randomised to the 
RT-CGM group and 217 subjects to the control group. At 26 weeks, CGM 
profile data were available for all the 231 subjects in the RT-CGM group and 
214 subjects in the control group (blinded CGM). At 52 weeks, data were 
available for 207 subjects in the control group (unblinded control). Baseline 
characteristics were similar between the 2 groups (table 6.2). 
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 Control RT CGM 
Number 217 231 
Female sex – no.(%) 124 (57.1%) 122 (52.8%) 
Age – no. (%) 
 8 – 14 yrs 
 15 – 24 yrs 
 ≥ 25 yrs 
 
68 (31.35%) 
70 (32.25%) 
79 (36.4%) 
 
74 (32%) 
71 (30.7%) 
86 (37.2%) 
 White race – no. (%) 205  (94.4%) 218 (94.3%) 
Duration of diabetes – yr   13.42 (11.54) 13.85 (11.96) 
Insulin administration – no. (%) 
  Pump 
  MDI 
 
175 (80.6%) 
42 (19.4%) 
 
190 (82.2%) 
41 (17.8%) 
HbA1c - % 
  < 7.0% - no. (%) 
 7.0 – 8.0% - no. (%) 
 8.1 – 8.9% - no. (%) 
 ≥ 9.0% - no. (%) 
 
61 (28.1%) 
109 (50.2%) 
39 (18%) 
8 (3.7%) 
 
67 (29%) 
109 (47.2%) 
44 (19%) 
11 (4.8%) 
≥ one episode of severe hypoglycaemia 
in last 6 months – no. (%) 
17 (7.8%) 21 (9.1%) 
Self-reported daily SMBG – no./day 6.26 (2.73) 6.11 (2.42) 
College graduate (patient or primary 
care giver) – no. (%)  
194  (89.4%) 197 (85.3%) 
 
Table 6.2: Baseline characteristics of participants in the control and 
intervention groups. 
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6.4.2. Measures of GV and glycaemic control at baseline: 
A normative range for 13 measures for GV and quality of glycaemic control, 
computed using EasyGV, was previously described by analysing CGM 
profiles of 70 non-diabetic subjects (table 6.3) (Hill et al., 2011). Figure 6.2 
shows a comparison between these measures in subjects with type 1 
diabetes, obtained by analysis of the glycaemic profiles of the 448 subjects 
enrolled in the JDRF CGM study, and the normal range in non-diabetic 
subjects. The mean values of GV indices at baseline in the 448 subjects with 
type 1 diabetes were all outside the normal range (P<0.001). Measures that 
showed the largest difference between the two groups were ADRR (33.35 vs 
0.4, P<0.001), LI (6.17 vs 0.4, P<0.001), HBGI (12.03 vs 0.2, P<0.001), 
GRADE (8.37 vs 0.4, P<0.001) and J-index (52.72 vs 14.3, P<0.001). On the 
other hand, differences in SD and MAG were relatively smaller, (3.73 vs 1.5, 
P<0.001) and (2.7 vs 1.3, P<0.001), respectively. Mean glucose in type 1 
diabetes subjects was 9.27 mmol/L vs 5.1 mmol/L for the non-diabetic 
subjects. 
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Table 6.3: Descriptive statistics (mean, 95% CI) for GV indices in 70 subjects 
without diabetes representing normal reference range (Hill et al., 2011) and in 
the 448 subjects with type 1 diabetes at baseline. Difference between 
measures of GV and glycemic control in the two groups is statistically 
significant (P<0.001). 
GV measure Reference  
(mean, 95%CI) 
Type 1 DM 
(mean, 95%CI) 
Mean  5.10 (4.98, 5.22) 9.27 (9.10, 9.43) 
SD 1.50 (1.34, 1.66) 3.73 (3.64, 3.82) 
CONGA 4.60 (4.48, 4.72) 8.29 (8.13, 8.44) 
LI 0.40 (-0.12, 0.92) 6.17 (5.84, 6.51) 
J index 14.30 (13.20, 15.40) 52.72 (50.83, 54.67) 
LBGI 3.10 (2.65, 3.55) 4.10 (3.79, 4.43) 
HBGI 0.20 (-0.69, 1.09) 12.03 (11.53, 12.53) 
GRADE 0.40 (-0.09, 0.89) 8.37 (7.98, 8.76) 
MODD 0.80 (0.47, 1.13) 4.06 (3.95, 4.16) 
MAGE-CGM 1.40 (1.24, 1.56) 6.76 (6.54, 6.98) 
ADRR 0.40 (-0.56, 1.36) 33.35 (32.21, 34.48) 
M-value 4.70 (3.81, 5.59) 14.70 (13.83, 15.62) 
MAG 1.30 (1.21, 1.39) 2.70 (2.61, 2.79) 
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6.4.3. Intercorrelation between measures of GV at baseline and 
correlation with HbA1c: 
Statistically significant intercorrelation between measures of GV and quality 
of glycaemic control was common. ADRR showed the strongest 
intercorrelation with other measures with r>0.7 in 9 out of 12 intercorrelations. 
Other measures of intraday GV (e.g. SD, CONGA, GRADE and M-Value) 
and interday GV (e.g. MODD) also showed strong intercorrelation. By 
contrast, LBGI showed the weakest intercorrelation. Similarly, all these 
measures, apart from LBGI, correlated significantly with HbA1c, as shown in 
table 6.4.  
The relationship between percent of time spent in hypoglycaemia (glucose 
level ≤3.9 mmol/L (≤70mg/dL), ≤3.3 mmol/L (≤60 mg/dL) and ≤2.8 mmol/L 
(≤50 mg/dL)), LBGI and HbA1c was analysed using spearman correlation. As 
shown in table 6.5, only LBGI correlated strongly with time spent in 
hypoglycaemia at glucose levels of ≤ 3.9 mmol/L, ≤3.3 mmol/L or ≤2.8 
mmol/L (r>0.88, P<0.001). 
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  ≤2.8 mmol/L 
≤3.3 
mmol/L 
≤3.9 
mmol/L 
4-10 
mmol/L 
10.1-
13.9 
mmol/L 
≥14 
mmol/L SD LBGI 
HbA1c -.101* -.213** -.285** -.627** .507** .663** .514** -0.066 
≤2.8 
mmol/L   .888
** .822** -.119* -.281** -0.016 .306** .894** 
≤3.3 
mmol/L     .965
** 0.033 -.430** -.166** .217** .923** 
≤3.9 
mmol/l       .130
** -.522** -.247** .158** .889** 
4-10 
mmol/L         -.684
** -.897** -.75** -.170** 
10.1-
13.9 
mmol/L 
          .554** .266** -.254** 
≥14 
mmol/L             .842
** 0.042 
SD               .378** 
 
 
**Correlation is significant at the 0.01 level (2-tailed). 
*Correlation is significant at the 0.05 level (2-tailed). 
 
Table 6.5: Correlation matrix examining the relationship between time spent 
in various glucose ranges, HbA1c, SD and LBGI in 448 subjects with type 1 
diabetes at baseline. 
 
6.4.4. Effect of RT-CGM on GV measures in the intervention group: 
At 26 weeks, results available from all subjects in the intervention group and 
from 214 subjects in the control group, showed significant reduction in the 
majority of measures of GV and quality of glycaemic control from baseline in 
the intervention group in comparison to the control group (table 6.6 - figure 
6.3).   There was a significant reduction of HbA1c in the intervention group 
from 7.41% to 7.18% (P<0.001). Correspondingly, the largest reductions in 
measures of GV were observed in M-value, LBGI and GRADE (measures of 
quality of glycaemic control) with a relative reduction of 25.7%, 24.9% and 
16.5%, respectively (P<0.001). Similarly, a reduction in MODD, MAGE and 
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SD of 8.3%, 6.7% and 6.6%, respectively was observed. In contrast, there 
was no statistically significant reduction in any of the measures of GV in the 
control group at 26 weeks compared to baseline.  
Δ at 26 weeks 
RT-CGM group 
(n=231) 
Mean (SD) 
Control Group 
(n=214) 
Mean (SD) 
Difference 
in Mean P Value 
HbA1c -0.24(0.68) -0.01 (0.56) -0.23 <0.001 
Mean -0.34 (1.31) -0.04 (1.29) -0.30 0.016 
SD -0.24(0.67) 0.001 (0.74) -0.23 <0.001 
CONGA -0.43(1.3) -0.06 (1.27) -0.36 0.003 
LI -0.17(2.87) 0.09 (3.68) -0.27 0.382 
J-index -5.58 (16.4) -0.72 (15.67) -4.86 0.002 
LBGI -1.32 (3.3) -0.19 (4.48) -1.12 0.003 
HBGI -1.76 (3.9) -0.38 (3.9) -1.37 <0.001 
GRADE -1.38 (3.2) -0.31 (3.33) -1.06 0.001 
MODD -0.33 (0.82) 0.37 (1.12) -0.70 <0.001 
MAGE -0.45 (1.66) 0.2 (2) -0.66 <0.001 
ADRR -2.03 (8.6) 6.65 (12.6) -8.69 <0.001 
M-value -4.5 (8.5) -0.9 (9.17) -3.61 <0.001 
MAG 0.05 (0.89) 0.11(1.05) -0.07 0.451 
 
Table 6.6: comparing the change in mean of HbA1 and glycaemic variability 
indices in both the intervention (n=231) and control (n=214) groups at 26 
weeks.
220
!
22
1!
 
 
Fi
gu
re
 6
.3
: 
Th
e 
ef
fe
ct
 o
f 
R
T-
C
G
M
 a
t 
26
 w
ee
ks
 o
n 
re
la
tiv
e 
ch
an
ge
 i
n 
th
e 
m
ea
n 
of
 v
ar
io
us
 m
ea
su
re
s 
of
 g
ly
ca
em
ic
 
va
ria
bi
lit
y 
an
d 
qu
al
ity
 o
f g
ly
ca
em
ic
 c
on
tro
l i
n 
co
m
pa
ris
on
 to
 c
on
tro
l g
ro
up
.  
**
* 
P
<0
.0
01
, *
* 
P
<0
.0
1,
 *
p<
0.
05
.  
 
H
b
A
1c
&
M
ea
n
&
SD
&
CO
N
G
A
&
LI
&
J4
In
d
ex
&
LB
G
I&
H
B
G
I&
G
R
A
D
E&
M
O
D
D
&
M
A
G
E&
A
D
R
R
&
M
4V
al
u
e&
M
A
G
&
R
T4
CG
M
&
43
.2
4&
43
.6
8&
46
.5
8&
45
.2
1&
42
.4
5&
49
.9
6&
42
4.
91
&
41
4.
93
&
41
6.
55
&
48
.2
9&
46
.6
7&
46
.2
7&
42
5.
71
&
1.
41
&
Co
n
tr
o
l&
40
.1
6&
40
.4
3&
0.
03
&
40
.7
8&
1.
27
&
41
.2
5&
43
.5
0&
43
.1
2&
43
.7
7&
9.
01
&
2.
79
&
19
.3
1&
44
.9
1&
3.
89
&
43
0.
00
&
42
5.
00
&
42
0.
00
&
41
5.
00
&
41
0.
00
&
45
.0
0&
0.
00
&
5.
00
&
10
.0
0&
15
.0
0&
20
.0
0&
25
.0
0&
%&change&at&26&weeks&
**
*"
**
"
**
"
**
*"
**
*"
**
*"
**
*"
**
*"
**
*"
**
*"
*"
**
*"
221
! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!222!
6.4.5. Effect of unmasking of CGM in the control group:  
The effect of unmasking CGM in the control group at 26 weeks was 
evaluated by comparing GV measures at 52 weeks to those at 26 weeks 
(immediately prior to unmasking CGM). Despite the non-significant change in 
HbA1c at 52 weeks, there was significant reduction in most of the measures 
of GV and quality of glycaemic control from baseline (26 weeks). The largest 
reduction was observed in LBGI (21.8%, P<0.001). Correspondingly, ADRR, 
GRADE and HBGI (representing other risk measures) were reduced by 
21.2%, 6% and 9.5% respectively (P<0.001).  Other significant large 
reductions were observed in M-value, MODD and MAGE with a reduction of 
17.6%, 16% and 12% respectively (P<0.001).  (figure 6.4 - table 6.7). 
  
Mean         
(26 
weeks) 
Mean     
(52 
weeks) 
Paired Differences 
% 
Difference 
P 
value Mean SD SEM 
HbA1c 7.44 7.42 -0.02 0.61 0.04 -0.27 0.63 
Mean 9.27 9.16 -0.11 0.90 0.06 -1.22 0.07 
SD 3.85 3.56 -0.28 0.57 0.04 -7.36 <0.001 
CONGA 8.29 8.05 -0.24 0.95 0.07 -2.90 <0.001 
LI 7.62 7.55 -0.07 2.91 0.20 -0.94 0.72 
J-INDEX 57.23 53.66 -3.56 11.49 0.80 -6.23 <0.001 
LBGI 5.34 4.17 -1.16 2.40 0.17 -21.82 <0.001 
HBGI 11.99 10.85 -1.14 2.75 0.19 -9.51 <0.001 
GRADE 8.04 7.55 -0.48 2.14 0.15 -6.03 <0.001 
MODD 4.52 3.80 -0.72 0.86 0.06 -15.95 <0.001 
MAGE 7.41 6.52 -0.89 1.41 0.10 -12.04 <0.001 
ADRR 41.14 32.42 -8.72 10.39 0.72 -21.20 <0.001 
M-VALUE 17.30 14.25 -3.04 5.72 0.40 -17.59 <0.001 
MAG 3.08 3.05 -0.04 0.96 0.07 -1.19 0.58 
 
Table 6.7: showing mean values of measures of GV at 52 weeks compared to 
baseline (26 weeks) in the control group following unmasking of CGM. The 
table also shows the absolute and relative change in the mean values. 
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6.4.6. Factors predictive of response in the RT-CGM group:  
 As shown in table 6.8, baseline GV was found to be a significant predictor of 
change in measures of GV at 26 weeks in the intervention group, with higher 
baseline GV associated with greater reduction in GV at 26 weeks. Baseline 
HbA1c was also a significant predictor of change in GV in the majority of the 
evaluated GV measures (except LBGI, LI and MAG). Treatment with insulin 
pump and frequent use of SMBG predicted a reduction in some of the 
evaluated GV measures. 
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6.5.    DISCUSSION: 
 The development and advances in CGM have paved the way for 
researchers to investigate short-term GV and its potential role in the 
pathogenesis of diabetes-related complications and ITU mortality, even in 
non-diabetics. However, there remain controversies particularly related to the 
role of post-prandial hyperglycaemia and short-term GV as a risk factor for 
diabetes-related vascular complications particularly in type 1 diabetes. Apart 
from clinical studies that were conducted in very specific subgroups (e.g. 
HEART2D in type 2 diabetes subjects post-MI and STOP-NIDDM that was 
conducted in subjects with impaired glucose tolerance), the evidence is 
largely based on pathophysiological studies and observational studies with 
conflicting results. Most of the evidence evaluating role of short-term GV in 
development of diabetes-related vascular complications in type 1 is from 
analysis of the DCCT. It was previously estimated that only around 20% of 
the total type 1 diabetes population would meet the selection criteria of the 
DCCT, affecting the ability to generalise findings based on DCCT data to the 
overall type 1 diabetes population (Kilpatrick et al., 2007). Furthermore, as 
highlighted by Mounnier et al, the role of exogenous insulin as an anti-
inflammatory in neutralising the deleterious effect of GV on oxidative stress 
can be a confounding factor when evaluating the relationship between GV 
and the risk of development of diabetes-related vascular complications in 
insulin-treated diabetic subjects (Monnier et al., 2012).  
Several GV measures have been proposed, with a lack of consensus on a 
gold standard measure, causing increasing confusion with regards to the 
significance of some of these measures and whether they add any further 
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clinically relevant information for glucose profile assessment (Rodbard, 
2012). An ideal GV measure should accurately reflects and predicts risks of 
both hypoglycaemic and hyperglycaemic excursions in relation to both 
frequency and severity. An ideal measure should also result in clinical 
improvement once targeted by therapeutic interventions and should have 
prognostic value. As existing GV measures assign different weights and 
importance to hypoglycaemic and hyperglycaemic components of the 
glucose profile, it might be important, as shown in this analysis, to identify 
two “gold standard” GV measures that can accurately assess each 
component of the glycaemic profile. 
The data reported here are from the largest continuous glucose dataset with 
evaluation of GV, quality of glycaemic control, the effect of RT-CGM on these 
measures and predictors of changes to variability. Since the normal range of 
several GV measures was not identified when these measures were 
proposed, several studies were conducted aiming to establish the range of 
GV measures in non-diabetic subjects. The normal ranges for the measures 
of GV evaluated in this analysis have been previously described by analysing 
CGM profiles of 70 non-diabetic subjects of mixed ethnicities using EasyGV 
(Hill et al., 2011). Another study assessed the normal range of MAGE and 
SD in 434 non-diabetic Chinese subjects recommended a MAGE level of 
<3.9 mmol/L and SD<1.4 mmol/L as the normal reference ranges for GV in 
Chinese adults (Zhou et al., 2011). Our analysis demonstrates the magnitude 
of variability in people with type 1 diabetes and the distinct difference 
between measures of GV at baseline between subjects with type 1 diabetes 
and non-diabetic subjects. These findings are consistent with the findings of 
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the ADAG study that reported MAGE, CONGA4 and SD of its cohort of 268 
subjects with type 1 diabetes, 159 subjects with type 2 diabetes and 80 non-
diabetic subjects (Borg et al., 2010). However, our data also extend the 
description to other measures of GV in a larger cohort of subjects with type 1 
diabetes. 
It was previously reported that GV measures show strong intercorrelation in 
non-diabetic subjects, whereas the intercorrelation between these measures 
in 48 subjects with type 1 diabetes was relatively weaker (Cameron et al., 
2010). In contrast to this, the present analysis shows there is a large level of 
agreement between the evaluated measures with 75 out of 78 correlations 
being significant at the P<0.05 level. Although it is expected that measures 
that assess quality of glycaemic control will show stronger intercorrelation 
compared to their correlation with measures of GV, that was not the case 
with ADRR showing close correlation with 9 out of 12 measures. Similarly, 
SD, J-index, M-value and HBGI showed close intercorrelation with both 
measures of GV and quality of glycaemic control. This suggests that these 
measures convey similar information and it might be sufficient, clinically, to 
rely on only one of them. The measure that showed the weakest correlation 
with other measures was LBGI. The likely explanation for this is while LBGI is 
designed to be sensitive to hypoglycaemia alone, other measures are more 
influenced by hyperglycaemic excursions.  
Despite the evidence suggesting that GV plays a role in the pathogenesis of 
development of diabetes-related complications, the issue remains 
controversial. To date, there has been no prospective randomised clinical 
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trial to examine the relationship between GV and diabetes-related 
complications independent of HbA1c. Examining the relationship between 
HbA1c and measures of GV at baseline, we identified significant correlations 
between HbA1c at baseline and most of these measures (with the exception 
of LBGI). This is consistent with results from the ADAG study, where MAGE, 
CONGA and SD showed significant intercorrelation alongside significant 
correlation with HbA1c (Borg et al., 2010). This implies that GV measures 
convey similar information to HbA1c for assessment of glycaemic status. 
These intercorrelations between markers of variability and their close 
relationship with HbA1c in a large cohort suggest that there may only be a 
very limited role for the metrics over and above HbA1c.  
However, LBGI, designed to be sensitive to hypoglycaemia alone, correlated 
poorly with other GV measures and not at all with HbA1c. This support the 
hypothesis that HbA1c may have a limited role in reflecting or predicting the 
risk of hypoglycaemia (Kovatchev et al., 2006) and suggests that LBGI may 
offer additional information to HbA1c when assessing CGM data. This 
observation is supported by further correlation analysis between time spent in 
hypoglycaemia, LBGI and HbA1c, which demonstrated that only LBGI 
correlates strongly with time spent in hypoglycaemia (glucose level ≤3.9 
mmol/L (≤70mg/dL), ≤3.3 mmol/L (≤60 mg/dL) and ≤2.8 mmol/L (≤50 
mg/dL)). However, the relationship between time spent in hypoglycaemia and 
LBGI may suggest that LBGI can be replaced by direct assessment of the 
percent of time spent in hypoglycaemia, which is routinely reported when 
downloading CGM data. 
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This analysis also demonstrates the positive effect of RT-CGM on GV 
measures. RT-CGM results in significant improvement in the majority of the 
evaluated measures of GV and quality of glycaemic control. After 26 weeks 
of RT-CGM in the intervention group, there was a statistically significant 
reduction in all measures of quality of glycaemic control. These findings are 
consistent with previous studies that demonstrated the effect of RT-CGM on 
HbA1c reduction and increasing the time spent in target glucose range 
(Tamborlane et al., 2008). The findings are also consistent with study that 
looked at the effect of unmasking CGM in participants with type 1 diabetes 
over a period of three weeks (Rodbard et al., 2009). The largest reductions 
were in M-value (25.71, P<0.001) and in LBGI  (24.91, P<0.001). All 
measures of GV (with the exception of LI and MAG) showed significant 
reduction in the range between 5.21% and 8.29% (P<0.001). Similarly, 
unmasking of CGM in the control group resulted in statistically significant 
reduction in LBGI, ADRR and M-value (all measures of quality of glycaemic 
control) by 22%, 21% and 18% respectively.  
On assessing factors predictive of change in HbA1c at 6 months in the 
intervention group, the JDRF CGM group included only subjects with baseline 
HbA1c ≥ 7% (162 subjects). A univariate analysis has demonstrated that only 
age, baseline HbA1c and number of days per week of sensor use during six 
months showed significant relationship. In a multivariate analysis, age lost its 
significance when corrected for number of days of sensor use per week 
during the six months. The study has also demonstrated that factors 
associated with sensor use of ≥6 days per week during the sixth months were 
age, frequency of self-reported prestudy daily blood glucose meter 
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measurements, CGM use during the first months and percentage of sensor 
glucose values between 4 – 10 mmol/L during first month (Beck et al., 2009a). 
In our analysis, we used data from all subjects in the intervention group (231 
subjects) to study the potential predictors of change in GV measures at 6 
months. Using regression models to study baseline clinical and demographic 
factors as potential predictors of change in GV measures at 26 weeks in the 
CGM group showed baseline GV as a negative predictor for all GV measures, 
with higher GV at baseline predicting greater reduction of GV at 26 weeks in 
the intervention group. Further analysis showed the effect to be independent 
from the effect of regression to the mean. Baseline HbA1c predicted change 
in GV in the majority of the evaluated GV measures. However, although a 
higher HbA1c was a significant predictor of reduction in GV at 26 weeks in the 
CGM group according to univariate analysis, its predictive value changed after 
adjustment for baseline GV in a multivariate model.  This indicates that the 
negative univariate association between baseline HbA1c and change in GV 
was dependent on baseline GV and that when variation in baseline GV is 
taken into account, increasing HbA1c is associated with less of a reduction in 
GV. Interestingly, education level of caregiver did not predict change in any of 
the GV measures.  
Limitations of this analysis include the reliability of some of the evaluated GV 
measures. ADRR requires data collected typically over one month (at least 
14 days) with typical frequency of 3-5 glucose measurements per day, 
whereas CGM data used to compute ADRR in this analysis were collected 
for 96 hours. Also, calculation of MAGE using EasyGV software (as in this 
analysis) was shown to have weak correlation with the other three tools to 
231
! !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!232!
calculate MAGE. However, none of the four calculators, evaluated in that 
paper, was evaluated against the “gold standard” graphical “ruler and pencil” 
approach (Sechterberger et al., 2014). EasyGV allows the use of modified 
method (MAGE-CGM) for MAGE calculation (Hill et al., 2011). Accuracy of 
CGM systems used in the study, particularly at the hypoglycaemic range, can 
be considered as another limitation as it can affect GV measurements. Since 
the JDRF CGM study was conducted, accuracy of available CGM systems 
has improved significantly and the large volume of data analysed here 
mitigates much of this problem. 
 
6.6.  CONCLUSION: 
Despite the evidence supporting a role for GV, its contribution to diabetes-
related complications remains controversial and its value as an additional 
marker to HbA1c remains unclear. This data analysis suggests that the 
evaluated GV measures are of limited value in addition to HbA1c but that a 
measure of hypoglycaemia is a useful adjunct to HbA1c. Very importantly this 
analysis describes the clear beneficial impact of RT-CGM on glucose 
variability, which is a significant source of distress to people with diabetes. 
A large-scale longitudinal interventional study involving subgroups of subjects 
with different types of diabetes and treatment modalities is required to identify 
the HbA1c-independent role of GV in development of diabetes-related 
vascular complications, role of insulin therapy, effect of targeting GV and 
identification of a “gold-standard” GV measure.  
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7.1.   CONCLUSION: 
Despite the advances in the field of continuous glucose monitoring (CGM) and 
the improvement of CGM systems’ accuracy in recent years, there remain 
several challenges facing the CGM technology. The development of an 
accurate, safe, cost effective and user-friendly CGM system may help 
improvement in compliance with CGM use, clinical effectiveness and 
widespread implementation in management of people with diabetes. It may 
also allow realisation of non-adjuvant use of CGM, which is an important 
aspect in the development of closed-loop systems.  
The use of microneedle technology for CGM provides the potentials to 
overcome some of these challenges. It provides a minimally invasive access 
to dermal interstitial fluid (ISF) which is associated with less risk of pain, skin 
reaction, bleeding or infection. The novel system also offers the potential to 
enhance sensor accuracy through simultaneous multi-glucose sensing in the 
dermal compartment. While existing CGM technology targets the 
subcutaneous tissue for measurement of its ISF glucose content, current 
evidence suggests that measurement of glucose content of dermal ISF is 
superior to that of the subcutaneous tissue.  
This thesis describes the work done towards the development and evaluation 
of a novel microprobe array sensor for continuous glucose monitoring aiming 
to move the technology from bench side to bedside.  It describes work done to 
capture patient’s views regarding continuous glucose monitoring and 
microneedle technology aiming to identify barriers for its use and how to make 
the technology more acceptable from patients’ perspective. This has 
highlighted the importance of perceived CGM accuracy and cost. The thesis 
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also highlights the impact of effective patient and public involvement at an 
early stage in diabetes technology research. 
Detailed description of steps of fabrication, functionalisation and pre-clinical 
evaluation of the sensor are presented. To ensure that microprobes are of the 
correct geometry to penetrate the stratum corneum and reach dermal ISF, the 
fabrication technique was changed from photolithography to micromoulding. 
In addition, this technique allowed for more reproducible, lower cost and 
scalable production. In vitro and ex vivo mechanical characterisation studies 
of the pyramidal shaped microprobes showed that they were able to access 
the dermal compartment without mechanical failure. The microprobe arrays 
are fabricated using SU-8 polymer and sputtered with gold to serve as 
electrodes for electrochemical glucose sensing. The gold surface is 
functionalised with glucose oxidase. To protect the enzyme layer, reduce 
interference and to increase the linear working range of the sensor, epoxy-
polyurethane (epoxy-PU) membrane was used. Electrochemical studies of the 
sensor showed a linear detection range (0-20 mmol/L), sensitivity of 7 
nA/mmol and no negative impact related to gamma ray sterilisation or skin 
insertion. However, similar to existing CGM sensors, acetaminophen 
interference was present.  
To assess safety and performance of the device in a clinical study, approval 
from regulatory bodies was obtained to conduct the clinical study over four 
phases in healthy volunteers and in people with type 1 diabetes. The thesis 
describes work done so far in phase 1 aiming to assess safety of the device in 
healthy volunteers. Sensor application for six hours was not associated with 
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skin reaction, bleeding, infection or pain. Most of the subjects described a 
“pricking” sensation only during device application. 
Finally, the thesis describes several indices of glycaemic variability (GV) and 
the effect of RT-CGM on the evaluated indices. The analysis of glucose 
profiles of 448 subjects with type 1 diabetes that were recruited in the 
landmark Juvenile Diabetes Research foundation CGM study showed that GV 
is significantly higher in subjects with type 1 diabetes than in non-diabetic 
subjects. Use of RT-CGM reduces GV and improves measures of glucose risk 
compared with SMBG in children, adolescents and adults with type 1 
diabetes. There were significant inter-correlations with HbA1c suggesting a 
limited role for GV indices in clinical practice. However, the lack of correlation 
between either low blood glucose index or time spent in hypoglycaemia with 
HbA1c suggest a potential place for an additional metric assessing risk of 
hypoglycaemia.  
 
7.2.   FUTURE WORK AND RECOMMENDATION FOR FUTURE STUDIES: 
7.2.1. Further clinical evaluation: 
Phase 1 of the clinical study is in progress. The second phase is planned to 
assess sensor’s performance over the first six hours, as a primary outcome, 
and safety over 24 hours in healthy volunteers. In the first six hours, sensor 
output will be compared to venous blood glucose measured every 15 minutes 
using YSI to evaluate the device’s performance. During these six hours, the 
development of skin reaction, bleeding or pain during insertion or throughout 
its use will be evaluated to assess safety of the device. For the remaining 18 
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hours, subjects will be allowed to go home with the sensor to further assess 
sensor safety over the whole 24 hour period. 
The sensor performance and safety in people with type 1 diabetes will be 
assessed in phases 3 and 4. The third phase is planned to take place in 20 
subjects with type 1 diabetes over 24 hours. Performance will be assessed 
against venous blood glucose measured using YSI and against ISF glucose 
measured using a commercially available CGM system (iPro®2–enlite CGM 
system - Medtronic, Northridge, California). Phase 4 will assess sensor 
performance and safety in 20 subjects with type 1 diabetes in an ambulatory 
circumstance over 5 days in comparison to ISF glucose measured using 
iPro2–enlite CGM system. 
Initial results from phase 1 of the clinical study have highlighted the need for 
further optimisation of the epoxy-PU coating membrane to reduce the risk of 
its disruption during skin insertion. Findings from phase 1 of clinical study also 
suggest the potential benefit of the use of a skin imaging tool (e.g. optical 
coherence tomography or confocal microscopy) for confirmation of stratum 
corneum penetration by microprobes and visualisation of the created 
microchannels. This could be used for evaluation of the relationship between 
length of created microchannels, application force used and the magnitude of 
measured current. In addition, the use of an applicator for microprobe array 
insertion could be beneficial. Other than enhancing the ability of microprobes 
to penetrate stratum corneum, it could also ensure consistent penetration and 
reduce inter-person variability. The use of an applicator for microprobe 
insertion was one of the themes identified by patients in our focus group.  
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Further electrochemical evaluation, following any required modification in the 
sensor guided by findings of clinical studies, will be required to assess sensor 
stability and effect of other potential interferents. 
7.2.2. Automation and Scalability 
Currently the microprobe array sensor is hand fabricated which, other than 
being time- and resource-intensive, can result in higher sensor-to-sensor 
variability. The use of injection-moulding for device fabrication and automation 
of the functionalisation process allow the possibility to scale up sensor 
fabrication and functionalisation, minimise cost and reduce sensor to sensor 
variability.  
 
7.2.3.Development of other components of microprobe array CGM 
system 
While the novelty of the proposed CGM system is mainly related to the 
microprobe array sensor, several factors need to be considered in relation to 
other components of the CGM system for the realisation of our vision in 
developing an accurate minimally invasive and cost-effective “smart patch 
CGM”. These include miniaturisation of other components of the CGM 
system, power supply, connectivity, algorithm development and data display.  
 
7.2.4.Human factor analysis 
An important part for the design of the microprobe continuous glucose-
monitoring device is human factor studies. These need to assess the physical 
component (e.g, use of the applicator to apply the sensor, the adhesive used 
to fix the sensor at the insertion site, the process of connecting the sensor to 
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the transmitter unit). It also evaluates the informational component (e.g: 
interaction with data displayed). This ensures that the final device is user-
friendly, effective and safe. 
 
7.2.5.Multi-analyte sensing in dermal ISF: 
Other than providing the potential to enhance accuracy of ISF glucose 
measurement while reducing invasiveness, the microprobe array provides the 
potential for simultaneous multi-analyte sensing. This requires 
characterisation of dermal ISF analytes’ content and dynamics.  
7.2.6.Further research in glycaemic variability: 
While there is mounting evidence supporting the pathophysiological effect of 
GV, a large-scale longitudinal intervention study is required to evaluate the 
HbA1c-independent role of GV in development of diabetes-related vascular 
complications, role of insulin therapy, effect of targeting GV and identification 
of a “gold-standard” GV measure.  !
!
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Diabetes  Technology  Questionnaire
We  are  diabetes  technology  researchers  from  Imperial  College  and  would  like  to  hear  from  
people  with  diabetes  (and  their  carers)  about  their  views  on  new  technology  and  how  it  can  
help  people  with  diabetes.  This  will  help  us  and  others  to  focus  our  research  on  what  would  
be  most  helpful  to  you.    You  can  answer  this  survey  either  as  yourself,  or  on  behalf  of  
someone  else  with  diabetes.    The  survey  is  anonymous  and  the  results  will  be  kept  
confidential.  
The  survey  contains  questions  about:  glucose  monitors  including  continuous  glucose  
monitors  (CGM),  insulin  pumps  and  pens,  and  CGM  enabled  pumps.  At  the  end  of  the  
survey,  there  is  a  space  for  additional  comments  about  any  issues  not  covered  in  the  
questions.
We  estimate  that  this  survey  will  take  20  minutes  to  complete.
Thank  you  for  your  help.  
*  Required
1.   I  am:  *
Mark  only  one  oval.
  a  person  with  diabetes.   Skip  to  question  2.
  a  carer  for  a  child  with  diabetes.   Skip  to  question  9.
2.   I  am:  *
Mark  only  one  oval.
  Male
  Female
3.   I  am  aged:  *
Mark  only  one  oval.
  16-­25
  26-­40
  41-­65
  over  65
4.   I  live  in:  *
Mark  only  one  oval.
  UK
  Europe
  North  America
  Other:  
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5.   I  have:  *
Mark  only  one  oval.
  Type  1  diabetes
  Type  2  diabetes
  Other:  
6.   I  have  been  diagnosed  with  diabetes  for:  *
Mark  only  one  oval.
  less  than  1  year
  1-­5  years
  6-­10  years
  more  than  10  years
7.   To  manage  my  diabetes  I  use:  *
Tick  ALL  that  apply
Check  all  that  apply.
  Lifestyle  measures  (diet  &  exercise)
  Glucose-­lowering  tablets  (like  metformin,  sulfonylurea...etc)
  Injections  that  are  not  insulin  (like  Byetta,  Victoza  or  Lyxumia)  
  1-­2  insulin  injections  daily
  3-­5  insulin  injections  daily
  Insulin  pump
  Other:  
8.   How  many  times  per  week  do  you  exercise  30  minutes  or  more  ?  *
Check  all  that  apply.
  I  don't  exercise  regularly
  1-­3  times  per  week
  4-­7  times  per  week
Skip  to  question  14.
9.   My  child  is:  *
Mark  only  one  oval.
  Male
  Female
10.   My  child  is  aged:  *
Mark  only  one  oval.
  0-­5
  6-­15
  Over  15  years  old
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11.   We  live  in:  *
Mark  only  one  oval.
  UK
  Europe
  North  America
  Other:  
12.   My  child  has  been  diagnosed  with  diabetes  for:  *
Mark  only  one  oval.
  less  than  1  year
  1-­5  years
  6-­10  years
  more  than  10  years
13.   My  child  manages  diabetes  using  mainly:  *
Choose  from  the  list  below.
Check  all  that  apply.
  1-­2  insulin  injections  daily
  3-­5  insulin  injections  daily
  Insulin  pump
  Other:  
Skip  to  question  16.
Monitoring  your  blood  glucose  levels.
14.   How  often  do  you  carry  out  finger  prick  glucose  monitoring?  *
Mark  only  one  oval.
  Never
  1  -­  5  times  per  week
  2  -­  4  times  per  day
  more  than  5  times  daily
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15.   Where  1  is  most  important,  and  9  is  least  important,  please  rank  the  challenges  you
may  have  faced  using  finger  prick  glucose  testing.  *
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9
Pain
Inaccurate  reading
Difficult  to  use
Does  not  provide  me  with  enough
information  on  my  glucose  level  to
correctly  adjust  my  treatment
Keeping  a  schedule  for  regular
testing  and  remembering  to  test
Recording  glucose  level  readings
Access  to  test  strips
Need  to  carry  the  glucose  meter
wherever  I  go
Not  being  able  to  test  at  certain
times  (driving,  exercise  or  at
night)  
Skip  to  question  18.
Monitoring  your  child's  blood  glucose  levels.
16.   How  often  does  your  child  carry  out  finger  prick  glucose  monitoring?  *
Mark  only  one  oval.
  Never
  1  -­  5  times  per  week
  2  -­  4  times  per  day
  more  than  5  times  daily
17.   Where  1  is  most  important,  and  9  is  least  important,  please  rank  the  challenges  you
/  your  child  may  have  faced  using  finger  prick  glucose  testing.  *
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9
Pain
Inaccurate  reading
Difficult  to  use
Does  not  provide  enough
information  on  glucose  levels  to
correctly  adjust  treatment
Keeping  a  schedule  for  regular
testing  and  remembering  to  test
Recording  glucose  level  readings
Access  to  test  strips
Need  to  carry  the  glucose  meter
wherever  we  go
Difficulty  to  test  at  certain  times
(school,  play-­time  or  at  night)  
Skip  to  question  27.
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Continuous  Blood  Glucose  Monitoring
The  following  questions  are  about  the  use  of  continuous  blood  glucose  monitors.  Typically,  a  
continuous  glucose  monitoring  system  (CGM)  consists  of  a  sensor  sensor  that  is  applied  on  
the  body  to  measure  glucose  concentrations  in  the  interstitial  fluid,  a  transmitter  that  is  
attached  to  the  sensor,  and  a  monitor  that  displays  glucose  levels.  The  sensor  needs  to  be  
replaced  every  5  -­  7  days.
18.   Have  you  ever  used  a  Continuous  Glucose  Monitor  (CGM)?  *
Mark  only  one  oval.
  Yes,  I  currently  use  CGM
  Yes,  I  have  used  CGM  in  the  past
  No
19.   If  you  are  a  current  or  previous  user  of  a  CGM,  what  is  the  reason  you  started  using
one?
(Please  type  in  your  answer  below.)
  
  
  
  
  
20.   How  do  you  view  CGM  technology?  *
Mark  only  one  oval.
  I  feel  positive  about  it.
  I  am  undecided/neutral
  I  feel  negative  towards  it.
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21.   In  order  of  importance,  please  rank  potential  advantages  a  continuous  glucose
monitor  might  offer  for  you  and  for  people  with  diabetes:  *
1  is  most  important,  and  9  is  least  important
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9
Provides  full  information  on
glucose  level  throughout  the  day
Provides  information  on  glucose
level  when  I  am  not  able  to  use
finger  prick  glucose  monitoring
(while  asleep,  driving  or  doing
exercise)
Saves  time  of  repeated  finger
prick  glucose  measurements
Provides  more  flexibility  with  daily
activity  like  food  and  exercise
Reassures  me  by  providing
alarms  if  my  glucose  is  too  high  or
low
Helps  me  to  avoid  hypos  (low
blood  sugar)
Improves  my  hypoglycaemia  (low
blood  sugar)  awareness  by
providing  alarms
Helps  me  to  better  manage  my
diabetes  and  therefore  reduce
risks  of  complications
Helps  me  modify  my  behaviour
around  food  choices
265
22.   In  order  of  importance,  please  rank  features  that  you  think  an  ideal  CGM  should
have  *
1  is  most  important,  and  12  is  least  important
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9 10 11 12
Accurate
Painless
Affordable
Discrete
Alarms  if  my
glucose  levels  are
low  or  high
Water-­resistant
Easy  interpretation
of  data  from  the
monitoring  device
Ability  to  use  my
mobile  phone  to
display  CGM  
Ability  to  suspend
insulin  delivery  if  I
am  low  (for  pump
users)
Easy  readability  of
data  screen
User-­friendly
software  to
download  data  on
my  computer
Longer  sensor  life
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23.   If  you  are  a  current  or  previous  CGM  user,  please  rank  challenges  of  using  CGM
device  in  order  of  importance
1  is  most  challenging,  and  13  is  least  challenging
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9 10 11 12 13
Inaccurate
glucose  readings
Lag  time
between  finger
prick  and  CGM
readings
Pain
Expensive
Interfering  with
daily  activities
Too  much
information
about  my
glucose  readings
Getting  access
to  training  and
support  
Makes  me
anxious  by
reminding  me
about  diabetes
all  the  time
Alarms  disturb
my  life
Visible
Need  to  do  finger
pricks  to
calibrate  or  to
confirm  glucose
readings
Difficult  to  use
Another
electronic  device
to  manage
24.   How  often  do  you  think  you  would  like  to  use  a  CGM?  *
(Please  choose  one  of  the  options  below.)
Mark  only  one  oval.
  Intermittently  (one  week  every  few  months  to  get  an  insight  into  my  glucose  levels)
  Continuously
  I  don’t  want  to  use  a  CGM  device
25.   What  type  of  CGM  device  do  you  prefer  to  use?  *
Mark  only  one  oval.
  One  that  displays  glucose  level  on  a  monitor  (real  time  CGM)
  One  that  does  not  display  glucose  levels  but  stores  the  data  for  a  later  review  with
my  diabetes  team  
  I  don’t  want  to  use  a  CGM  device
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26.   Do  you  have  any  other  comments  about  CGM?
(Please  type  your  answer  in  the  box  below.)
  
  
  
  
  
Skip  to  question  36.
Continuous  Blood  Glucose  Monitoring  and  your  child.
The  following  questions  are  about  the  use  of  continuous  blood  glucose  monitors  and  your  
child.  Typically,  a  continuous  glucose  monitoring  system  (CGM)  consists  of  a  sensor  sensor  
that  is  applied  on  the  body  to  measure  glucose  concentrations  in  the  interstitial  fluid,  a  
transmitter  that  is  attached  to  the  sensor,  and  a  monitor  that  displays  glucose  levels.  The  
sensor  needs  to  be  replaced  every  5  -­  7  days.
27.   Has  your  child  ever  used  a  Continuous  Glucose  Monitor  (CGM)?  *
Mark  only  one  oval.
  Yes,  my  child  is  currently  using  a  CGM
  Yes,  my  child  used  CGM  in  the  past
  No
28.   If  your  child  is  a  current  or  previous  user  of  a  CGM,  what  is/was  the  reason  they
started  using  one?
(Please  type  in  your  answer  below.)
  
  
  
  
  
29.   How  do  you  or  your  child  view  CGM  technology?  *
Mark  only  one  oval.
  feel  positive  about  it.
  undecided/neutral
  feel  negative  towards  it.
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30.   In  order  of  importance,  please  rank  potential  advantages  a  continuous  glucose
monitor  might  offer  for  your  child  and  for  people  with  diabetes:  *
1  is  most  important,  and  8  is  least  important
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9
Provides  full  information  of
fluctuations  of  glucose  level
throughout  the  day
Provides  information  on  glucose
level  when  it  is  difficult  to  not  use
finger  prick  glucose  monitor  (while
asleep,  playing  or  at  school)
Save  time  of  repeated  finger  prick
glucose  measurements
Provides  more  flexibility  with  daily
activities  like  food  and  exercise
Reassures  me  by  providing
alarms  if  it  is  too  high  or  too  low
Helps  to  avoid  hypos  (low  blood
sugars)
Improves  hypoglycaemia  (low
blood  sugar)  awareness  by
providing  alarms
Supports  diabetes  self-­
management  and  therefore
reduce  risks  of  complications
Helps  me  modify  my  behaviour
around  food  choices
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31.   In  order  of  importance,  please  rank  features  that  you  think  an  ideal  CGM  should
have  *
1  is  most  important,  and  12  is  least  important
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9 10 11 12
Accurate
Painless
Affordable
Discrete
Alarms  if  glucose
levels  are  low  or
high
Water-­resistant
Easy  interpretation
of  data  from  the
monitoring  device
Ability  to  use  my
mobile  phone  to
display  CGM  data
(rather  than  having
a  separate  display
unit)    
Ability  of  the  CGM
to  suspend  insulin
delivery  if  low  blood
sugar  (for  pump
users)
Easy  readability  of
data  screen
User-­friendly
software  to
download  data  on
my  computer
Longer  sensor  life
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32.   If  your  child  is  a  current  or  previous  CGM  user,  please  rank  challenges  of  using
CGM  device  in  order  of  importance
1  is  most  challenging,  and  13  is  least  challenging
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9 10 11 12 13
Inaccurate
glucose  readings
Lag  time
between  finger
prick  and  CGM
readings
Pain
Expensive
Interfering  with
daily  activities
Too  much
information
about  glucose
readings
Getting  access
to  training  and
support  
Increases
anxiety  by
reminding  about
diabetes  all  the
time
Alarms  disturb
my  child's  life
and  mine.
Visible  
Need  to  do  finger
pricks  to
calibrate  or  to
confirm  glucose
readings
Difficult  to  use
Another
electronic  device
to  manage
33.   How  often  do  you  think  you  and  your  child  would  like  to  use  a  CGM?  *
(Please  choose  one  of  the  options  below.)
Mark  only  one  oval.
  Intermittently  (one  week  every  few  months  to  get  an  insight  into  my  glucose  levels)
  Continuously
  We  don’t  want  to  use  a  CGM  device
34.   What  type  of  CGM  device  would  you  and  your  child  prefer  to  use?  *
Mark  only  one  oval.
  One  that  displays  glucose  level  on  a  monitor  (real  time  CGM)
  One  that  does  not  display  glucose  levels  but  stores  the  data  for  a  later  review  by
my  doctor
  We  don’t  want  to  use  a  CGM  device
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35.   Do  you  have  any  other  comments  about  CGMs?
(Please  type  your  answer  in  the  box  below.)
  
  
  
  
  
Skip  to  question  45.
Insulin  pumps
The  following  questions  are  about  insulin  pens  and  pumps.  
36.   In  order  of  importance,  please  rank  the  challenges  you  may  have  faced  using
insulin  injection  pens.  *
1  is  most  important,  and  7  is  least  important
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7
Pain
Difficult  to  use
Using  in  places  with  other  people
near
Sometimes  I  forget  taking  insulin  
I  find  estimating  insulin  doses
based  on  carbohydrate  content  of
the  meal  very  difficult
Time  consuming
Need  to  carry  the  insulin  pen
wherever  I  go
37.   Have  you  ever  used  an  insulin  pump  ?  *
Mark  only  one  oval.
  Yes,  I  am  currently  using  an  insulin  pump
  Yes,  I  used  an  insulin  pump  in  the  past
  No
38.   If  you  are  a  current  or  previous  user  of  an  insulin  pump,  what  was  the  reason  for
this?
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39.   If  you  are  a  previous  pump  user,  why  you  are  no  longer  using  one?
  
  
  
  
  
40.   How  do  you  view  insulin  pump  technology  ?  *
Mark  only  one  oval.
  I  am  positive  about  it.
  I  am  undecided/neutral
  I  am  negative  towards  it.
41.   In  order  of  importance,  please  rank  potential  advantages  an  insulin  pump  might
offer  for  you  and  for  people  with  diabetes
1  is  most  important,  and  6  is  least  important
Mark  only  one  oval  per  row.
1 2 3 4 5 6
Discrete
Avoids  discomfort  of  repeated
insulin  injections  
Provides  more  flexibility  with  daily
activities  like  diet  and  exercise
Helps  me  to  estimate  insulin
doses  at  meal  time  more
accurately
Helps  me  to  avoid  hypos  (low
blood  sugar)
Helps  me  to  manage  my  diabetes  
42.   In  order  of  importance,  please  rank  features  that  you  think  an  ideal  insulin  pump
should  have
1  is  most  important,  and  10  is  least  important
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9 10
Small  in  size
Painless
Remote  control
Alarms  early  if  malfunctions
Water-­resistant
Simple  and  easy  to  use
Ability  to  transfer  my  data  to
my  computer  or  the  web  
Lightweight
Compatibility  with  a  CGM
Nice-­looking
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43.   If  you  are  a  current  or  previous  pump  user,  please  rank  challenges  of  using  insulin
pump  in  order  of  importance
1  is  most  challenging,  and  9  is  least  challenging
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9
Pain  at  insertion  site
Tubing  between  pump  and
cannula  gets  in  the  way
sometimes
Interfering  with  daily  activities
I  find  the  pump  too  complicated  to
use
Is  a  reminder  of  my  diabetes
Alarms  disturb  my  life
Another  electronic  device  to
manage
Visible
Getting  access  to  training  and
support
44.   Do  you  have  any  further  comments  about  the  use  of  insulin  pumps?
(Please  type  in  your  answer  in  the  box  below.)
  
  
  
  
  
Skip  to  question  54.
Insulin  pumps  and  your  child.
The  following  questions  are  about  insulin  pumps  and  your  child.  
45.   In  order  of  importance,  please  rank  the  challenges  your  child  may  have  faced  using
insulin  injection  pens.  *
1  is  most  challenging,  and  7  is  least  challenging
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7
Pain
Difficult  to  use
Using  in  places  with  other  people
near
Sometimes  I  forget  injecting
insulin  at  the  right  time.
I  find  estimating  insulin  doses
based  on  carbohydrate  content  of
the  meal  very  difficult
Time  consuming
Need  to  carry  the  insulin  pen
wherever  we  go
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46.   Has  your  child  ever  used  an  insulin  pump  ?  *
Mark  only  one  oval.
  Yes,  my  child  is  currently  using  an  insulin  pump
  Yes,  my  child  has  used  an  insulin  pump  in  the  past
  No
47.   If  your  child  is  a  current  or  previous  user  of  an  insulin  pump,  what  is  the  reason  for
this?
  
  
  
  
  
48.   If  your  child  no  longer  uses  an  insulin  pump,  why  is  this?
  
  
  
  
  
49.   How  do  you  and  your  child  view  insulin  pump  technology?  *
Mark  only  one  oval.
  Positively
  Undecided/neutral
  Negatively
50.   In  order  of  importance,  please  rank  potential  advantages  an  insulin  pump  might
offer  for  your  child  and  for  people  with  diabetes
1  is  most  important,  and  7  is  least  important
Mark  only  one  oval  per  row.
1 2 3 4 5 6
Discrete
Avoids  discomfort  from  repeated
insulin  injections  
Provides  more  flexibility  with  daily
activities  like  diet  and  exercise
Helps  me  to  estimate  insulin
doses  at  meal  time  more
accurately
Helps  to  avoid  hypos  (low  blood
sugar)
Helps  in  management  of  my
child's  diabetes  
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51.   In  order  of  importance,  please  rank  features  that  you  think  an  ideal  insulin  pump
should  have
1  is  most  important,  and  10  is  least  important
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9 10
Small  in  size
Painless
Remote  control  
Alarms  early  if  malfunctions
Water-­resistant
Simple  and  easy  to  use
Ability  to  transfer  data  to  my
computer  or  the  web  
Lightweight
Compatibility  with  a  CGM
Nice-­looking
52.   If  your  child  is  a  current  or  previous  pump  user,  please  rank  challenges  of  using
insulin  pump  in  order  of  importance
1  is  most  challenging,  and  9  is  least  challenging
Mark  only  one  oval  per  row.
1 2 3 4 5 6 7 8 9
Pain  at  insertion  site
Tubing  between  pump  and
cannula  gets  in  the  way
sometimes
Interfering  with  daily  activities
I  find  the  pump  too  complicated  to
use
Is  a  reminder  of  diabetes
Alarms  disturb  my  child's  life  and
mine
Another  electronic  device  to
manage
Visible
Getting  access  to  training  and
support
53.   Do  you  have  any  further  comments  about  the  use  of  insulin  pumps?
(Please  type  in  your  answer  in  the  box  below.)
  
  
  
  
  
Skip  to  question  57.
SENSOR  AUGMENTED  PUMP  THERAPY  (SAP)
This  is  where  information  about  blood  glucose  levels  from  the  CGM  is  sent  wirelessly  to  be  
displayed  on  your  pump's  monitor,  rather  than  having  a  separate  monitor  for  the  CGM.  This  
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reduces  the  number  of  devices  carried  by  the  patient.  Also,  establishing  a  communication  
between  the  CGM  and  the  insulin  pump  can  allow  pump  suspension  if  hypoglycaemia  is  
detected  by  the  CGM.
54.   If  you  are  a  current  or  previous  user  of  SAP,  what  is/was  the  reason  for  this  ?
  
  
  
  
  
55.   In  order  of  importance,  please  rank  potential  advantages  a  sensor  augmented
pump  might  offer  for  you  and  for  people  with  diabetes:
1  is  most  important,  and  6  is  least  important
Mark  only  one  oval  per  row.
1 2 3 4 5 6
Provides  more  flexibility  with  daily
activity  like  diet  and  exercise
Reassures  me  by  providing
alarms  if  it  is  too  high  or  too  low
Helps  me  to  avoid  hypos
Improves  hypo  awareness
Helps  me  to  control  my  diabetes
and  therefore  reduce  risks  of
complications
Ability  to  switch  off  insulin  delivery
if  I  am  low  
56.   How  do  you  view  the  use  of  insulin  pump  and  CGM  simultaneously  ?
Mark  only  one  oval.
  I  am  positive  about  it.
  I  am  undecided/neutral
  I  am  negative  towards  it.
Skip  to  question  60.
SENSOR  AUGMENTED  PUMP  THERAPY  (SAP)  and  your
child.
This  is  where  information  about  blood  glucose  levels  from  the  CGM  is  sent  wirelessly  to  be  
displayed  on  your  child's  pump's  monitor,  rather  than  having  a  separate  monitor  for  the  CGM.  
This  reduces  the  number  of  devices  carried  by  the  patient.  Also,  establishing  a  communication  
between  the  CGM  and  the  insulin  pump  can  allow  pump  suspension  if  hypoglycaemia  is  
detected  by  the  CGM.
57.   If  your  child  is  a  current  or  previous  user
of  SAP,  what  is/was  the  indication  for  this
?
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58.   In  order  of  importance,  please  rank  potential  advantages  a  sensor  augmented
pump  might  offer  for  your  child  and  for  people  with  diabetes:
1  is  most  important,  and  6  is  least  important
Mark  only  one  oval  per  row.
1 2 3 4 5 6
Provides  more  flexibility  with  daily
activity  like  diet  and  exercise
Reassures  by  providing  alarms  if  it
is  too  high  or  too  low
Helps  to  avoid  hypos  (low  blood
sugar)
Improves  hypo  awareness  by
providing  alarms
Helps  me  to  control  my  child's
diabetes  and  therefore  reduce
risks  of  complications
Ability  to  switch  off  insulin  delivery
if  I  am  low  
59.   How  do  you  view  the  use  of  insulin  pump  and  CGM  simultaneously,  in  relation  to
your  child?
Mark  only  one  oval.
  I  am  positive  about  it.
  I  am  undecided/neutral
  I  am  negative  towards  it.
Skip  to  question  62.
60.   How  do  you  view  diabetes  technology  ?  *
Mark  only  one  oval.
  I  am  positive  about  it.
  I  am  undecided/neutral
  I  am  negative  towards  it.
61.   Please  use  the  box  below  to  write  what  you  want  from  technology  in  the  future  to
help  you  manage  diabetes
  
  
  
  
  
Stop  filling  out  this  form.
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62.   How  do  you  and  your  child  view  diabetes  technology?  *
Mark  only  one  oval.
  I  am  positive  about  it.
  I  am  undecided/neutral
  I  am  negative  towards  it.
63.   Please  use  the  box  below  to  write  what  you  want  from  technology  in  the  future  to
help  your  child  manage  diabetes
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